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A B S T R A C T
Background
Low molecular weight heparins (LMWHs) have been shown to be effective and safe in preventing venous thromboembolism (VTE).
They may also be effective for the initial treatment of VTE. This is the third update of the Cochrane Review ﬁrst published in 1999.
Objectives
To evaluate the efﬁcacy and safety of ﬁxed dose subcutaneous low molecular weight heparin compared to adjusted dose unfractionated
heparin (intravenous or subcutaneous) for the initial treatment of people with venous thromboembolism (acute deep venous thrombosis
or pulmonary embolism).
Search methods
For this update the Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register (15 September
2016). In addition the CIS searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane
Library (searched 15 September 2016) and trials’ registries.
Selection criteria
Randomised controlled trials comparing ﬁxed dose subcutaneous LMWH with adjusted dose intravenous or subcutaneous unfraction-
ated heparin (UFH) in people with VTE.
Data collection and analysis
Two review authors independently selected trials for inclusion, assessed for quality and extracted data.
Main results
Six studies were added to this update resulting in a total of 29 included studies (n = 10,390). The quality of the studies was downgraded
as there was a risk of bias in some individual studies relating to risk of attrition and reporting bias; in addition several studies did not
adequately report on the randomisation methods used nor on how the treatment allocation was concealed.
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During the initial treatment period, the incidence of recurrent venous thromboembolic events was lower in participants treated with
LMWH than in participants treated with UFH (Peto odds ratio (OR) 0.69, 95% conﬁdence intervals (CI) 0.49 to 0.98; 6238
participants; 18 studies; P = 0.04; moderate-quality evidence). After a follow-up of three months, the period in most of the studies for
which oral anticoagulant therapy was given, the incidence of recurrent VTE was lower in participants treated with LMWH than in
participants with UFH (Peto OR 0.71, 95% CI 0.56 to 0.90; 6661 participants; 16 studies; P = 0.005; moderate-quality evidence).
Furthermore, at the end of follow-up, LMWH was associated with a lower rate of recurrent VTE than UFH (Peto OR 0.72, 95%
CI 0.59 to 0.88; 9489 participants; 22 studies; P = 0.001; moderate-quality evidence). LMWH was also associated with a reduction
in thrombus size compared to UFH (Peto OR 0.71, 95% CI 0.61 to 0.82; 2909 participants; 16 studies; P < 0.00001; low-quality
evidence), but there was moderate heterogeneity (I² = 56%). Major haemorrhages occurred less frequently in participants treated with
LMWH than in those treated with UFH (Peto OR 0.69, 95% CI 0.50 to 0.95; 8780 participants; 25 studies; P = 0.02; moderate-
quality evidence). There was no difference in overall mortality between participants treated with LMWH and those treated with UFH
(Peto OR 0.84, 95% CI 0.70 to 1.01; 9663 participants; 24 studies; P = 0.07; moderate-quality evidence).
Authors’ conclusions
This review presents moderate-quality evidence that ﬁxed dose LMWH reduced the incidence of recurrent thrombotic complications
and occurrence of major haemorrhage during initial treatment; and low-quality evidence that ﬁxed dose LMWH reduced thrombus
size when compared to UFH for the initial treatment of VTE. There was no difference in overall mortality between participants treated
with LMWH and those treated with UFH (moderate-quality evidence). The quality of the evidence was assessed using GRADE criteria
and downgraded due to concerns over risk of bias in individual trials together with a lack of reporting on the randomisation and
concealment of treatment allocation methods used. The quality of the evidence for reduction of thrombus size was further downgraded
because of heterogeneity between studies.
P L A I N L A N G U A G E S U M M A R Y
Fixed daily dose of a low molecular weight heparin compared with an adjusted dose of unfractionated heparin for treating
blood clots in the deep veins
Background
Venous thromboembolism (VTE) is a condition in which a blood clot forms in the deep veins of the leg or pelvis (DVT) or the
clot travels in the blood and blocks a blood vessel in the lungs (pulmonary embolism (PE)). The chances of getting a VTE can be
increased if people have risk factors such as previous clots, prolonged periods of immobility (such as travelling on aeroplanes or bed
rest), cancer, exposure to oestrogens (pregnancy, oral contraceptives or hormone replacement therapy), trauma and blood disorders
such as thrombophilia (abnormal blood clotting). People with a VTE are treated with an anticoagulant, which prevents further clots
from forming. Heparin is an anticoagulant and comes in two forms: low molecular weight heparin (LMWH) or unfractionated heparin
(UFH). UFH is an older drug and is given either intravenously or by injection. When administering UFH, clinicians have to monitor
blood-clotting factors carefully and adjust the dose, because of the variability of its effect. LMWH is given by subcutaneous injection
once or twice a day and does not need to be monitored as closely as UFH.
Study characteristics and key results
This review included 29 randomised controlled trials involving 10,390 participants (current to September 2016), which compared
LMWH or UFH for treating people with blood clots. Pooling the results of these trials showed that fewer participants treated with
LMWH formed further blood clots and that fewer cases of bleeding occurred. Use of LMWH also reduced the size of the original
blood clot when compared to the UFH group. There was no difference in number of deaths between participants treated with LMWH
and those treated with UFH.
Quality of the evidence
Results of this review indicate that LMWHmay prevent further blood clots and bleeding in people with VTE. However, these ﬁndings
must be interpreted with caution due to the moderate quality of the evidence as a result of lack of reporting of study methods and
problems with study design. Results indicating reduced size of blood clots when taking LMWH also must be interpreted with caution
due to the low quality of evidence as results were not similar across the studies.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LMWH compared to UFH for initial treatment of venous thromboembolism
Patient or population: people with venous thromboembolism (VTE)
Setting: hospital
Intervention: Low molecular weight heparin (LMWH)
Comparison: Unf ract ionated heparin (UFH)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with UFH Risk with LMWH
Incidence of recurrent
VTE1 af ter
init ial t reatment (up to
15 days)
Study populat ion OR 0.69
(0.49 to 0.98)
6238
(18 RCTs)
⊕⊕⊕©
MODERATE 2
24 per 1000 17 per 1000
(12 to 24)
Incidence of recurrent
VTE1
(3 months follow-up)
Study populat ion OR 0.71
(0.56 to 0.90)
6661
(16 RCTs)
⊕⊕⊕©
MODERATE 3
51 per 1000 37 per 1000
(29 to 46)
Incidence of recurrent
VTE1
(end of follow-up)
Study populat ion OR 0.72
(0.59 to 0.88)
9489
(22 RCTs)
⊕⊕⊕©
MODERATE 4
50 per 1000 36 per 1000
(30 to 44)
Reduct ion in thrombus
size
(pre- and post-treat-
ment venograms) 5
Study populat ion OR 0.71
(0.61 to 0.82)
2909
(16 RCTs)
⊕⊕⊕©
LOW 6
423 per 1000 342 per 1000
(309 to 375)
Incidence of major
haemorrhagic episodes
(during init ial t reatment
- up to 15 days) 7
Study populat ion OR 0.69
(0.50 to 0.95)
8780
(25 RCTs)
⊕⊕⊕©
MODERATE 8
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21 per 1000 15 per 1000
(11 to 20)
Overall mortality
(end of follow-up)
Study populat ion OR 0.84
(0.70 to 1.01)
9663
(24 RCTs)
⊕⊕⊕©
MODERATE 9
57 per 1000 48 per 1000
(41 to 57)
* The basis for the assumed risk f or ’study populat ion’ was the average risk in the comparison groups (i.e. total number of part icipants with events in the control group divided
by the number of part icipants in the comparison group). The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; LMWH; low molecular weight heparin; RCTs; randomised controlled trials OR: Peto odds rat io; UFH: unf ract ionated heparin; VTE: venous
thromboembolism
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Recurrent venous thromboembolism (VTE) def ined as recurrent deep vein thrombosis (DVT) or recurrent pulmonary
embolism (PE). The diagnosis of recurrent DVT was accepted if one of the following criteria was met: (a) a new, constant
intraluminal-f il l ing defect not present on the last available venogram; (b) if the venogram was not diagnost ic either an
abnormal 125I-f ibrinogen leg scan or abnormal impedance plethysmogram or ultrasound result , which had been normal
before the suspected recurrent episode (Buller 1991). The diagnosis of PE was accepted if one of the following criteria was
met: (a) a segmental defect on the perfusion lung scan that was unmatched on the vent ilat ion scan or chest roentgenogram;
(b) posit ive pulmonary angiography; (c) PE at autopsy.
2 Downgraded as risk of bias serious due to high risk of attrit ion bias in 4 studies (Fiessinger 1996; Lindmarker 1994; Ninet
1991; Thery 1992), high risk of report ing bias in 2 studies (Lindmarker 1994; Pérez de Llano 2003) and high risk of other bias
in 3 studies (Findik 2002; Harenberg 2000a; Lopaciuk 1992).
3 Downgraded as risk of bias serious due to high risk of attrit ion bias in 1 study (Breddin 2001), high risk of report ing bias in
one study (Pérez de Llano 2003), and high risk of other bias in 2 studies (Findik 2002; Lopaciuk 1992).
4 Downgraded as risk of bias serious due to high risk of attrit ion bias in 2 studies (Breddin 2001; Lindmarker 1994), high risk
of report ing bias in 2 studies (Lindmarker 1994; Pérez de Llano 2003), and high risk of other bias in 3 studies (Findik 2002;
Harenberg 2000a; Lopaciuk 1992)
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5 The number of part icipants in each group with an improved venographic score, if pre- and post-treatment venograms were
obtained and were assessed by persons unaware of treatment assignment.
6 Downgraded as risk of bias serious due to high risk of select ion bias in 1 study (Luomanmaki 1996), high risk of attrit ion bias
in 6 studies (Breddin 2001; Fiessinger 1996; Kakkar 2003; Lindmarker 1994; Ninet 1991; Thery 1992), high risk of report ing
bias in 1 study (Lindmarker 1994), and high risk of other bias in 4 studies (Harenberg 2000a; Kakkar 2003; Lopaciuk 1992;
Luomanmaki 1996). Downgraded further due to moderate heterogeneity (I² = 56%)
7 Haemorrhages were classif ied as major if they were intracranial, retroperitoneal, led direct ly to death, necessitated
transfusion or they led to the interrupt ion of ant ithrombotic treatment or (re)operat ion.
8 Downgraded as risk of bias serious due to high risk of select ion bias in 1 study (Luomanmaki 1996), high risk of attrit ion bias
in 5 studies (Fiessinger 1996; Kakkar 2003; Lindmarker 1994; Ninet 1991; Thery 1992), high risk of report ing bias in 2 studies
(Lindmarker 1994; Pérez de Llano 2003), and high risk of other bias in 5 studies (Findik 2002; Harenberg 2000a; Kakkar 2003;
Lopaciuk 1992; Luomanmaki 1996).
9 Downgraded as risk of bias serious due to high risk of select ion bias in 1 study (Luomanmaki 1996), high risk of attrit ion bias
in 4 studies (Breddin 2001; Kakkar 2003; Lindmarker 1994; Thery 1992), high risk of report ing bias in 2 studies (Lindmarker
1994; Pérez de Llano 2003), and high risk of other bias in 5 studies (Findik 2002; Harenberg 2000a; Kakkar 2003; Lopaciuk
1992; Luomanmaki 1996).
5
F
ix
e
d
d
o
se
su
b
c
u
ta
n
e
o
u
s
lo
w
m
o
le
c
u
la
r
w
e
ig
h
t
h
e
p
a
rin
s
v
e
rsu
s
a
d
ju
ste
d
d
o
se
u
n
fra
c
tio
n
a
te
d
h
e
p
a
rin
fo
r
th
e
in
itia
l
tre
a
tm
e
n
t
o
f
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Venous thromboembolism (presence of a blood clot in the veins,
VTE) has an incidence in the general population of approximately
0.1% per year. Its main manifestations are leg complaints, due
to deep venous thrombosis (DVT), in the lower limb (blood clot
in the deep veins of the leg), and signs of dyspnoea (shortness of
breath) and pleuritic thoracic pain (chest pain) when a throm-
bus (clot) becomes dislodged and forms an embolism obstructing
blood ﬂow in the pulmonary circulation. Evidence suggests that
although people may only complain about either DVT or pul-
monary embolism (PE), in many cases the pathological manifes-
tations are shared between these two clinically distinct conditions
(Huisman 1989; Hull 1983). Therefore, increasingly they are re-
ferred to as one disease and are treated with comparable anticoag-
ulant regimens.
Description of the intervention
Anticoagulant therapy is the treatment of choice for most people
with VTE (NICE 2012). Present guidelines recommend initial
therapy for DVT with a parenteral anticoagulant (unfractionated
heparin (UFH), lowmolecularweight heparin (LMWH)or fonda-
parinux) followedby vitaminK antagonist (VKA) therapy (Kearon
2012). Heparin is administered by either continuous intravenous
(IV) infusion or twice daily subcutaneous injection (NICE 2012).
Heparin dosage is monitored by the activated partial thrombo-
plastin time (APTT) and adjusted to maintain the anticoagulant
effect within a deﬁned therapeutic range. For intravenous heparin
therapy to achieve its minimal anticoagulant effect, the initial dos-
ing needs to be either weight based (80 units/kg then 18 units/
kg/hour) or a ﬁxed dose using a 5000 unit bolus followed by at
least 1250 units/hour (Kearon 2012). Laboratory monitoring is
necessary because the anticoagulant response to heparin is highly
variable among people with VTE. Inadequate heparin dosing is
related to an increased risk of VTE recurrence (Turpie 2002).
Why it is important to do this review
A number of LMWH preparations and heparinoids have been de-
veloped for clinical use. Compared with UFH, LMWH prepara-
tions have a longer plasma half-life, less inter-individual variability
in anticoagulant response to ﬁxed doses and, in animal models,
a more favourable antithrombotic to haemorrhagic ratio (Hirsh
1990; Hirsh 1992). As a result of their pharmacokinetic proper-
ties, a stable and sustained anticoagulant effect is achieved when
LMWHs are administered subcutaneously once or twice daily,
without laboratory monitoring. Although most experience with
LMWHs has been in the prevention of VTE, where they have
been shown to be safe and effective (Nurmohamed 1992), there
is accumulating evidence that these anticoagulants are also safe
and effective for the initial treatment of venous thromboembolic
events. This is the third update of the Cochrane Review ﬁrst pub-
lished in 1999.
O B J E C T I V E S
To evaluate the efﬁcacy and safety of ﬁxed dose subcutaneous low
molecular weight heparin compared to adjusted dose unfraction-
ated heparin (intravenous or subcutaneous) for the initial treat-
ment of people with venous thromboembolism (acute deep ve-
nous thrombosis or pulmonary embolism).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled clinical trials (RCTs) with prospective fol-
low-up.
Types of participants
People with venous thromboembolism (acute deep venous throm-
bosis or pulmonary embolism) conﬁrmed by objective tests.
Types of interventions
Initial treatment (usually in the ﬁrst ﬁve to 14 days) with ﬁxed
dose subcutaneous low molecular weight heparin (LMWH) and
adjusted dose unfractionated heparin (UFH) (intravenous or sub-
cutaneous).
Types of outcome measures
Primary outcomes
• Incidence of symptomatic recurrent venous
thromboembolism (deep venous thrombosis or pulmonary
embolism) during the initial treatment and during follow-up.
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Secondary outcomes
• Number of participants in whom the thrombus size
reduced based on pre- and post-treatment venograms.
• Frequency of major haemorrhagic episodes during initial
treatment or within 48 hours after treatment cessation.
• Overall mortality at the end of follow-up.
Search methods for identification of studies
There were no language restrictions.
Electronic searches
For this update the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials.
• The Cochrane Vascular Specialised Register (searched 15
September 2016).
• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 8) in the Cochrane Library (searched
15 September 2016).
See Appendix 1 for details of the search strategy used to search
CENTRAL.
The Cochrane Vascular Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINEOvid, EmbaseOvid, CINAHL, AMED, and through hand-
searching relevant journals. The full list of the databases, journals
and conference proceedings which have been searched, as well as
the search strategies, used are described in the Specialised Register
section of the Cochrane Vascular module in the Cochrane Library
(www.cochranelibrary.com).
The CIS searched the following trial registries for details of ongo-
ing and unpublished studies.
• ClinicalTrials.gov (www.ClinicalTrials.gov).
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch).
• ISRCTN Register (www.isrctn.com/).
Searching other resources
We also reviewed the reference lists of relevant papers identiﬁed
from these searches.
Data collection and analysis
Selection of studies
For this 2016 update, two review authors (LR and LJ) indepen-
dently assessed studies identiﬁed by the searches for eligibility. Any
disagreements were resolved by discussion.
Studies were excluded if:
(1) they were dose-ranging studies using higher doses of LMWH
than are currently in use;
(2) they used LMWH intravenously;
(3) they adjusted LMWH dosages after initiation of treatment;
(4) the difference in initial treatment was confounded by differ-
ences in concomitant medication or long-term medication;
(5) a true LMWH was not used (by true LMWH we mean that
no compounds other than heparins were present);
(6) the administration ofUFHwas suboptimal (i.e. not an adjusted
dose);
(7) the report was an abstract with incomplete data.
Data extraction and management
Data were extracted by two review authors (LR and LJ) and in-
cluded route of administration, intensity of heparin therapy, in-
tensity of oral anticoagulant therapy and the performance of in-
dependent assessment of study outcomes.
In addition, the following data were extracted.
(1) The incidence of symptomatic recurrent DVT and PE during
the initial treatment and during follow-up (if active follow-up was
conducted prospectively at the study centres); whether this inci-
dence was assessed by persons unaware of treatment assignment;
and if valid criteria were used for the diagnosis of recurrent VTE.
The diagnosis of recurrent DVT was accepted if one of the fol-
lowing criteria was met.
(a) A new, constant intraluminal ﬁlling defect not present on the
last available venogram.
(b) If the venogram was not diagnostic, either an abnormal 125I-
ﬁbrinogen leg scan or abnormal impedance plethysmogram or
ultrasound result, which had been normal before the suspected
recurrent episode (Buller 1991).
The diagnosis of PE was accepted if one of the following criteria
was met.
(a) A segmental defect on the perfusion lung scan that was un-
matched on the ventilation scan or chest roentgenogram.
(b) Positive pulmonary angiography.
(c) Pulmonary embolism at autopsy.
(2) The number of participants in each group with an improved
venographic score, if pre- and post-treatment venograms were ob-
tained and were assessed by persons unaware of treatment assign-
ment.
(3) The frequency of major haemorrhagic episodes during initial
treatment. Haemorrhages were classiﬁed as major if they were in-
tracranial, retroperitoneal, led directly to death, necessitated trans-
fusion or they led to the interruption of antithrombotic treatment
or (re)operation. All other haemorrhages were classiﬁed as minor.
(4) The overall mortality at the end of follow-up, speciﬁed for
participants with or without malignant disease, if active follow-up
was prospectively conducted at the study centres.
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Assessment of risk of bias in included studies
The risk of bias for all newly included studies was assessed by two
review authors (LR andLJ) according to the guidelines given in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a). The following domains were assessed as being at either a
low risk of bias, high risk of bias or unclear risk of bias using the
criteria as described in Chapter 8.5 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b).
1. Sequence generation: was the allocation sequence
adequately generated?
2. Allocation treatment: was allocation adequately concealed?
3. Blinding: was knowledge of the allocated interventions
adequately prevented during the study?
4. Incomplete data: were incomplete outcome data adequately
addressed?
5. Selective outcome reporting: were reports of the study free
of suggestion of selective outcome reporting?
6. Other potential threats to validity: was the study apparently
free of other factors that could put it at risk of bias?
We resolved disagreements by discussion and consensus.
Measures of treatment effect
We based reduction in thrombus size on the number of partici-
pants whose thrombus size reduced between pre- and post-treat-
ment venograms. We used this outcome and each of the other di-
chotomous outcomes for the different treatments to calculate an
odds ratio (OR) with 95% conﬁdence intervals (CI) separately for
each trial. We then combined these ORs across studies, giving due
weight to the number of events in each of the two treatment groups
in each separate study using the Peto procedure, which assumes
a ﬁxed treatment effect (Collins 1987; Mantel 1959). We inves-
tigated pulmonary vascular obstruction by calculating the mean
difference (MD) between the groups.
We performed all these analyses with the individual LMWH
preparations for VTE (that is DVT and PE combined).
We performed an analysis for all LMWHpreparations combined if
the treatment effects of the individual LMWH preparations were
compatible with each other, in view of the biochemical hetero-
geneity as well as the heterogeneity in animal experiments.
We addressed the validity of combining the trials with a statistical
test of homogeneity, which considers whether differences in treat-
ment effect over the individual trials are consistent with natural
variation around a constant effect (Collins 1987).
Unit of analysis issues
The unit of analysis in this review was the individual participant.
Dealing with missing data
We sought information about drop-outs, withdrawals and other
missing data and, if not reported, we contacted study authors for
this information but did not get a response.
Assessment of heterogeneity
We assessed heterogeneity between the trials by visual examination
of the forest plot to check for overlapping CIs, the Chi² test for
homogeneity with a 10% level of signiﬁcance and we used the
I² statistic to measure the degree of inconsistency between the
studies. An I² result of greater than 50% may represent moderate
to substantial heterogeneity (Deeks 2011).
Assessment of reporting biases
We assessed publication bias by funnel plots if a sufﬁcient number
of studies (10 or more) were available in the meta-analyses. There
are many reasons for funnel plot asymmetry, and we consulted the
Cochrane Handbook for Systematic Reviews of Interventions to aid
the interpretation of the results (Sterne 2011).
Data synthesis
One review author (LR) entered the data into Review Manager 5
(RevMan 2014), and the second review author (LJ) cross-checked
data entry.We resolved any discrepancies by consulting the source
publication.We used a ﬁxed-effectmodel tometa-analyse the data.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analysis for the different heparin drugs
versus unfractionated heparin for all the primary and secondary
outcomes of the review.
We also performed the following additional analyses by different
groups of interest.
• Proximal deep vein thrombosis.
• Pulmonary embolism.
• Venous thromboembolism with or without malignant
disease.
• Subcutaneous UFH versus LMWH.
• Intravenous UFH versus LMWH.
For these additional analyses, for the outcome ’recurrent VTE’ we
report the time point ’end of follow-up’ data only.
We also performed a separate analysis to explore any trend over
time.
Sensitivity analysis
We performed sensitivity analyses by excluding studies with inad-
equate concealment of allocation prior to randomisation.
We also performed a sensitivity analysis by excluding studies that
did not use the following International Society on Thrombosis
and Haemostasis (ISTH) criteria of major bleeding (Schulman
2005).
• Fatal bleeding.
• Symptomatic bleeding in a critical area or organ, such as
intracranial, intraspinal, intraocular, retroperitoneal, intra-
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articular or pericardial, or intramuscular with compartment
syndrome.
• Bleeding causing a fall in haemoglobin level of 20 g/L (1.24
mmol/L) or more, or leading to transfusion of two or more units
of whole blood or red cells.
• Any combination of the above.
Summary of findings
We created ’Summary of ﬁndings’ tables for LMWH compared
with UFH in participants with VTE (Summary of ﬁndings for
the main comparison). We used GRADEpro GDT software and
the GRADE approach to assess the quality of the evidence for the
most clinically relevant outcomes as described inTypes of outcome
measures. We downgraded the evidence from ’high quality’ for
serious or very serious study limitations (risk of bias, indirectness
and inconsistency of evidence, imprecision of effect estimates or
potential publication bias) according to the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a) and the
GRADE Working Group (GRADE Working Group 2008).
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Six additional studies were included in this update (Kakkar 2003;
Leizorovicz 2011; Meyer 1995; Moreno-Palomares 2001; Pérez
de Llano 2003; Thery 1992). In total, 29 studies were truly ran-
domised trials, published between 1988 and the end of 2011, with
a total of 10,390 participants. Fourteen of the 29 studies included
participants with symptomatic deep venous thrombosis of the leg
without symptoms of pulmonary embolism. In eight of these 14
studies people with distal deep venous thrombosis were included
as well as people with proximal deep venous thrombosis. In nine
studies participants were included if they had symptomatic deep
venous thrombosis of the leg, with or without symptomatic pul-
monary embolism; or asymptomatic deep venous thrombosis of
the leg with symptomatic pulmonary embolism; or symptomatic
deep venous thrombosis or pulmonary embolism. In four studies
participants with pulmonary embolism only were included. All
studies used objective diagnostic tests to conﬁrm the diagnosis.
All of the included studies considered ﬁxed dose subcuta-
neous LMWH once daily (Fiessinger 1996; Hull 1992; Kakkar
2003; Leizorovicz 2011; Lindmarker 1994; Luomanmaki 1996;
Simonneau 1997), twice daily (Belcaro 1999; Breddin 2001;
Columbus 1997; Decousus 1998; Faivre 1988; Findik 2002;
Goldhaber 1998; Harenberg 2000a; Kirchmaier 1998; Koopman
1996; Levine 1996; Lopaciuk 1992; Meyer 1995; Ninet 1991;
Pérez de Llano 2003; Prandoni 1992; Prandoni 2004; Riess
2003; Simonneau 1993; Thery 1992), or both (Merli 2001;
Moreno-Palomares 2001) compared with adjusted intravenous
dose UFH (Breddin 2001; Columbus 1997; Decousus 1998;
Fiessinger 1996; Findik 2002;Goldhaber 1998;Harenberg 2000a;
Hull 1992; Kakkar 2003; Kirchmaier 1998; Koopman 1996;
Levine 1996; Lindmarker 1994; Luomanmaki 1996; Merli 2001;
Meyer 1995; Moreno-Palomares 2001; Ninet 1991; Pérez de
Llano 2003; Prandoni 1992; Simonneau 1993; Simonneau 1997;
Thery 1992) or subcutaneous unfractionated heparin (Faivre
1988; Lopaciuk 1992; Prandoni 2004) or both (Belcaro 1999;
Leizorovicz 2011). Nine different preparations of LMWH were
identiﬁed (nadroparin, tinzaparin, enoxaparin, dalteparin, CY
222, certoparin, ardeparin, reviparin and bemiparin). Ten trials
did not have any post-randomisation exclusions or losses to fol-
low-up. Eleven trials reported the number of participants lost to
follow-up, which ranged from 1.0% to 12.7%. One trial did not
report the dropouts (see Characteristics of included studies).
Excluded studies
Five additional studieswere excluded for this update (Quiros 2001;
Riess 2014; Siguret 2011; Stricker 1999; Ucar 2015). A total
of 26 trials were excluded for the following reasons: dosage of
UFH was not adjusted (four trials: Kearon 2006; Notarbartolo
1988; Tedoldi 1993; Zanghi 1988); dose-ranging study (three
trials: Banga 1993; de Valk 1995; Handeland 1990); LMWH
dosage was adjusted (four trials: Aiach 1989; Bratt 1990; Holm
1986; Ly 1985); intravenous administration of LMWH (four tri-
als: Bratt 1985; Lockner 1985; Lockner 1986; Vogel 1987); results
from participants treated for venous thrombosis of the upper limb
and for pulmonary embolism could not be distinguished from
those of participants with leg vein thrombosis and the outcome
was incompletely evaluated (four trials: Albada 1989; Harenberg
1989; Harenberg 1990; Harenberg 2000b); a difference in long-
term treatment between the two treatment regimens (two tri-
als: Monreal 1993; Monreal 1994); no UFH comparison group
(Siguret 2011); one study looked at the effect of heparin onhaemo-
static markers and therefore the outcomes were not relevant for
this review (Stricker 1999); a substudy of a study already included
in the original review (Riess 2003); not an RCT (Quiros 2001);
and treatment with thrombolytic therapy (Ucar 2015).
One ongoing study has been identiﬁed (NCT00796692). See
Characteristics of ongoing studies.
Risk of bias in included studies
See Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
12Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Thirteen of the 29 included studies adequately described random
sequence generation through the use of a computer or telephone
system (Columbus 1997; Decousus 1998; Goldhaber 1998; Hull
1992; Koopman 1996; Leizorovicz 2011; Luomanmaki 1996;
Merli 2001; Pérez de Llano 2003; Prandoni 1992; Prandoni
2004; Simonneau 1993; Simonneau 1997). In the remaining 16
studies, there was insufﬁcient information about the random se-
quence generation to permit a judgement of selection bias. In four-
teen of the 29 included studies the assigned treatment was ade-
quately concealed prior to allocation (Columbus 1997; Decousus
1998; Goldhaber 1998; Hull 1992; Kirchmaier 1998; Koopman
1996; Levine 1996; Lopaciuk 1992; Merli 2001; Prandoni 1992;
Prandoni 2004; Riess 2003; Simonneau 1993; Simonneau 1997),
while in the other 14 trials concealment of allocation was unclear,
based on the information given in the publication. One study was
deemed to be at high risk of selection bias as there was no central
allocation (Luomanmaki 1996). Instead, randomisation was con-
ducted separately at each participating centre (see Characteristics
of included studies).
Blinding
In two of the studies, authors did not state whether the participants
and staff were blinded to the treatment or not and therefore the risk
of performance bias for these two studies was unclear (Harenberg
2000a; Moreno-Palomares 2001). In the remaining 27 included
studies treatment allocation was not blinded due to the difference
in route of administration between subcutaneous LMWH and
intravenous UFH. However, given the clinical outcomes of the
study, we judged that the non-blinding of the participants and
staff was unlikely to have affected the outcomes and therefore
we judged these studies to be at low risk of bias. Even the three
studies of subcutaneous UFH versus subcutaneous LMWH were
not blinded for treatment allocation due to an initial intravenous
bolus in the UFH group (Faivre 1988; Lopaciuk 1992; Prandoni
2004). There was only one double-blinded clinical trial in which
participants received either intravenous UFH with subcutaneous
placebo or subcutaneous LMWH with intravenous placebo (Hull
1992).
Four of the 29 included studies did not report whether outcome
assessors were blinded to treatment and were therefore judged to
be at an unclear risk of detection bias (Findik 2002; Goldhaber
1998; Moreno-Palomares 2001; Pérez de Llano 2003). In the re-
maining 25 studies, outcome assessors were blinded to treatment
and therefore these studies were judged to be at low risk of detec-
tion bias.
Incomplete outcome data
Six studies were judged to be at high risk of attrition bias as data
were missing or imbalanced across the groups (Breddin 2001;
Fiessinger 1996; Kakkar 2003; Lindmarker 1994; Ninet 1991;
Thery 1992); 18 were judged to be at low risk (Belcaro 1999;
Columbus 1997; Decousus 1998; Harenberg 2000a; Hull 1992;
Koopman 1996; Leizorovicz 2011; Levine 1996; Lopaciuk 1992;
Luomanmaki 1996; Merli 2001; Meyer 1995; Pérez de Llano
2003; Prandoni 1992; Prandoni 2004; Riess 2003; Simonneau
1993; Simonneau 1997); while ﬁve did not provide enough in-
formation to permit a judgement (Faivre 1988; Findik 2002;
Goldhaber 1998; Kirchmaier 1998; Moreno-Palomares 2001).
Selective reporting
Two studies were judged to be at high risk of reporting bias
(Lindmarker 1994; Pérez de Llano 2003). In the study by
Lindmarker 1994, participants who had died or had a VTE were
not included in the analysis. In the study by Pérez de Llano 2003,
length of stay was not a prespeciﬁed outcome but authors reported
data on it in the discussion. Twenty-two studies were at low risk
while the remaining ﬁve did not provide enough information to
permit judgement on reporting bias (Faivre 1988; Fiessinger 1996;
Lopaciuk 1992; Moreno-Palomares 2001; Prandoni 1992).
Other potential sources of bias
Five studies were judged to be at high risk of bias (Findik 2002;
Harenberg 2000a; Kakkar 2003; Lopaciuk 1992; Luomanmaki
1996). Two studies were sponsored by the pharmaceutical com-
panies that provided the study drug (Harenberg 2000a; Kakkar
2003). The study by Findik 2002 had a low statistical power due
to low numbers of participants and few outcome events. Lopaciuk
1992 had an imbalance in exclusion of participants at baseline
while the study by Luomanmaki 1996 had a higher incidence
of malignancy in participants treated with UFH. Twenty stud-
ies were judged to be free from other sources of bias; while in
the remaining four, there was not enough information to per-
mit judgement (Decousus 1998; Faivre 1988; Leizorovicz 2011;
Moreno-Palomares 2001).
Effects of interventions
See: Summary of findings for the main comparison
LMWH compared to UFH for initial treatment of venous
thromboembolism
None of the trials individually demonstrated protection from re-
current symptomatic venous thromboembolic complications dur-
ing the initial treatment period. One trial showed that LMWH
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conferred protection from recurrent symptomatic venous throm-
boembolic complications at the end of follow-up (Breddin 2001).
Only Hull 1992 demonstrated a reduction in major haemor-
rhage after treatment with LMWH. Six studies showed a reduc-
tion in thrombus size, between pre-treatment and post-treatment
venograms, in favour of LMWH(Breddin 2001;Goldhaber 1998;
Kakkar 2003; Lopaciuk 1992; Prandoni 1992; Simonneau 1993).
Incidence of symptomatic recurrent venous
thromboembolism (Analysis 1.1 to Analysis 1.5)
(’Summary of findings’ table 1)
The occurrence of symptomatic recurrent venous thromboem-
bolism was evaluated during the initial treatment period (
Columbus 1997; Decousus 1998; Fiessinger 1996; Findik 2002;
Harenberg 2000a; Kakkar 2003; Kirchmaier 1998; Koopman
1996; Levine 1996; Lindmarker 1994; Lopaciuk 1992; Meyer
1995; Ninet 1991; Pérez de Llano 2003; Prandoni 1992; Riess
2003; Simonneau 1993; Simonneau 1997; Thery 1992); at one
month’s follow-up (Columbus 1997; Levine 1996; Pérez de
Llano 2003; Prandoni 1992); at three months’ follow-up (Belcaro
1999; Breddin 2001; Columbus 1997; Decousus 1998; Findik
2002; Hull 1992; Koopman 1996; Levine 1996; Lopaciuk 1992;
Merli 2001; Meyer 1995; Moreno-Palomares 2001; Pérez de
Llano 2003; Prandoni 1992; Prandoni 2004; Simonneau 1993;
Simonneau 1997); and at six months’ follow-up (Harenberg
2000a; Kirchmaier 1998; Koopman 1996; Lindmarker 1994;
Pérez de Llano 2003; Prandoni 1992; Riess 2003). Combining
all trials with long-term follow-up gave a comparison of recurrent
thromboembolism at the end of follow-up. AlthoughKakkar 2003
reported incidence of recurrent VTE, there was a query regarding
the exact number of participants reported to have this outcome.
The author was contacted to clarify the data but did not respond
and therefore this study was not included in the analysis.
Analysis of the pooled data from these studies demonstrated a re-
duction in recurrent venous thromboembolic events with LMWH
during the initial treatment period (Peto OR 0.69, 95% CI 0.49
to 0.98; moderate-quality evidence; participants = 6238; studies
= 18; P = 0.04); at the end of follow-up (Peto OR 0.72, 95% CI
0.59 to 0.88; participants = 9489; studies = 22; P = 0.0005), at
three months’ follow-up (Peto OR 0.71, 95% CI 0.56 to 0.90;
moderate-quality evidence; participants = 6661; studies = 16; P =
0.005); and at six months’ follow-up (Peto OR 0.68, 95%CI 0.48
to 0.96; participants = 2841; studies = 7; P = 0.03). However, at
one month’s follow-up, no difference was found between LMWH
and UFH (Peto OR 0.90, 95% CI 0.56 to 1.44; participants =
1741; studies = 4; P = 0.65).
During the initial treatment, 54 (1.7%) of the 3123 participants
allocated to LMWH had thrombotic complications versus 76
(2.4%) of the 3115 participants allocated to UFH. After a follow-
up of three months, the period in most of the studies for which
oral anticoagulant therapy was given, 122 (3.5%) of the 3440 par-
ticipants treated with LMWH had a recurrent thrombotic event
versus 164 (5.2%) of the 3221 participants treated with UFH.
When different preparations of heparin were compared, a reduc-
tion in recurrent VTE was noted during the initial treatment pe-
riod for enoxaparin (Peto OR 0.51, 95% CI 0.27 to 0.98; partic-
ipants = 1143; studies = 5; P = 0.04) and at the end of follow-up
for certoparin (Peto OR 0.63, 95% CI 0.40 to 0.99; participants
= 2007; 3 studies; P = 0.05) versus UFH. Overall, no differences
were observed between the heparin preparations during the initial
treatment period and at the end of follow-up.
Reduction in thrombus size (Analysis 1.6)
Venograms were obtained before and after heparin treatment
in 16 studies (Breddin 2001; Faivre 1988; Fiessinger 1996;
Goldhaber 1998; Harenberg 2000a; Kakkar 2003; Kirchmaier
1998; Lindmarker 1994; Lopaciuk 1992; Luomanmaki 1996;
Meyer 1995; Moreno-Palomares 2001; Ninet 1991; Prandoni
1992; Simonneau 1993; Thery 1992). In all studies these
venograms were adjudicated by investigators unaware of treatment
allocation. The combined results of the 16 studies demonstrated a
reduction of thrombus size in 51% of the participants (741 out of
1467) treated with LMWH and in 42% of participants (610 out
of 1442) treated with UFH. LMWHwas associated with a reduc-
tion in thrombus size compared with UFH (Peto OR 0.71, 95%
CI 0.61 to 0.82; moderate-quality evidence; participants = 2909;
studies = 16; P < 0.00001). However there was moderate hetero-
geneity in this analysis (I² = 56%). When we performed analysis
by studies reporting on DVT, the heterogeneity was reduced (I² =
34%) (Analysis 2.4). See also below.
Subgroup analysis showed adifference between the LMWHprepa-
rations (P = 0.004). Of the individual LMWH preparations, a
better venographic outcome was observed for ardeparin (Peto OR
0.37, 95% CI 0.14 to 0.99), enoxaparin (Peto OR 0.34, 95% CI
0.17 to 0.71), reviparin (Peto OR 0.59, 95% CI 0.43 to 0.80),
certoparin (Peto OR 0.70, 95% CI 0.50 to 0.98) and bemiparin
(Peto OR 0.42, 95% CI 0.24 to 0.74).
Incidence of major haemorrhage during the initial
treatment (Analysis 1.7)
Twenty-ﬁve of the included trials evaluated the occurrence of
major haemorrhage during the initial treatment (Belcaro 1999;
Columbus 1997; Decousus 1998; Faivre 1988; Fiessinger 1996;
Findik 2002; Harenberg 2000a; Hull 1992; Kakkar 2003;
Kirchmaier 1998; Koopman 1996; Leizorovicz 2011; Levine
1996; Lindmarker 1994; Lopaciuk 1992; Luomanmaki 1996;
Meyer 1995; Ninet 1991; Pérez de Llano 2003; Prandoni 1992;
Prandoni 2004; Riess 2003; Simonneau 1993; Simonneau 1997;
Thery 1992). Analysis of the pooled data showed a reduction in
major haemorrhagic complications in favour of LMWH (Peto
OR 0.69, 95% CI 0.50 to 0.95; participants = 8780; studies =
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25; moderate-quality evidence; P = 0.02). At the end of the ini-
tial treatment period, 65 (1.5%) of the 4333 participants in the
LMWH group versus 94 (2.1%) of the 4447 participants in the
UFH group suffered a major haemorrhage.
Subgroup analysis showed no difference between the LMWH
preparations (P = 0.10).
Overall mortality at the end of follow-up (Analysis
1.8)
Twenty-four studies prospectively evaluated the overall mortal-
ity at the end of follow-up (Breddin 2001; Columbus 1997;
Decousus 1998; Findik 2002;Goldhaber 1998;Harenberg 2000a;
Hull 1992; Kakkar 2003; Kirchmaier 1998; Koopman 1996;
Leizorovicz 2011; Levine 1996; Lindmarker 1994; Lopaciuk
1992; Luomanmaki 1996; Merli 2001; Meyer 1995; Pérez
de Llano 2003; Prandoni 1992; Prandoni 2004; Riess 2003;
Simonneau 1993; Simonneau 1997; Thery 1992). There was no
difference in overall mortality at the end of follow-up between
participants treated with LMWH and UFH (Peto OR 0.84, 95%
CI 0.70 to 1.01; moderate-quality evidence; participants = 9663;
studies = 24; P = 0.07). In the LMWH group, 234 (4.7%) of the
5004 participants died versus 265 (5.7%) of the 4659 participants
in the UFH group.
When analysed by LMWH preparation, certoparin was the only
drug found to be associated with a reduction in overall mortality
at the end of follow-up (Peto OR 0.59, 95% CI 0.36 to 0.97; P =
0.04). Overall, no differences were observed between the heparin
preparations in mortality at the end of follow-up.
Analysis in participants with proximal deep venous
thrombosis (Analysis 2.1 to Analysis 2.6)
A total of 4878 participants with proximal deep venous throm-
bosis were enrolled in eleven studies (Belcaro 1999; Breddin
2001; Harenberg 2000a; Hull 1992; Kakkar 2003; Koopman
1996; Levine 1996; Moreno-Palomares 2001; Prandoni 1992;
Riess 2003; Simonneau 1993). Seven preparations of LMWH
were used: nadroparin (three trials, 864 participants), dalteparin
(one trial, 30 participants), tinzaparin (one trial, 432 participants),
enoxaparin (two trials, 634 participants), reviparin (one trial, 763
participants), certoparin (two trials, 1758 participants) and be-
miparin (one trial, 397 participants). In the three-armed trial by
Kakkar 2003 two bemiparin groups were compared with an UFH
control group. However, in one of the bemiparin groups, partic-
ipants did not receive concomitant VKA therapy. All other stud-
ies included in this review used concomitant VKA therapy and
in order for our results to be comparable, data for this group of
participants in the Kakkar 2003 study was not included in the
analysis.
At the end of follow-up, 80 (3.5%) of the 2303 participants treated
with LMWH had a symptomatic recurrent venous thromboem-
bolic event versus 143 (6.0%) of the 2369 participants treated
with UFH. This reduction was in favour of LMWH (Peto OR
0.57, 95% CI 0.44 to 0.75; participants = 4672; studies = 10;
P < 0.0001) (Analysis 2.1). When analysed by LMWH prepara-
tion, reviparin was the only drug associated with a reduction in
recurrent VTE (Peto OR 0.31, 95% CI 0.15 to 0.63). Overall,
no differences were observed between the heparin preparations in
symptomatic recurrent venous thromboembolism at the end of
follow-up.
LMWH was also associated with a reduction in the incidence
of symptomatic, recurrent deep venous thrombosis as well as a
reduction in the incidence of pulmonary embolism (respectively
PetoOR0.61, 95%CI 0.41 to 0.91; participants = 2681; studies =
7; P = 0.02; and Peto OR 0.45, 95% CI 0.28 to 0.74; participants
= 3024; studies = 7; P = 0.002) (Analysis 2.2; Analysis 2.3). When
analysed by type of LMWH preparation, reviparin and certoparin
were the only drugs associated with a reduction in the incidence
of pulmonary embolism (respectively PetoOR 0.27, 95%CI 0.10
to 0.73; and Peto OR 0.32, 95% CI 0.11 to 0.92). Overall, no
differences were observed between the heparin preparations in
symptomatic recurrent deep venous thrombosis and pulmonary
embolism at the end of follow-up.
Pooled analysis of two studies demonstrated a reduction of
thrombus size in 73% of the participants treated with LMWH
and in 56% of participants treated with UFH (Kakkar 2003;
Moreno-Palomares 2001). LMWH was associated with a better
venographic outcome - Peto OR 0.47, 95% CI 0.27 to 0.80; par-
ticipants = 230; studies = 2; P = 0.006 (Analysis 2.4) - with the
result heavily inﬂuenced by the Kakkar 2003 study on bemiparin
showing a reduction in thrombus size with LMWH (Peto OR
0.42, 95% CI 0.24 to 0.74; participants = 203; studies = 1; P =
0.003) compared with UFH.
Analysis of the pooled data showed a reduction in major haemor-
rhagic complications in favour of LMWH (PetoOR0.50, 95%CI
0.29 to 0.85; participants = 3589; studies = 8; P = 0.01) (Analysis
2.5). At the end of the initial treatment period, 18 (1.0%) of the
1804 participants in the LMWH group versus 37 (2.1%) of the
1785 participants in the UFH group suffered a major haemor-
rhage. Tinzaparin was the only LMWH preparation associated
with reduced rates ofmajor haemorrhagic complications (PetoOR
0.19, 95% CI 0.06 to 0.59). Overall, no differences were observed
between the heparin preparations in incidence of major haemor-
rhages during initial treatment.
Overall mortality at the end of follow-up demonstrated a reduc-
tion in favour of LMWH (Peto OR 0.63, 95% CI 0.47 to 0.85;
participants = 4331; studies = 9; P = 0.002) (Analysis 2.6). In the
LMWHgroup, 72 (3.3%) of the 2183participants died versus 112
(5.2%) of the 2148 participants in the UFH group. Certorparin
was the only LMWH preparation associated with a reduction in
overall mortality (Peto OR 0.54, 95% CI 0.30 to 0.96). Overall,
no differences were observed between the heparin preparations in
overall mortality at the end of follow-up.
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Analysis in participants with pulmonary embolism
(Analysis 3.1)
A total of 1407 participants with pulmonary embolism were en-
rolled in seven studies (Columbus 1997; Findik 2002;Merli 2001;
Meyer 1995; Pérez de Llano 2003; Simonneau 1997;Thery 1992).
Four preparations of LMWH were used: tinzaparin (one trial,
612 participants), enoxaparin (three trials, 396 participants), dal-
teparin (two trials, 128 participants), and reviparin (one trial, 271
participants). In the study by Thery 1992, two other treatment
groups were given a high dose of nadroparin (600 and 900 anti-
factor Xa IU/kg). Data from these groups were not included in
the analysis in this review.
All seven studies measured the rate of recurrent thromboembolic
events at the end of follow-up. Analysis of pooled data showed no
difference between participants treated with LMWH and UFH
(Peto OR 0.90, 95% CI 0.50 to 1.61; participants = 1407; studies
= 7; P = 0.73) (Analysis 3.1). No individual LMWH preparation
was associated with a reduction in the rate of recurrent VTE.
Two studies measured change in thrombus size (Meyer 1995;
Thery 1992). Pooled analysis showed no difference in the number
of LMWH and UFH participants whose thrombus size improved
(Peto OR 1.36, 95% CI 0.23 to 8.16; participants = 106; studies
= 2; P = 0.74) (Analysis 3.2). Both studies also measured change
in thrombus size according to improvement in the Miller (Thery
1992) or peripheral vascular obstruction score (PVOS) (Meyer
1995). Pooled analysis showed an improvement (MD−3.14, 95%
CI−4.39 to−1.90; participants = 106; studies = 2; P < 0.00001)
(Analysis 3.3). No individual LMWH preparation was associated
with a change in thrombus size.
Three studiesmeasured the incidence ofmajor haemorrhagic com-
plications during initial treatment or within 48 hours after treat-
ment cessation (Meyer 1995; Pérez de Llano 2003; Thery 1992).
Pooled analysis showed no difference in the incidence of major
bleeding between the LMWH and UFH groups (Peto OR 0.44,
95% CI 0.04 to 4.29; participants = 178; studies = 3; P = 0.48)
(Analysis 3.4). However there was signiﬁcant heterogeneity in this
analysis (I² = 58%). No individual LMWH preparation was asso-
ciated with a reduction in the rate of major haemorrhagic compli-
cations.
Three studies measured overall mortality (Meyer 1995; Pérez de
Llano 2003; Thery 1992). We found no difference in the overall
mortality incidence between the LMWH and UFH groups (Peto
OR 1.70, 95% CI 0.17 to 16.71; participants = 178; studies = 3;
P = 0.65) (Analysis 3.5). No individual LMWH preparation was
associated with reduced overall mortality.
Analysis in participants with venous
thromboembolism with or without malignant disease
(Analysis 4.1 to Analysis 5.1)
Six studies evaluated mortality at the end of follow-up in par-
ticipants with and without malignant disease (Columbus 1997;
Hull 1992; Lindmarker 1994; Lopaciuk 1992; Prandoni 1992;
Simonneau 1997). One of these studies individually showed a re-
duction in deaths at the end of follow-up with LMWH (Peto OR
0.16, 95% CI 0.03 to 0.72; P = 0.02) (Prandoni 1992). Combin-
ing the six studies also demonstrated a reduction in overall mor-
tality in participants with cancer who were treated with LMWH
(Peto OR 0.53, 95% CI 0.33 to 0.85; participants = 446; P =
0.009) (Analysis 4.1). In participants without cancer who received
LMWH, the reduction in overall mortality of approximately 1%
was not different between LMWH andUFH (PetoOR0.97, 95%
CI 0.61 to 1.56; participants = 2139; P = 0.91) (Analysis 5.1).
Data on recurrent VTE, reduction in thrombus size and major
haemorrhage during initial treatment were not available for the
group of participants with or without malignant disease.
Analysis of studies of subcutaneous UFH versus
LMWH (Analysis 6.1; Analysis 6.2; Analysis 6.3)
In four studies the UFH in the control group was administered
subcutaneously although they did not all report on all outcomes
(Faivre 1988; Leizorovicz 2011; Lopaciuk 1992; Prandoni 2004).
The analysis of the pooled data from these studies demonstrated
no reduction in recurrent venous thromboembolism at the end of
follow-up (Peto OR 1.05, 95% CI 0.56 to 1.95; participants =
1403; studies = 3; P = 0.88). However there was signiﬁcant het-
erogeneity (I² = 58%). There was no difference in the incidence of
major haemorrhagic complications (Peto OR 0.91, 95% CI 0.50
to 1.67; participants = 1471; studies = 4; P = 0.76), nor overall
mortality (Peto OR 1.46, 95% CI 0.91 to 2.35; participants =
1403; studies = 3; P = 0.12), between groups treated with subcu-
taneous UFH and LMWH.
Data on reduction in thrombus size were not available for the
group of participants who received subcutaneous UFH versus
LMWH.
Analysis of studies of intravenous UFH versus LMWH
(Analysis 7.1; Analysis 7.2; Analysis 7.3)
In the 21 studies which compared LMWHwith intravenous UFH
we found a reduction in recurrent venous thromboembolism at the
endof follow-up (PetoOR0.69, 95%CI0.56 to 0.86; participants
= 8375; studies = 21; P = 0.0007); in major haemorrhages (Peto
OR 0.62, 95% CI 0.43 to 0.90; participants = 7309; studies =
21; P = 0.01); and in overall mortality (Peto OR 0.77, 95% CI
0.63 to 0.93; participants = 8260; studies = 21; P = 0.008) (
Belcaro 1999; Breddin 2001; Columbus 1997; Decousus 1998;
Findik 2002; Goldhaber 1998; Harenberg 2000a; Hull 1992;
Kakkar 2003; Kirchmaier 1998; Koopman 1996; Levine 1996;
Lindmarker 1994;Merli 2001;Meyer 1995; Pérez de Llano 2003;
Prandoni 1992; Riess 2003; Simonneau 1993; Simonneau 1997;
Thery 1992).
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Data on reduction in thrombus size were not available for the
group of participants who received intravenous UFH versus
LMWH.
Sensitivity analysis of studies with adequate
concealment of allocation prior to randomisation
(Analysis 8.1 to Analysis 8.6)
Fourteen studies had clear concealment of allocation prior to
randomisation based on the information given in the publica-
tions (Columbus 1997; Decousus 1998; Goldhaber 1998; Hull
1992; Kirchmaier 1998; Koopman 1996; Levine 1996; Lopaciuk
1992; Merli 2001; Prandoni 1992; Prandoni 2004; Riess 2003;
Simonneau 1993; Simonneau 1997). The analysis of the pooled
data from these studies demonstrated no difference between
LMWH and UFH in recurrent venous thromboembolism during
the initial treatment period (Peto OR 0.72, 95% CI 0.50 to 1.05;
participants = 4862; studies = 10; P = 0.09) nor at three months
(Peto OR 0.79, 95% CI 0.60 to 1.02; participants = 5435; studies
= 11; P = 0.07). However, LMWH was associated with both a
reduction in the incidence of recurrent VTE at the end of follow-
up (Peto OR 0.76, 95% CI 0.60 to 0.96; participants = 6984;
studies = 14; P = 0.02) and overall mortality (Peto OR 0.80, 95%
CI 0.65 to 0.99; participants = 6984; studies = 14; P = 0.04).
Major haemorrhage (Peto OR 0.68, 95% CI 0.45 to 1.03; par-
ticipants = 6014; studies = 12; P = 0.07) was not different after
treatment with LMWH compared with UFH. The reduction in
the thrombus size, however, was in favour of LMWH (Peto OR
0.49, 95% CI 0.37 to 0.66; participants = 753; studies = 5; P <
0.00001). Therefore, while reductions in recurrent venous throm-
boembolism, major haemorrhages and overall mortality were ob-
served in the LMWH group compared with UFH when all stud-
ies were combined, in a sensitivity analysis of studies with ade-
quate concealment of treatment allocation before randomisation,
no differences were observed in the incidence of recurrent venous
thromboembolism during initial treatment and after threemonths
nor in the incidence of major haemorrhages between LMWH and
UFH.
Sensitivity analysis of studies that used the
International Society on Thrombosis and
Haemostasis (ISTH) definition of major and clinically
relevant bleeding (Analysis 9.1)
Only one study did not use the ISTH deﬁnition of major bleeding
and was excluded for the sensitivity analysis (Faivre 1988). Analy-
sis of the pooled data showed a reduction in major haemorrhagic
complications in favour of LMWH (Peto OR 0.71, 95% CI 0.52
to 0.98; participants = 8712; studies = 24; P = 0.04). These re-
sults are similar to the results from the analysis including all stud-
ies irrespective of their deﬁnition of major and clinically relevant
bleeding (Analysis 1.7).
Trends over time (Analysis 10.1 to Analysis 10.4)
In order to investigate the trend over time, we performed analyses
in which all studies were ordered by their date of publication. The
forest plots of these analyses did not show an obvious trend over
time.
D I S C U S S I O N
Summary of main results
Our review of lowmolecular weight heparin (LMWH) for the ini-
tial treatment of venous thromboembolism (VTE) includes more
than 9000 participants and indicates that this drug may be more
efﬁcacious than unfractionated heparin (UFH) for preventing re-
current VTE. Many of the included studies reported on other
advantages of LMWH over UFH. Firstly, the route of admin-
istration (subcutaneous once or twice daily) is more convenient
and increases the mobility of participants with VTE. Secondly,
the pharmacokinetics are more predictable, which abolishes the
need for laboratory monitoring and subsequent dose adjustments.
Hence, LMWH can be advocated as the standard therapy for peo-
ple with conﬁrmed VTE. Treatment in an outpatient setting has
been demonstrated to be feasible, safe and cost-effective for people
with DVT (Koopman 1996; Levine 1996; van den Belt 1998).
Analysis of all studies, regardless ofmethodological quality, showed
that LMWH was associated with a lower incidence of recurrent
VTE at the end of follow-up and at three and six months, with
95% CIs less than one (Peto OR 0.72, 95% CI 0.59 to 0.88,
Peto OR 0.71, 95% CI 0.56 to 0.90 and Peto OR 0.68, 95%
CI 0.48 to 0.96 respectively) but not after one month follow-up
(Peto OR 0.90, 95% CI 0.56 to 1.44). However, when sensitivity
analysis was performed on studies that concealed allocation of
treatment only, no differences were observed in the incidence of
recurrent venous thromboembolism during initial treatment and
after three months nor in the incidence of major haemorrhages
between LMWH and UFH. We therefore judge that the quality
of the evidence is moderate.
When we performed analyses according to the type of VTE index
event, the rate of recurrent VTE at the end of follow-up remained
lower in DVT participants treated with LMWH compared with
DVT participants treated with UFH (PetoOR 0.57, 95%CI 0.44
to 0.75). However, analysis in participants with PE showed no
difference in the rate of recurrent VTE between the two treatment
groups (Peto OR 0.90, 95% CI 0.50 to 1.61). When we per-
formed analyses according to mode of delivery of UFH, we found
that LMWH was associated with fewer recurrent VTEs than in-
travenous UFH (Peto OR 0.69, 95% CI 0.56 to 0.86) but that
there was no difference when LMWH was compared with subcu-
taneous UFH (Peto OR 1.05, 95% CI 0.56 to 1.95).
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The tendency to improved efﬁcacy with LMWH treatment was
not at the cost of a higher rate of major haemorrhage. On the
contrary, a reduction in major haemorrhage was demonstrated
during the initial treatment period with LMWH. This is largely
because the LMWHprovides amore stable level of anticoagulation
whereas unfractionated heparin dose adjustments may result in
more peaks and troughs of anticoagulant effect.
Overall completeness and applicability of
evidence
Although these results are promising, there are a number of unre-
solved issues. Firstly, since only approximately 25% of the partic-
ipants included in this critical review had a diagnosis of primary
pulmonary embolism, it can be argued thatmore data are required
before conclusions can be drawn in this population. Secondly, al-
though the combination of all preparations of LMWH seems log-
ical, and heterogeneity could not be identiﬁed, current data do
not discriminate between different LMWH preparations. A dif-
ference between LMWHpreparations was only found for one out-
come of the review, reduction in thrombus size. However, studies
with large sample sizes and which include comparisons of differ-
ent preparations are needed to determine whether the efﬁcacy and
safety of the individual LMWHs is actually comparable. Thirdly,
Prandoni and colleagues noted that the route of administration
might be relevant to heparin efﬁcacy (Prandoni 2004). When we
limited the analysis to studies that used intravenous UFK, similar
results as in the main analyses were observed. When the analysis
was conﬁned to those studies that used subcutaneous UFH we
found no difference in the incidence of recurrent VTE and major
haemorrhages. The lack of difference could be due to the smaller
groups in this analysis.
The protocol for this review was published in 1997 and the ﬁrst
version of the review was published in 1998. Initial treatment of
VTE has changed since then and, as a result, the current objective
of this review is no longer as clinically relevant as before. There-
fore, to reﬂect current practice, future updates of this review will
include studies on ﬁxed dose subcutaneous UFH. Additionally,
in accordance with current VTE trials on direct-acting oral anti-
coagulants, future updates will assess symptomatic PE and symp-
tomatic proximal DVT as the primary outcome. We will also as-
sess side effects of treatment other than bleeding as an additional
outcome.
Quality of the evidence
The quality of the evidence was downgraded to moderate due to
concerns arising from risk of bias in individual studies. One study
was at risk of selection bias (Luomanmaki 1996), six studies were at
risk of attrition bias (Breddin 2001; Fiessinger 1996; Kakkar 2003;
Lindmarker 1994; Ninet 1991; Thery 1992), two studies were at
risk of reporting bias (Lindmarker 1994; Pérez de Llano 2003),
and three studies were at risk for other types of bias including
baseline differences between the groups (Findik 2002; Lopaciuk
1992; Luomanmaki 1996). A further reason for downgrading the
evidence to moderate was that several studies did not adequately
report on the methods used to generate the random sequence nor
how treatment allocation was kept concealed.
While reductions in recurrent VTE and major haemorrhages were
observed in the LMWH group compared with UFH when all
studies were combined, in a sensitivity analysis of studies with
adequate concealment of treatment allocation before randomisa-
tion, no differences were observed in the incidence of recurrent
VTE during initial treatment and after three months nor in the
incidence of major haemorrhages between LMWH and UFH. An
explanation for these differences in effect size could be that the
overall reductions are possibly biased by including less adequately
performed studies without adequate concealment.
Where there were 10 or more studies in an analysis, we tested
for publication bias using funnel plots. We found a suggestion of
publication bias for three of the outcomes: incidence of recurrent
VTE during initial treatment (Analysis 1.1, Figure 3);incidence
of recurrent VTE at three months (Analysis 1.4, Figure 4); and
reduction in thrombus size (Analysis 1.6, Figure 5). However, we
felt it was insufﬁcient to downgrade for publication bias. For the
remaining outcomes, we found no evidence of publication bias
for the analyses we tested (Analysis 1.2; Analysis 1.7; Analysis
1.8; Analysis 2.1; Analysis 7.1; Analysis 7.2; Analysis 7.3; Analysis
8.1; Analysis 8.2; Analysis 8.3; Analysis 8.5; Analysis 8.6; Analysis
10.1; Analysis 10.2; Analysis 10.3; Analysis 10.4).
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Figure 3. Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism,
outcome: 1.1 Incidence of recurrent venous thromboembolism during initial treatment.
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Figure 4. Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism,
outcome: 1.4 Incidence of recurrent venous thromboembolism at 3 months’ follow-up.
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Figure 5. Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism,
outcome: 1.6 Reduction in thrombus size (pre- and post-treatment venograms).
Potential biases in the review process
Neither of the authors of this review was involved in any of the
included or excluded studies. Furthermore, neither has any com-
mercial or other conﬂict of interest. The search was as comprehen-
sive as possible; and the two review authors independently assessed
all studies for inclusion. We are conﬁdent that we have included
all relevant studies and we have attempted to reduce bias in the
review process by performing data extraction and assessing study
quality independently. However, the possibility remains that we
may have missed studies which have not been published.
The original review did not set out to use the ISTH bleeding
deﬁnition. However, given that this is now the standard accepted
deﬁnition for major bleeding, we performed a post hoc sensitivity
analysis for ISTH bleeding deﬁnitions in order to assess the ef-
fect of bleeding deﬁnitions used. The results from this sensitivity
analysis (Analysis 9.1) are similar to the results from the analysis
including all studies (Analysis 1.7) irrespective of their deﬁnition
of major and clinically relevant bleeding.
Agreements and disagreements with other
studies or reviews
One network meta-analysis of four studies compared three
LMWH preparations (tinzaparin, nadroparin and enoxaparin) in
terms of safety and efﬁcacy for the treatment of deep vein throm-
bosis (Diaz 2015). Authors found no evidence of differences be-
tween tinzaparin, nadroparin and enoxaparin for recurrence of
DVT and major bleeding.
A U T H O R S ’ C O N C L U S I O N S
21Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Implications for practice
This review presents moderate-quality evidence that ﬁxed dose
LMWH reduced the incidence of recurrent thrombotic compli-
cations and occurrence of major haemorrhage during initial treat-
ment and low-quality evidence that ﬁxed dose LMWH reduced
thrombus size when compared to UFH for the initial treatment of
VTE. There was no difference in overall mortality between partic-
ipants treated with LMWH and those treated with UFH (moder-
ate-quality evidence).
Implications for research
Further studies are required to compare LMWH with UFH in
the treatment of people with pulmonary embolism. In addition, a
large RCT of at least two years’ duration should be performed to
determine the effects of dosing frequency on long-term sequelae
of venous thromboembolism, such as the development of post-
thrombotic syndrome. Individual low molecular weight heparin
preparations could be compared with each other and new drugs
should now be compared with LMWH.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Belcaro 1999
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: 31 participants.
Lost to follow-up: none.
Participants Country: not stated.
Setting: hospital.
No.: 197 participants.
Age: mean 54 years.
Sex: M:F 111:84.
Inclusion criteria: informed consent.
Exclusion criteria: twoormore previous episodes ofDVTorPE, currently active bleeding,
active ulcers, known familial bleeding or coagulation disorder (i.e. known deﬁciency of
antithrombin III, protein C or protein S), concurrent PE, treatment for the DVT with
standard heparin lasting more than 48 hours, or impossibility of being or inability to
be treated at home with LMWH or standard heparin. Also excluded were: people with
neoplastic disorders requiring surgery or chemotherapy in the following 3 months, and
those with likelihood of low or no compliance and/or inability to be included in a follow-
up, pregnancy and a platelet count below 100,000 per mm³
Interventions Treatment: LMWH: administered primarily at home and body weight adjusted
(nadroparin 0.1 mL per kg twice daily). Doses were 0.6, 0.8 and 1 mL (respectively
equivalent to 6150, 8200 and 10,250 anti-factor Xa IU). Dose most suitable to the
participant’s weight was chosen
Control: UFH: i.v. bolus of 5000 IU initially, followed by continuous infusion of 20,
000 IU. Dose was adjusted to maintain APTT between 60 and 85 seconds
Treatment duration:
• LMWH: 5.1 days;
• UFH: 5.4 days.
Oral anticoagulation: more than 3 months.
Outcomes Primary: symptomatic or asymptomatic (detected by colour duplex scanning) recurrent
DVT or DVT extension in 3 months after randomisation
Secondary: bleeding during administration of the study medication or within 48 hours
after discontinuation; PE; number of hospital days; number of participants treated di-
rectly at home without hospital admission
Notes Follow-up: 3 months. 2 UFH groups (s.c. and i.v.).
Risk of bias
Bias Authors’ judgement Support for judgement
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Belcaro 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All reported outcome events were reviewed
by a central panel unaware of the treatment
assigned and participant’s identity
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups
Selective reporting (reporting bias) Low risk The published report includes all expected
outcomes.
Other bias Low risk The study appears to be free of other
sources of bias.
Breddin 2001
Methods Study design: randomised controlled trial.
Method of randomisation: stratiﬁed according to site.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: Argentina, Austria, Czech Republic, Denmark, Germany, Hungary, Israel,
Poland, Norway, United Kingdom
Setting: hospital.
No.: 1137 participants.
Age: mean 58 years.
Sex: 621 males.
Inclusion criteria: acuteDVTconﬁrmed by venographywithout symptoms lasting longer
than 14 days
Exclusion criteria: presence of thrombi only in isolated calf veins or isolated muscle
veins; clinically symptomatic PE; treatment with UFH, LMWH, or VKA for 24 hours
or more before enrolment; uncontrolled hypertension; stroke within 3 weeks of enrol-
ment; cerebral vascular aneurysm or active gastroduodenal ulcer; bacterial endocarditis;
thrombocytopenia (< 100,000 platelets/mm³; severe liver or renal insufﬁciency; receipt
of spinal or epidural anaesthesia or lumbar puncture in the 5 days before enrolment;
surgery in the 5 days before enrolment; concomitant treatment with ﬁbrinolytic agents
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Breddin 2001 (Continued)
or platelet function inhibitors; a body weight of less than 35 kg; pregnancy and known
drug abuse
Interventions Treatment: LMWH: Reviparin (Clivarin, Knoll, Ludwigshafen, Germany) twice daily,
body weight adjusted (7000 anti-factor Xa IU for a weight of 35 to 45 kg, 8400 IU for
46 to 60 kg and 12,600 IU for more than 60 kg)
Control: 5000 IU i.v. UFH plus continuous i.v. infusion of 1250 IU/hour (dose-adjusted
APTT × 1.5 to 2.5
Treatment duration: LMWH 5 to 7 days, UFH until INR > 2.0 (and maintained)
Oral anticoagulation: in both groups (started day 1) for 90 days
Outcomes Primary: change in venographically determined thrombus size (Marder’s score) between
base line and day 21 (± 2 days)
Secondary:
Clinical outcomes: recurrent DVT or PE during initial treatment and 3 months’ follow-
up; major haemorrhagic events between day 0 and 21
Notes Follow-up: 90 days.
LMWH once daily group (374 participants) not included in analysis because LMWH
was given for 28 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded assessment of outcomes.
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for missing second venogram and
therefore exclusion for efﬁcacy analysis are
not provided and missing outcome data
imbalanced in numbers across intervention
groups
Selective reporting (reporting bias) Low risk The published report includes all expected
outcomes.
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Breddin 2001 (Continued)
Other bias Low risk The study appears to be free of other
sources of bias.
Columbus 1997
Methods Study design: randomised controlled trial.
Method of randomisation: stratiﬁed according to whether the participant presented with
DVT only or with PE, according to clinical centre
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: Netherlands, France, Italy, Germany, Spain, Australia, New Zealand, Canada
Setting: hospital.
No.: 1021 participants.
Age: mean 60.
Sex: 525 males.
Inclusion criteria: acute symptomatic DVT and/or PE requiring antithrombotic therapy.
DVT documented by ultrasonography or venography and PE by ventilation-perfusion
lung scanning (high probability of PE), pulmonary angiography or, if lung scanning was
non-diagnostic, by demonstrating DVT by compression ultrasonography or venography
Exclusion criteria: therapeutic doses of LMWH, UFH or oral anticoagulant therapy for
more than 24 hours; contraindications for anticoagulant therapy; planned thrombolytic
therapy; gastrointestinal bleeding in the preceding 14 days; surgery requiring anaesthesia
within the previous 3 days; a stroke in the preceding 10 days; platelet count < 100,000/
mm³ ; weight < 35 kg; pregnant or of childbearing potential and not using adequate
contraception; in a location that made follow-up difﬁcult
Interventions Treatment: LMWH: Reviparin sodium (Clivarin, Knoll, Luwigshafen, Germany) in
body weight adjusted ﬁxed-dose, s.c., twice daily. Decision to treat participants at home
left to treating physician
Control: UFH: APTT-adjusted dose, continuous i.v. infusion in hospital after initial
intravenous bolus of 5000 IU
Treatment duration: at least 5 days; treatment cessation if INR was 2.0 or above for 2
consecutive days
Oral anticoagulation: started on ﬁrst or second day and continued for a total of 12 weeks;
INR 2.0 to 3.0
Outcomes Primary: symptomatic DVT or PE during initial treatment and within 12 weeks of
randomisation
Secondary: major haemorrhage during initial treatment and within 12 weeks of ran-
domisation; death within 12 weeks of randomisation
Notes Follow-up: 12 weeks.
DVT only: LMWH 372 (73%) and UFH 378 (74%).
PE: 138 (27%) versus 133 (26%).
In retrospect, 3 participants with DVT only and 2 with PE should have been excluded
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Columbus 1997 (Continued)
at entry as they did not have abnormal test results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas performedwith a com-
puter algorithm.
Allocation concealment (selection bias) Low risk Central allocation by a 24-hour telephone
service.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Information on all suspected outcome
events and deaths was reviewed and clas-
siﬁed by a central adjudication committee
whose members were unaware of the treat-
ment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk The published report includes all expected
outcomes.
Other bias Low risk The study appears to be free of other
sources of bias.
Decousus 1998
Methods Study design: randomised controlled trial.
Method of randomisation: stratiﬁed according to centre.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: 4 (1 vital status; 3 for the assessment of non-fatal events)
Participants Country: France (44 centres).
Setting: hospital.
No.: 400 participants.
Age: mean 72.
Sex: 190 males.
Inclusion criteria: acute proximal DVT conﬁrmed by venography with or without symp-
tomatic PE; at high risk for PE
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Decousus 1998 (Continued)
Exclusion criteria: placement of previous ﬁlter; contraindication to or failure of anticoag-
ulant therapy; curative anticoagulant therapy lasting more than 48 hours; indication for
thrombolysis; short life expectancy; allergy to iodine; hereditary thrombophilia; severe
renal or hepatic failure; pregnancy; likelihood of non-compliance
Interventions Treatment: LMWH: Enoxaparin (Rhone-Poulenc Rorer) body weight-adjusted ﬁxed
dose (1 mg per kg body weight), s.c., twice daily (100 anti-factor Xa IU per mg)
Control: UFH: APTT-adjusted, continuous i.v. infusion (started with 500 IU per kg of
body weight per day), after initial i.v. bolus dose of 5000 IU
Treatment duration: 8 to 12 days; discontinuation if INRwas 2 ormore for 2 consecutive
days
Oral anticoagulation: warfarin or acenocoumarol started on day 4 and continued for at
least 3 months
Outcomes Primary: symptomatic or asymptomatic PE within the ﬁrst 12 days after randomisation;
all symptomatic recurrent VTE
Secondary: major haemorrhage during the initial treatment period; mortality
Notes Follow-up: 2 years.
The outcome of recurrent VTE was only reported for a follow-up period of 3 months
(also included as the incidence at the end of follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by a com-
puter system.
Allocation concealment (selection bias) Low risk Allocation was performed by a central 24-
hour telephone system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All pulmonary investigations and all doc-
umented symptomatic events, including
deaths, were validated by an independent
adjudication committee whose members
were unaware of the treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely
to be related to true outcome
Selective reporting (reporting bias) Low risk The published report includes all expected
outcomes.
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Decousus 1998 (Continued)
Other bias Unclear risk The study has a potential source of bias due
to the fact that 2 interventions (the effec-
tiveness of a vena cava ﬁlter and the efﬁcacy
of LMWH) are investigated in the same
population. There is insufﬁcient Informa-
tion about the number of participants with
a vena cava ﬁlter across intervention groups
Faivre 1988
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusion post-randomisation: 1 in UFH group (thrombocytopenia)
Lost to follow-up: 9 participants had no second phlebography (3 CY 222, 6 UFH)
Participants Country: France.
Setting: hospital.
No.: 68 participants.
Age: mean 66 years.
Sex: 39 males.
Inclusion criteria: symptomatic DVT and/or symptomatic PE, or symptomatic PE con-
ﬁrmed by ventilation-perfusion scan and a positive phlebogram
Exclusion criteria: > 2 weeks symptoms of DVT or PE with massive PE; extension of
the thrombus into the inferior vena cava
Interventions Treatment: LMWH: CY 222 starting with a bolus injection i.v. 5000 U anti-factor Xa
IU and continued with body weight-adjusted ﬁxed dose: 155 IU/kg (750 U anti-factor
Xa IU/kg/24 hours), s.c., twice daily
Control: UFH: starting with a bolus injection i.v. 5000 IU of UFH and continued with
500 IU/kg/24 hours s.c., twice daily; dose-adjusted APTT × 2.0 to 3.0
Treatment duration: 10 days.
Oral anticoagulation: not deﬁned for treatment or control groups
Outcomes Primary: change in thrombus size (Marder’s score); recurrent DVT and PE
Secondary: major haemorrhage during the initial treatment.
Notes Baseline characteristics: difference in presence of PE (66% of participants allocated to
LMWH and 34% of participants allocated to UFH had a PE).
Repeated venography; participants with thrombotic and bleeding events excluded from
venographic evaluation.
Unclear from publication whether valid criteria for diagnosis of recurrent VTE were
used.
No prospective follow-up.
Risk of bias
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Faivre 1988 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded for outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information.
Selective reporting (reporting bias) Unclear risk Insufﬁcient information.
Other bias Unclear risk Insufﬁcient information. ? baseline differ-
ences mentioned above?
Fiessinger 1996
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: 10 participants in dalteparin group and 5 participants
in UFH group did not have DVT
Lost to follow-up: 32 participants (13 versus 19) did not have a second phlebogram; 2
(1 versus 1) participants were considered not to have DVT; 20 participants (8 versus 12)
were incorrectly included
Participants Country: Austria, France, Spain and Sweden (16 centres).
Setting: hospital.
No.: 253 participants.
Age: mean 61 years.
Sex: 115 males.
Inclusion criteria: distal and/or proximal DVT with 8 or more days of symptoms
Exclusion criteria: clinical signs suggestive of PE; history of recent DVT (< 1 year) or
sequelae of a previous DVT in the same leg; treatment with therapeutic doses of UFH or
LMWH prior to randomisation; malignant hypertension; renal or hepatic insufﬁciency;
platelet count <100 x10 /litre; knownhypersensitivity to contrastmedia; surgerywithin
5 days of starting treatment; intracerebral bleeding in previous 2months, gastrointestinal
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Fiessinger 1996 (Continued)
bleeding in previous 2 weeks; pregnancy/lactation
Interventions Treatment: LMWH: 1 mL active substance equivalent to 10,000 anti-factor Xa IU
(Dalteparin, Fragmin) s.c. injection (200 IU/kg) o.d.. Bolus dose of 5000 IU. s.c. if
randomisation before phlebography, otherwise a ﬁrst full-dose
Control: UFH: before phlebography: bolus dose of 5000 IU i.v. followed by continuous
i.v. infusion of 20,000 to 40,000 IU/24 hours APTT-adjusted (1.5 to 3.0 ×). After
phlebography a bolus i.v. injection administered prior to infusion of UFH at discretion
of attending physician
Treatment duration: 5 to 10 days, when the prothrombin time (INR) was within thera-
peutic range (2 to 3) on 2 consecutive days
Oral anticoagulation: started on day of inclusion or day after. Period determined by
attending physician; mean period of treatment 5.3 months in both groups
Outcomes Primary: change in thrombus size (Marder’s score); recurrent VTE during initial treat-
ment (prospective follow-up) and at the end of 6 months’ follow-up; PE during initial
treatment and at the end of 6 months’ follow-up
Secondary: major haemorrhage during initial treatment; mortality; mortality in partici-
pants with malignancy at entry
Notes 20 participants not correctly included; 32 participants without second phlebography.
Follow-up: 6 months, but 23 participants lost to follow-up; of these 13 were alive
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was blinded and the
non-blinding of others is unlikely to intro-
duce bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing outcome data imbalanced in num-
bers across intervention groups
Selective reporting (reporting bias) Unclear risk Insufﬁcient information.
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Fiessinger 1996 (Continued)
Other bias Low risk The study appears to be free of other
sources of bias.
Findik 2002
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not blinded for treatment allocation
Exclusion post-randomisation: none.
Lost to follow-up: none.
Participants Country: Turkey.
Setting: hospital.
No.: 59 participants.
Age: mean 50 years.
Sex: 29 males.
Inclusion criteria: patients with clinically suspected acute PE, objectively conﬁrmed
by ventilation-perfusion lung scan, showing a high probability or in the case of an
indeterminate result accompanied by DVT conﬁrmed by compression ultrasonography
Exclusion criteria: massive PE requiring thrombolytic therapy or embolectomy; con-
traindication for anticoagulant therapy (active bleeding or haematologic disorders); an-
ticoagulant therapy at a therapeutic dose within 24 hours before study; a life expectancy
≤ 3 months, severe hepatic or renal failure; pregnancy; suspicion of non-compliance
Interventions Treatment: LMWH: Enoxaparin s.c. 1 mg/kg, 100 anti-factor Xa IU per kg of body
weight twice daily
Control: UFH: Starting with a bolus injection i.v. 5000 IU followed by a continuous i.
v. infusion of 1000 IU/hour. UFH dose was adjusted (APTT-1.5 to 2.5 × control value)
Treatment duration: approximately 7 days.
Oral anticoagulation: started on the second day for a total of 6 months
Outcomes Primary: recurrent VTE, major haemorrhage and mortality during initial treatment and
at 3 months
Notes Blinding for outcome assessment was not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
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Findik 2002 (Continued)
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insuffcient information.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information about missing outcome
data provided.
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias High risk The low participant numbers in both
LMWHandUFHarms and low event rates
reduced the statistical power of the study to
detect a signiﬁcant difference between the
arms
Goldhaber 1998
Methods Study design: randomised controlled trial.
Method of randomisation: computerised, not stratiﬁed.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: not stated.
Participants Country: United States.
Setting: hospital.
No.: 81 participants.
Age: mean 54 years.
Sex: 43 males.
Inclusion criteria: acute (within 14 days) symptomatic DVT of the legs documented by
ultrasound and participants had to be deemed appropriate for discharge home
Exclusion criteria: high-risk DVT involving 3 proximal veins; pelvic vein thrombosis;
current symptomatic PE; expected prolonged hospitalisation for other reasons; haemo-
globin < 85 g/litre or platelet count < 100 × 10 /litre
Interventions Treatment: LMWH: 130 anti-factor Xa IU/kg ardeparin sodium twice daily subcuta-
neously for 5 to 15 days
Control: UFH, heparin sodium 5000- to 7500-unit bolus followed by continuous i.
v. administration to achieve APTT of 1.5 to 2.5. Titration guided by Cruickshank
nomogram
Treatment duration: LMWH 5 to 15 days, UFH 5 days or more to achieve target APTT
Oral anticoagulation: 6 weeks.
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Goldhaber 1998 (Continued)
Outcomes Primary: change in thrombus size; recurrent DVT or PE.
Secondary: major and minor haemorrhage.
Notes Repeated venography at the end of follow-up (6 weeks).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation and allocation was accom-
plished by calling a central computerised
service
Allocation concealment (selection bias) Low risk Randomisation and allocation was accom-
plished by calling a central computerised
service
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No reasons for missing data provided.
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk The study appears to be free of other
sources of bias.
Harenberg 2000a
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: blinded for outcome assessment.
Exclusions post-randomisation: not stated.
Lost to follow-up: not stated.
Participants Country: Austria, Germany, Switzerland, Czech Republic.
Setting: hospital.
No.: 541 were eligible of which 3 withdrew informed consent; therefore 538 participants
were assigned
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Harenberg 2000a (Continued)
Age: 30 years and older.
Sex: Males and females (breakdown not supplied).
Inclusion criteria: acute symptomatic proximal DVT (thrombosis of the popliteal vein
or proximal) documented by ascending venography
Exclusion criteria: indication for surgical or ﬁbrinolytic treatment of DVT; duration of
symptoms for more than 3 weeks; ongoing oral anticoagulation; renal failure; severe hy-
pertension (> 200 mmHg systolic and > 105 mmHg diastolic while on antihypertensive
treatment); severe hepatic failure; currently active bleeding or disorders contraindicating
anticoagulant therapy; contraindication to oral anticoagulants; pregnancy; known intol-
erance to heparins; intolerance to contrast media; any operation within the past 8 days;
acute severe PE; platelet count < 100,000/µL; treatment with heparin > 24 hours before
inclusion; treatment with platelet-inhibiting drugs (100 mg or more acetylsalicylic acid
daily allowed)
Interventions Treatment: LMWH: ﬁxed dose 8000 anti-factor Xa IU (Certoparin) s.c., twice daily
Control: UFH: adjusted to APTT 2 to 3 × the reference value.
Treatment duration: 7 to 15 days.
Oral anticoagulation: at least 6 months.
Outcomes Primary: change in thrombus size (Marder’s score), recurrent VTE, major bleeding and
death during treatment and after 6 months’ test follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufﬁcient information.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data on all potential outcome events were
evaluated by an independent committee,
whichwas unaware of the treatment assign-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
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Harenberg 2000a (Continued)
Other bias High risk The study was sponsored byNovartis Phar-
macological GmbH, Nuremberg, Ger-
many
Hull 1992
Methods Study design: randomised controlled trial.
Method of randomisation: computerised and stratiﬁed to groups according to study
centre
Concealment of allocation: blinded for treatment allocation and outcome assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: USA, Canada (15 centres).
Setting: hospital.
No.: 432 participants.
Age: 161 participants under 60 years, 270 participants over 60 years
Sex: 140 males, 291 females.
Inclusion criteria: symptomatic or asymptomatic proximal DVT with or without symp-
tomatic PE
Exclusion criteria: active bleeding or disorders contraindicating anticoagulant therapy;
allergy to heparin, bisulphites or ﬁsh; pregnancy; 2 or more previously documented
episodes of DVT or PE; history of protein C deﬁciency; history of heparin-associated
thrombocytopenia; severe malignant hypertension (blood pressure 250 mmHg or more
systolic and 130 mmHg or more diastolic); severe hepatic failure (hepatic encephalopa-
thy); severe renal failure; requiring dialysis; geographic inaccessibility preventing atten-
dance at follow-up visits. Eligible participants were excluded if they had received treat-
ment with warfarin, LMWH or heparinoids within the previous 7 days; treatment with
therapeutic s.c. heparin within the preceding 12 hours; received i.v. heparin (265 par-
ticipants) or declined to give written informed consent (148 participants)
Interventions Treatment: LMWH: logiparin body weight adjusted ﬁxed dose 175 anti-factor Xa IU/
kg, s.c., o.d
Control: UFH: dose-adjusted APTT × 1.5 to 2.5, continuous i.v. infusion starting with
40,320 Units/24 hours; or in people at high risk, 29,760 Units/24 hours. Initial i.v. bolus
of 5000 Units
Treatment duration: 6 days provided the INR was 2.0 or more.
Oral anticoagulation: warfarin sodium was given for at least 3 months and was started
on day 2 of the initial heparin treatment
Outcomes Primary: recurrent DVT and PE; major haemorrhage during or immediately after initial
treatment
Secondary: minor haemorrhage; mortality.
Notes Placebo controlled.
Follow-up: 3 months.
More women in UFH group; no signiﬁcant effect of gender demonstrated
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Hull 1992 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomised computer-derived treatment
schedule was used to assign the participants
to the treatment group
Allocation concealment (selection bias) Low risk A randomised computer-derived treatment
schedule was used to assign the participants
to the treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk A double-blind clinical trial. Participants
received either intravenous UFH with
subcutaneous placebo or subcutaneous
LMWH with intravenous placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A double-blind clinical trial. The outcome
assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk Thereweremorewomen in the intravenous
heparin group. To assess the possible effect
of this potential gender imbalance, multi-
ple logistic regression was used. No signif-
icant effect was found. The study seems to
be free of other sources of bias
Kakkar 2003
Methods Study design: multicentre, randomised, open-label, parallel group comparison trial
Method of randomisation: not stated
Concealment of allocation: not stated
Exclusions post-randomisation: 54 participants
Lost to follow-up: none
Participants Country: Spain, Poland and United Kingdom
Setting: 27 hospitals
No.: 324 participants: 94 bemiparin, 105 bemiparin + VKA, 98 UFH
Age: bemiparin mean 63.2 (45.1 to 70.8) years, bemiparin + VKA mean 61.2 (44.4 to
69.5) years, UFH mean 61.2 (49.9 to 70.5) years,
Sex: bemiparin 58 M/36 F, bemiparin + VKA 61 M/44 F, UFH 63 M/35 F,
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Kakkar 2003 (Continued)
Inclusion criteria: people with an acute DVT of the legs, conﬁrmed by venography and
who had symptoms for no more than 14 days
Exclusion criteria: people receiving therapeutic doses of heparin or a vitamin K antag-
onist for more than 48 hours prior to enrolment, clinically symptomatic pulmonary
embolism, pregnancy conﬁrmed by urine analysis, ischaemic cerebral vascular accident
1 month prior to enrolment, known cerebral vascular aneurysm, active duodenal ul-
cer or bacterial endocarditis, severe liver or renal failure, spinal or epidural anaesthesia
or lumbar puncture 3 days prior to enrolment, uncontrolled hypertension, allergy to
heparin, warfarin, sodium or iodinated contrast medium, history of heparin-associated
thrombocytopenia or platelet count of less than 100,000 platelets per mm³, concurrent
treatment with ﬁbrinolytic agents, a body weight of less than 35 kg, treatment with an
investigational drug in the last 4 weeks prior to enrolment, inability to attend follow-up
due to geographic inaccessibility and known drug use
Interventions Treatment 1: 115 anti-Xa IU per kg of bemiparin as 1 injection every 24 hours based on
participants’ weight (5000 anti-Xa for weight < 50 kg, 7,500 anti-Xa for weight 50 to
70 kg and 10,000 anti-Xa IU for more than 70 kg) followed by VKA from day 3 10 mg
per day for ﬁrst 3 days then adjusted to achieve an INR between 2 and 3 for 12 weeks
Treatment 2: 115 anti-Xa IU per kg of bemiparin as 1 injection every 24 hours based
on participants’ weight (5000 anti-Xa for weight < 50 kg, 7500 anti-Xa for weight 50 to
70 kg and 10,000 anti-Xa IU for more than 70 kg) followed by ﬁxed daily dose of 3500
anti-Xa units for 90 days
Control: i.v. bolus of 5000 UFH followed by a continuous i.v. infusion at a dose of 40,
000 IU per 24 hours in participants at low risk of bleeding and 30,000 IU per 24 hours
in participants at high risk of bleeding followed by VKA from day 3 10 mg per day for
ﬁrst 3 days then adjusted to achieve an INR between 2 and 3 for 12 weeks
Treatment duration: 12 weeks.
Outcomes Primary: venographically conﬁrmed change in thrombus size betweenbaseline andday 14
assessed with the use of theMarder score and patency of deep venous system determined
by venography or Doppler ultrasound at 12 weeks
Secondary: symptomatic recurrence of DVT and PE, major bleeding (clinically overt
and associated with a fall in haemoglobin level of at least 2.0 g per decilitre) and death
Notes Follow-up: 7 days, 14 days, 12 weeks and 28 weeks.
In this 3-armed trial, 2 bemiparin groups were compared with an UFH control group.
However, in 1 of the bemiparin groups (treatment 2), participants did not receive con-
comitant VKA therapy. All other studies included in this review used concomitant VKA
therapy and in order for our results to be comparable, data for this group of participants
in the Kakkar 2003 study were not included in the analysis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned”.
Comment: insufﬁcient information to per-
mit judgement.
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Kakkar 2003 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly assigned”.
Comment: insufﬁcient information to per-
mit judgement.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Open label
Quote: “The venograms were indepen-
dently assessed by two radiologists of an in-
dependent committee who were unaware
of the patients treatment assignments”
Comment: outcome assessors were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 324 participants in intention-to-treat
group but only 297 participants included
in the per protocol population and only
255 followed up to day 84. Numbers lost
to follow-up not adequately reported
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias High risk The study was sponsored by Laboratorios
Farmaceuticos Rovi, Madrid, Spain
Kirchmaier 1998
Methods Study design: randomised controlled trial.
Method of randomisation: computerised.
Concealment of allocation: partly blinded for treatment allocation
Exclusions post-randomisation: 6 participants.
Lost to follow-up: none.
Participants Country: Austria, Czech Republic, Germany (total 23 centres)
Setting: hospital.
No.: 257 participants.
Age: median 61 years.
Sex: 133 males.
Inclusion criteria: symptomatic DVT of the lower leg.
Exclusion criteria: thrombi only in 1or 2 calf veins; treatmentwith vitaminK antagonists;
use of contrast media; surgery in the previous week; thrombocytopenic (< 100,000/µL)
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Kirchmaier 1998 (Continued)
Interventions Treatment: subcutaneous LMWH (certoparin) 8000 IU/kg twice daily
Control: UFH: initial bolus of 5000 IU followed by 20 IU/kg/hour
Inboth groups phenprocoumonwas started betweenday 12 and14.Heparinwas stopped
until an INR range between 2.0 and 3.5 was reached
Treatment duration: at least 14 days.
Oral anticoagulation: Oral anticoagulant therapy was continued for at least 6 months
Outcomes Primary: recurrent VTE; major haemorrhage during initial treatment; change in throm-
bus size; mortality at the end of follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation performed by a statistician,
but there is insufﬁcient information about
the sequence generation
Allocation concealment (selection bias) Low risk Allocation was performed centrally by tele-
phone.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Partly blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment by an investigator,
who was blinded to the treatment the par-
ticipants had received
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for missing phlebograms and per-
fusion scans were not provided
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk The study appears to be free of other
sources of bias.
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Koopman 1996
Methods Study design: randomised controlled trial.
Method of randomisation: stratiﬁed according to centre.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: Netherlands, France, Italy, Australia, New Zealand.
Setting: hospital.
No.: 400 outpatients.
Age: Mean 61 years.
Sex: 203 males.
Inclusion criteria: acute symptomatic proximal DVT documented by venography and/
or ultrasonography
Exclusion criteria: VTE in last 2 years; suspectedPE; previous treatmentwith heparin >24
hours; life expectancy < 6months; post-thrombotic syndrome; geographic inaccessibility
Interventions Treatment: LMWH (Nadroparin-Ca, Fraxiparine) in body weight-adjusted ﬁxed dose,
s.c., twice daily. If appropriate, at home
Control: UFH: APTT-adjusted dose, continuous i.v. infusion in hospital after initial i.
v. bolus of 5000 Units
Treatment duration: at least 5 days; treatment cessation if INR was 2.0 or above in 2
measurements 24 hours apart
Oral anticoagulation: started on ﬁrst day and continued for 3 months unless persistence
of risk factors required its continuation beyond that period. INR 2.0 to 3.0
Outcomes Primary: symptomatic recurrent VTE (DVT or PE) during initial treatment, after 3
months’ follow-up and at the end of follow-up (6 months); major haemorrhage during
initial treatment and after 3 months of follow-up
Secondary: minor haemorrhage or death during initial treatment, after 3 months of
follow-up and at the end of follow-up (6 months); other potential outcome events;
quality of life
Notes Follow-up: 6 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation
and allocation was achieved by means of a
central 24-hour telephone service
Allocation concealment (selection bias) Low risk Randomisation
and allocation was achieved by means of a
central 24-hour telephone service
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Koopman 1996 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Documentation of all potential outcome
events was submitted to an independent
adjudication committee whose members
were unaware of the treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk Study appears to be free of other sources of
bias.
Leizorovicz 2011
Methods Study design: international, multicentre, centrally randomised, open, parallel-group
study
Method of randomisation: computer generated randomisation scheme in a 1:1 ratio with
central telephone randomisation
Concealment of allocation: no allocation concealment mechanism was attempted
Exclusions post-randomisation: none
Lost to follow-up: none
Participants Country: 8 countries (Belgium, France, Germany, Spain, Serbia, Croatia, Romania and
Poland)
Setting: 109 hospitals
No.: 269 tinzaparin, 270 UFH
Age: tinzaparin mean 82.9 ± 5.7 years, UFH mean 82.6 ± 5.8 years
Sex: tinzaparin 92 M/177 F, UFH 102 M/168 F
Inclusion criteria: people ≥ 70 years with an acute objectively conﬁrmed (compression
ultrasonography or venography) symptomatic proximal or distal lower limb DVT or
asymptomatic DVT if proximal and associated with a PE
Exclusion criteria: people who had received treatment doses of heparins or thrombolytic
agents within the previous 4 weeks prior to randomisation, received oral anticoagulation
within the preceding week, planned use of high doses of acetylsalicylic acid (> 300mg/
day) or an NSAID, had a requirement for thrombolytic therapy, end stage renal dis-
ease requiring dialysis, hepatic insufﬁciency, bacterial endocarditis, planned epidural or
spinal anaesthesia, planned or recent (within 2 weeks) surgery, thrombocytopenia, severe
uncontrolled hypertension, overt bleeding or recent stroke
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Leizorovicz 2011 (Continued)
Interventions Treatment: tinzaparin 175 IU/kg subcutaneous injection once daily
Control: UFH (50 IU/kg i.v. bolus followed by twice daily subcutaneous injections in
initial doses between 400 to 600 IU/kg/day then adjusted by APTT)
Treatment duration: 5 days.
Oral anticoagulation: VKA treatment initiated between days 1 and 3 and continued
until at least day 90 ± 5
Outcomes Primary: clinically relevant bleeding by day 90 ± 5.
Secondary: symptomatic recurrent VTE prior to day 90 ± 5, major and minor bleedings
prior to day 90 ± 5, heparin-induced thrombocytopenia and death
Notes Follow-up: 90 ± 5 days.
Study was unexpectedly terminated early as at a predeﬁned interim analysis conducted
after completion of 350 participants, an excess mortality was observed in the tinzaparin
group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Treatment assignment was pre-
planned according to a computer generated
randomisation scheme in a 1:1 ratio with
central telephone randomisation”
Comment: low risk of bias.
Allocation concealment (selection bias) Unclear risk Quote: “No allocation concealment mech-
anismwas attempted as the studywas open”
Comment: insufﬁcient information to per-
mit judgement.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The study was open but care was
taken to ensure that outcome assessors and
data analysts were kept blinded to the allo-
cation”
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors and data analysts were
kept blinded to the allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
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Leizorovicz 2011 (Continued)
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Unclear risk Study sponsored by LEO Pharma.
Levine 1996
Methods Study design: randomised controlled trial.
Method of randomisation: stratiﬁed according to centre, mode of diagnosis (venography
or ultrasonography), and category of participants (outpatients, admitted at weekend or
at night, hospitalised)
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: Canada.
Setting: hospital.
No.: 500 outpatients and inpatients.
Age: mean 58 years.
Sex: males and females (breakdown not supplied).
Inclusion criteria: acute proximal DVT.
Exclusion criteria: 2 or more previous episodes of DVT or PE; active bleeding; active
peptic ulcer disease; familial bleeding disorder; concurrent symptomatic PE; > 48 hours
heparin treatment; inability to be treated with LMWH as outpatient because of coexist-
ing condition (e.g. cancer, infection, stroke) or likelihood of non-compliance; inability
to make follow-up visits because of geographical inaccessibility; presence of known de-
ﬁciency of anti-thrombin III, protein C or protein S; pregnancy
Interventions Treatment: LMWH: enoxaparin (Rhone-PoulencRorer) bodyweight-adjusted ﬁxeddose
(1 mg/kg body weight), s.c., twice daily, at home. 1 vial: 1 mL/100 mg = 100 anti-factor
Xa IU/mg)
Control: UFH: APTT-adjusted, continuous i.v. infusion (started with 20,000 Units in
500 mL of 5% dextrose solution) in hospital after an initial i.v. bolus of 5000 Units
Treatment duration: at least 5 days; discontinuation if INRwas 2or above andmaintained
for 2 consecutive days
Oral anticoagulation warfarin sodium started on day 2 and continued for 3 months
Outcomes Primary: symptomatic recurrent VTE within 90 days of follow-up; major haemorrhage
during the initial treatment or 48 hours after treatment cessation
Secondary: minor haemorrhage; mortality.
Notes Some participants received 1 or 2 days UFH before randomisation; this was considered
part of the overall duration of heparin treatment.
Follow-up: 3 months.
Risk of bias
49Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Levine 1996 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Low risk Allocation over the telephone from a cen-
tral site.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All reported outcome events were reviewed
by a central adjudication committee whose
members were unaware of the treatment
assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk The study appears to be free of other
sources of bias.
Lindmarker 1994
Methods Study design: randomised controlled trial.
Method of randomisation: centrally organised using sealed envelopes and stratiﬁed for
centre
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: 6 (1 UFH versus 5 fragmin).
Lost to follow-up: for venographic assessment 18 (13 UFH versus 5 fragmin); for clinical
outcome assessment 16 participants
Participants Country: Sweden.
Setting: hospital.
No.: 204 outpatients.
Age: mean 61 years.
Sex: 116 males.
Inclusion criteria: symptomatic distal and proximal DVT.
Exclusion criteria: UFH treatment already given for more than 24 hours; surgery < 5
days before; previous DVT in the ipsilateral leg; suspected or veriﬁed PE; thrombectomy
or thrombolysis indicated; DVT proximal of inguinal arch; intracranial bleeding within
50Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lindmarker 1994 (Continued)
previous 2 weeks; known haemorrhagic diathesis or disorders; platelet count below 100
× 10 /litre; renal insufﬁciency (S-creatinine < 300 µM); hepatic insufﬁciency with a
prothrombin time < 40% (INR > 1.5); allergy to UFH, fragmin or contrast media;
pregnancy or breastfeeding; severe hypertension
Interventions Treatment: initial i.v. bolus injection of UFH 5000 Units followed by continuous i.v.
infusion of UFH 800 to 1700/hour for a maximum of 24 hours after randomisation:
LMWH (fragmin) body weight-adjusted ﬁxed dose of 200 anti-factor Xa IU/kg with a
maximum of 18,000 IU, s.c., o.d
Control: initial i.v. bolus injection of UFH 5000 Units followed by continuous i.v.
infusion of UFH 800 to 1700/hour; after randomisation: continuation of i.v. infusion
with UFH dose-adjusted APTT × 1.5 to 3.0
Treatment duration: at least 5 days; treatment cessation if INR was within therapeutic
range (2.0 to 3.0) for 2 consecutive days. Treatment duration no longer than 9 days
Oral anticoagulation: warfarin sodium started on the day that venography was carried
out and continued for a minimum of 3 months; INR 2.0 to 3.0
Outcomes Primary: change in thrombus size (Marder’s score); recurrent VTE; major haemorrhage
Secondary: mortality; mortality in participants with malignant disease
Notes Repeated venography onday 1 andwithin 4days after discontinuationof heparin therapy.
Follow-up: 6 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk The participants who died or had a recur-
rent VTE were not included in the analyses
which may result in an underestimation of
the number of participants with extended
or unchanged thrombosis
51Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lindmarker 1994 (Continued)
Selective reporting (reporting bias) High risk Participants who died or had a recurrent
VTE were not included in the analyses
Other bias Low risk The study appears to be free of other
sources of bias.
Lopaciuk 1992
Methods Study design: randomised controlled trial.
Method of randomisation: sealed envelopes, stratiﬁed for site of DVT
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: 3 participants in UFH group judged to be ineligible (2
with recent history of DVT and 1 deﬁcient in antithrombin III)
Lost to follow-up: 6 in LMWH group and 6 in UFH group (poor phlebogram, 6;
absent phlebogram, 4; protocol violation (treatment for 15 days), 1; major bleeding with
treatment cessation, 1)
Participants Country: Poland (6 centres).
Setting: hospital.
No.: 149 participants of which 117 participants had proximal DVT
Age: mean 48 years.
Sex: 81 males.
Inclusion criteria: symptomatic proximal or calf DVT (phlebographically proven)
Exclusion criteria: clinically suspected PE; phlegmasia caerulea dolens; treatment with
heparin or oral anticoagulants prior to admission; history of VTE in previous 2 years;
surgery or trauma within previous 3 days; contraindication to heparin therapy; preg-
nancy; documented antithrombin III deﬁciency
Interventions Treatment: LMWH: fraxiparine ﬁxed dose: 92 anti-factor Xa IU/kg, s.c., twice daily
Control: UFH: initial i.v. bolus of 5000 IU followed by 250 IU/kg s.c., twice daily; dose-
adjusted APTT × 1.5 to 2.5 s.c
Treatment duration: 10 days.
Oral anticoagulation: acenocoumarol started on day 7 and continued for at least 3
months; INR 2.0 to 3.0
Outcomes Primary: change in thrombus size (Arnesen score); recurrent DVT; PE
Secondary: major and minor haemorrhage; mortality; mortality in participants with
malignant disease
Notes Proximal DVT: 58 (LMWH) versus 59 (UFH).
Distal DVT: 16 (LMWH) versus 13 (UFH).
12 participants excluded from repeated venography analysis.
Follow-up: 3 months.
Risk of bias
Bias Authors’ judgement Support for judgement
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Lopaciuk 1992 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Low risk Sealed envelopes were used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind evaluation of phlebographic results.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups
Selective reporting (reporting bias) Unclear risk Insufﬁcient information.
Other bias High risk There was an imbalanced exclusion at base-
line.
Luomanmaki 1996
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not blinded for treatment allocation and for clinical outcome
assessment; blinded for assessment of venograms at entry to study and at the end of the
initial treatment period
Exclusions post-randomisation: 78 randomised participants excluded because DVT
found not to be present after randomisation
Lost to follow-up: no information given.
Participants Country: Sweden and USA (2 centres).
Setting: hospital.
No.: 248 participants.
Age: mean 57.5 years (LMWH); mean 60.5 years (UFH).
Sex: 125 males.
Inclusion criteria: clinically suspected or veriﬁed DVT.
Exclusion criteria: none stated.
Interventions Treatment: LMWH: dalteparin ﬁxed dose body weight-adjusted (200 IU/kg), s.c., o.d
Control: UFH: dose-adjusted APTT × 1.5 to 3.0, continuous i.v. infusion
Treatment duration: 5 to 10 days until therapeutic effect of oral anticoagulants was
reached
Oral anticoagulation: started during the initial heparin treatment
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Luomanmaki 1996 (Continued)
Outcomes Primary: change in thrombus size (Marder’s score); recurrent VTE (no blind assessment)
; major haemorrhage; mortality at the end of follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was conducted using a Sta-
tistical Analysis System Program
Allocation concealment (selection bias) High risk No central allocation: randomisation was
conducted separately at each participating
centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded evaluations of venograms.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely
to be related to true outcome
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias High risk There was a signiﬁcantly higher incidence
of malignancy in participants randomised
to UFH
Merli 2001
Methods Study design: randomised controlled trial.
Method of randomisation: block randomisation without stratiﬁcation
Concealment of allocation: partly blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: not stated.
Lost to follow-up: not stated.
Participants Country: Australia, Austria, Belgium, Denmark, France, Hungary, Ireland, Israel, Italy,
Netherlands, Norway, Poland, Spain, Sweden, United Kingdom and USA
Setting: hospital.
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Merli 2001 (Continued)
No.: 900 participants.
Age: mean 61 years.
Sex: 492 males.
Inclusion criteria: symptomatic lower extremity DVT conﬁrmed by venography or ul-
trasonography (if venography was inconclusive), symptomatic PE conﬁrmed by high
probability ventilation-perfusion scanning or positive pulmonary angiography with con-
ﬁrmation of lower extremity DVT. All those who were eligible underwent baseline lung
scanning or angiography
Exclusion criteria: more than 24 hours of previous treatment with heparin or warfarin;
need for thrombolytic therapy; known haemorrhagic risk, including active haemorrhage,
active intestinal ulcerative disease, known angiodysplasia or eye, spine or central ner-
vous system surgery within the previous month; renal insufﬁciency (serum creatinine
concentration > 180 µmol/litre (2.03 mg/dL)); severe hepatic insufﬁciency; allergy to
heparin, protamine, porcine products, iodine or contrast media; history of heparin-as-
sociated thrombocytopenia or heparin- or warfarin-associated skin necrosis; treatment
with other investigational therapeutic agents within the previous 4 weeks; inferior vena
cava interruption; known pregnancy or lactation
Interventions Treatment: LMWH: enoxaparin weight-adjusted s.c. dose (1.0 mg/kg of body weight
twice daily or 1.5 mg/kg of body weight o.d.)
Control: UFH: initial i.v. bolus injection followed by an infusion based on an approved
nomogram. In general: 6 hours after initial bolus an adjusted dose was given to maintain
APTT between 55 and 80 seconds. APTT was measured daily
Treatment duration: enoxaparin and heparin treatment were continued for at least 5
days, and warfarin was started within 72 hours of initial study drug administration. 43
participants received phenprocoumon in place of warfarin sodium. INR between 2.0
and 3.0
Oral anticoagulation: oral anticoagulation was continued for at least 3 months
Outcomes Primary: worsening or recurrence of DVT or PE within 3 months
Secondary: clinical overt minor or major haemorrhage.
Notes Participants who received LMWH (2 groups; o.d. and twice daily) were analysed as 1
group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The authors refer to a random number ta-
ble.
Allocation concealment (selection bias) Low risk The randomisation numbers were afﬁxed
to sealed treatment kits
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Partly blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
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Merli 2001 (Continued)
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The Outcome Adjudication Committee
provided blinded outcome assessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk The study appears to be free of other
sources of bias.
Meyer 1995
Methods Study design: randomised, multicentre pilot study.
Method of randomisation: not stated.
Concealment of allocation: sealed envelopes, not blinded for treatment allocation,
blinded for outcome assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: France.
Setting: hospital.
No.: 60 participants: 29 LMWH, 31 UF heparin.
Age: mean 60 (range 26 to 84) years LMWH, mean 61 (20 to 88) years UF heparin
Sex: LMWH 9 M/20 F, UF heparin 17 M/14 F
Inclusion criteria: men and women > 18 years, weighing 45 to 90 kg and with onset of
symptoms suggestive of acute PE within the 5 preceding days
Exclusion criteria: known pregnancy or breastfeeding, major surgical procedure or organ
biopsy within the last 5 days, ischaemic cerebrovascular accident within the past 30
days or cerebral haemorrhage within the last 3 months, known haemorrhagic diathesis,
active peptic ulcer, pre-existing signiﬁcant cardiorespiratory disease, known proliferative
diabetic retinopathy, known allergy to heparin or contrast media, platelet count < 100 10
/L, chronic renal failure, chronic liver disease, treatment with UFH or LMWH at full
dosage for more than 24 hours before randomisation, planned hospital stay < 10 days,
oral anticoagulant therapywithin 5 days before randomisation and any clinical condition
which in the opinion of the physician in charge would not allow safe fulﬁlment of the
protocol
Interventions Treatment: LMWH: fragmin at a ﬁxed dose of 120 anti-Xa IU/kg subcutaneously twice
daily and without any laboratory adjustment
Control: UFH as a continuous intravenous infusion at an initial dosage of 500 IU/kg/
24 hours and adjusted daily to maintain APTT between 2 to 3 times the control value
Treatment duration: 10 days
Oral anticoagulation: acenocoumarol started onday 7 and continued for at least 3months
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Outcomes Primary: incidence of PE recurrence within the ﬁrst 10 days of treatment
Secondary: pulmonary scintigraphic vascular obstruction score (PVOS), major bleeding
Notes Follow-up: 3 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Treatment was randomly allo-
cated”.
Comment: insufﬁcient information to per-
mit judgement.
Allocation concealment (selection bias) Unclear risk Quote: “Treatmentwas randomly allocated
using sealed envelopes”
Comment: although the use of assignment
envelopes is described, it remains unclear
whether envelopes were sequentially num-
bered and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Open study. All angiograms were
reviewed and scored blindly by 3 indepen-
dent readers unaware of the treatment al-
location and clinical events that occurred
during the trial. Perfusion lung scans were
reviewed and scored blindly by 2 indepen-
dent readers according to the same proce-
dure”
Comment: review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes.
Furthermore, the blinding of outcome as-
sessment was ensured
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data accounted for.
Selective reporting (reporting bias) Low risk Study reports data on all pre-speciﬁed out-
comes.
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Other bias Low risk Study appears to be free from other sources
of bias.
Moreno-Palomares 2001
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: Spain.
Setting: hospital.
No.: 32: 17 LMWH, 15 UFH.
Age: mean 70 years LMWH, mean 63 years UFH.
Sex: LMWH 5 M/12 F, UFH 6 M/9 F.
Inclusion criteria: people with DVT diagnosed by Doppler
Exclusion criteria: people withDVT secondary to cancer, hypercoagulability or PE,DVT
exclusively in iliac or popliteal vein
Interventions Treatment: LMWH: sodium dalteparin subcutaneously 200 U/kg over 24 hours. If the
participant needed more than 180,000 U/day, the doses were divided into 2 and each
given over 12 hours
Control: UFH: heparin sodium 400 U/kg as an intravenous continuous infusion
Treatment duration: not stated.
Oral anticoagulation: oral dicocoumarol on 2nd day for 3 months
Outcomes Primary: progress of the Doppler.
Secondary: post-phlebitic syndrome.
Notes Follow-up: 3, 6 and 12 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufﬁcient information.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information.
Selective reporting (reporting bias) Unclear risk Insufﬁcient information.
Other bias Unclear risk Insufﬁcient information.
Ninet 1991
Methods Study design: randomised controlled trial.
Method of randomisation: stratiﬁed to medical or surgical context in which VTE oc-
curred
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: 18participants for assessment of change in thrombus size on venogram.
No participants lost to follow-up for assessment of bleeding events
Participants Country: France (17 centres).
Setting: hospital.
No.: 166 participants undergoing medical or surgical procedures
Age: estimated overall mean age 63 years.
Sex: not stated.
Inclusion criteria: recent (< 5 days) proximal DVT.
Exclusion criteria: thrombosis affecting inferior vena cava; contraindication to heparin;
platelets < 100,000/mm³; blood disease; surgery < 3 days previously; contraindication
for isotopic/venographic investigation; pulmonary vascular obstruction 30% or more
(lung scan); 24 hours or more heparin or oral anticoagulant therapy; recent history (< 2
years) of cerebrovascular accident or thromboembolic episode; pregnancy
Interventions Treatment: LMWH: fraxiparine body weight-adjusted ﬁxed dose (± 90 anti-factor Xa
IU/kg, s.c., twice daily)
Control: UFH: dose-adjusted APTT × 1.5 to 2.0, continuous i.v. infusion started with
20 IU/kg/hour. No bolus injection
Treatment duration: 10 days.
Oral anticoagulation: not deﬁned for either group.
Outcomes Primary: change in thrombus size (Marder’s score); recurrent venous thromboembolism
(VTE) during initial treatment
Secondary: haemorrhagic episodes during initial treatment; mortality at the end of fol-
low-up
Notes Repeated venography on day 0 and day 10.
Follow-up was not conducted prospectively at the study centre. 18 (8 versus 10) partic-
ipants lost to follow-up.
Follow-up by assessment on information noted and communicated by general practi-
tioners
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Venography was evaluated blind by 2 inde-
pendent radiologists (coded ﬁlms)
Incomplete outcome data (attrition bias)
All outcomes
High risk Recurrences were excluded.
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk There are more baseline risk factors in
the UFH group compared to the CY 216
group.However, this differencewas not sta-
tistically signiﬁcant
Prandoni 1992
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: Italy.
Setting: hospital.
No.: 170 outpatients.
Age: 86 (number over 65 years)..
Sex: 86 males.
Inclusion criteria: proximal DVT.
Exclusion criteria: clinically suspected PE at referral; episode of VTE in same leg within
previous 2 years; anticoagulant treatment at referral; contraindication to heparin; preg-
nancy; allergy to contrast material; residence far from hospital
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Interventions Treatment: LMWH: fraxiparine body weight-adjusted ﬁxed dose; ± 90 anti-factor Xa
IU/kg s.c., twice daily
Control: UFH: dose-adjusted APTT × 1.5 to 2.0, continuous i.v. infusion started with
35,000 Units/24 hours. Initial bolus: 100 Units/kg i.v
Treatment duration: at least 10 days; treatment cessation in INR > 2.0
Oral anticoagulation: Coumarin therapy initial dosage 5 mg started on day 7 of heparin
treatment; INR 2.0 to 3.0
Outcomes Primary: change in thrombus size (venogram day 1 and day 10); symptomatic recurrent
DVT (including extension) or symptomatic PE; major haemorrhage during initial treat-
ment
Secondary: mortality; change in number of segmental defects on day 10 and day 0 lung
scans
Notes Follow-up: 6 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated treatment by a
prescribed randomisation schedule
Allocation concealment (selection bias) Low risk Treatment was allocated by sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The venograms and perfusion lung scans of
each participant were scored by a panel of
3 experienced observers who were unaware
of treatment allocation and the sequence in
which the tests were done (before or after
treatment). All clinical end points were also
reviewed by an adjudication committee un-
aware of treatment allocation or other de-
tails of participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. No participant
was lost to follow-up
Selective reporting (reporting bias) Unclear risk Insufﬁcient information.
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Other bias Low risk The study appears to be free of other
sources of bias.
Prandoni 2004
Methods Study design: randomised controlled trial.
Methodof randomisation: computerised. Stratiﬁed according towhether the participants
presented with DVT only or with PE, and also stratiﬁed according to clinical centre
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: Italy.
Setting: hospital.
No.: 720.
Age: mean 66 years.
Sex: 325 male, 395 female.
Inclusion criteria: inpatients and outpatients with the clinical suspicion of an acute (less
than 3 weeks old) DVT of the lower extremities and/or PE. A positive result of at least 1
of the following tests was required: ascending phlebography, compression ultrasound of
the proximal vein system, echo colour Doppler scan of the calf vein system in the case of
clinical suspicion of DVT, ventilation-perfusion scanning, spiral computed tomographic
scanning, and pulmonary angiography in the case of clinical suspicion of PE. In the
presence of abnormal results of an ultrasound test of the lower extremities, the diagnosis
of PE was also accepted if a perfusion lung scan was compatible with a high probability
of PE when compared with the chest x-ray
Exclusion criteria: age less than 18 years, pregnancy, contraindications to anticoagulant
treatment, full-dose anticoagulant treatment (either heparin or oral anticoagulants) for
more than 24 hours, haemodynamic instability, previous (less than 1 year earlier) episode
of VTE, life expectancy less than 3 months, poor compliance, and geographic inacces-
sibility for follow-up
Interventions Treatment: LMWH: nadroparin calcium, subcutaneous administration of nadroparin,
85 IU/kg twice daily
Control: UFH: an i.v. bolus of heparin sodium and a s.c. injection of heparin calcium in
doses adjusted to body weight (4000 IU i.v. plus 12500 IU s.c. in participants weighing
less than 50 kg; 5000 IU plus 15,000 IU, respectively, in participants weighing 50 to 70
kg; and 6000 IU plus 17,500 IU, respectively, in participants weighingmore than 70 kg).
The ﬁrst APTTwas measured after 6 hours, and subsequent dose adjustments during the
ﬁrst 48 hours were scheduled twice daily. After the ﬁrst 48 hours, UHF administration
was managed on the basis of daily APTT determinations
Treatment duration: At least 5 days; heparin cessation if INR was > 2.0 for 2 consecutive
days
Oral anticoagulation: warfarin sodium was started within the ﬁrst 2 days and continued
for a total of 12 weeks
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Outcomes Primary: recurrent thromboembolism and mortality during heparin treatment and fol-
low-up
Secondary: Major bleeding during the period of heparin treatment and the subsequent
48 hours
Notes Follow-up: 3 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas performedwith a com-
puter algorithm.
Allocation concealment (selection bias) Low risk Central allocation by a 24-hour telephone
service.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Information on all suspected outcome
events and deaths was reviewed and clas-
siﬁed by a central adjudication committee
blinded to treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk The study appears to be free of other
sources of bias.
Pérez de Llano 2003
Methods Study design: multicentre, prospective open study
Method of randomisation: SAS statistics computer program
Concealment of allocation: none
Exclusions post-randomisation: none
Lost to follow-up: none
Participants Country: Spain.
Setting: 3 hospitals.
No.: enoxaparin 29, UFH 21
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Age: enoxaparin mean 66.5 ± 16.2 years, UFH mean 65.9 ± 16.3 years
Sex: enoxaparin 20 M/9 F, UFH 14 M/ 7 F
Inclusion criteria: people diagnosed with pulmonary thromboembolism (PTE) diag-
nosed by ventilation-perfusion scan or plethysmography
Exclusion criteria: people with a previous DVT, PTE with haemodynamic repercussion,
known factor of hypercoagulability, anticoagulant treatment, pregnancy, formal consid-
eration for anticoagulation or serious concomitant illnesses
Interventions Treatment: enoxaparin 1 mg/kg weight every 12 hours.
Control: 5% sodium heparin 5000 IU initial bolus through an infusion pump adjusted
to the partial thromboplastin time results to an approximated dose of 35,000 IU/day
Treatment duration: until a target INR of 2 to 3 was reached
Oral anticoagulation: acenocoumarol.
Outcomes Primary: recurrence of DVT (if plethysmography showed a new venous region affected,
if there was a proximal thrombus extension > 5 cm or if arteriography showed new intra-
luminal defects) or PE (if perfusion scan showed perfusion defects that had not existed
in the initial exploration) and major bleeding (intracranial, retroperitoneal, requiring
transfusion or haemoglobin < 2 or more points)
Notes Follow-up: 1, 3 and 6 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patientswere randomised from the
lists of enrolled patients at each centre using
the SAS statistics program”
Comment: low risk of bias.
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated.
Comment: insufﬁcient information to per-
mit judgement of low or high risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether the outcome asses-
sors were blinded to treatment and there-
fore the risk of bias was deemed unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data accounted for.
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Selective reporting (reporting bias) High risk Study authors discuss the length of hospital
stay but it was not a prespeciﬁed outcome
Other bias Low risk Study appears to be free from other sources
of bias.
Riess 2003
Methods Study design: randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: 92 participants.
Lost to follow-up: 22 participants.
Participants Country: 121 centres in Germany and the Czech Republic.
Setting: hospital and out of hospital.
No.: 1220 participants.
Age: mean 61 years.
Sex: 677 males.
Inclusion criteria: men older than 18 years with objectively conﬁrmed acute proximal
DVT for fewer than 3 weeks after given written informed consent
Exclusion criteria: isolated calf vein thrombosis; planned ﬁbrinolysis or operation; clini-
cally severe PE; heparin application within 8 days of enrolment (except treatment in the
past 24 hours), treatment with VKA for > 24 hours before start of study medication;
hypertension with systolic blood pressure > 200 mmHg and diastolic blood pressure >
105 mmHg; known malignant tumour as known cause for the venous occlusion; severe
renal or hepatic insufﬁciency; surgery of the head, chest or abdomen in the past 8 days;
intervention in the central nervous system in the past 14 days; evident disseminated
intravascular coagulation; clinical condition with an increased risk of bleeding compli-
cations during the treatment time; gastrointestinal bleeding or gastric ulcer in the past
4 weeks; contraindication against VKA or known intolerability against heparin; platelet
count < 100,000/µL; pregnancy, treatment with platelet inhibitors
Interventions Treatment: LMWH: certoparin ﬁxed unadjusted dose 8000 anti-factor Xa IU s.c., b.d.
for 10 to 14 days
Control: UFH: initial bolus i.v. of 5000 IU followed by continuous infusion starting
dose of 20 IU/kg/hour of an adjusted dose UFH to maintain an APTT of 1.5 to 2.5 ×
the control value
Outcomes Primary: incidence of VTE at the end of follow-up.
Secondary: incidence of recurrent VTE and major bleeding during initial treatment;
mortality at the end of follow-up
Notes Follow-up: 6 months.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information about sequence
generation.
Allocation concealment (selection bias) Low risk Randomisationwas carried out using a cen-
tral telephone system. The assignment to 1
of the treatment groups was documented
and could not be changed afterwards
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All events were evaluated by an indepen-
dent end point committee blinded for
treatment groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk An intent-to-treat analysis conﬁrmed the
results of the primary ’per protocol’ analysis
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk The study appears to be free of other
sources of bias.
Simonneau 1993
Methods Study design: randomised controlled trial.
Methodof randomisation: treatment assignments: sealed envelopes, block randomisation
using standard random number table and sealed envelopes
Concealment of allocation: not blinded for treatment allocation; blinded for outcome
assessment
Exclusion post-randomisation: 1 (distal DVT).
Lost to follow-up: for qualitative and quantitative venogram assessment: 17 participants
lost to follow-up (treatment cessation before day 10 (5 participants); exclusion post
randomisation (1 participant); unassessable venograms due to technical problems (11
participants))
Participants Country: 16 European centres.
Setting: hospital.
No.: 134 participants.
Age: Mean 63 years.
Sex: 73 males.
Inclusion criteria: proximal DVT with or without suspected PE, but with symptoms <
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5 days
Exclusion criteria: active bleeding or disorders contraindicating anticoagulant therapy;
surgery in previous 7 days; pregnancy; aspirin, ticlopidine, sulﬁnpyrazone or non-
steroidal anti-inﬂammatory treatment within 7 days before study entry; associated severe
PE requiring thrombolytic therapy or surgery; use of curative heparin therapy for > 24
hours or > 25,000 Units of heparin during 24 hours before referral; previous implanta-
tion of vena cava ﬁlter
Interventions Treatment: LMWH: enoxaparin, clexane body weight-adjusted ﬁxed dose (1 mg/kg ±
100 anti-factor Xa IU/kg, s.c., twice daily)
Control: UFH: dose-adjusted APTT × 1.5 to 2.5, continuous i.v. infusion started with
500 Units/kg/24 hours (25,000 Units/5 mL in saline)
Treatment duration: 10 days.
Oral anticoagulation: started on day 10 for at least 3 months; INR 2.0 to 3.0
Outcomes Primary: change in thrombus size (quantitative venographic score,Marder) betweenday 0
and day 10; recurrent VTE during 10 days of treatment (asymptomatic and symptomatic
DVT and PE); major bleeding during 10 days of treatment
Secondary: minor bleeding; follow-up at 3 months to record VTE recurrence, bleeding
and deaths; qualitative assessment of venogram evolution between day 0 and day 10
Notes Repeated venography on day 10.
Follow-up: 3 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation code was drafted by
means of a standard random number table
randomising in blocks of 4
Allocation concealment (selection bias) Low risk The participants’ treatment assignments
were taken from sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Venograms, perfusion lung scans and pul-
monary angiograms were subsequently re-
viewed by a central independent panel of 2
consultant specialists unaware of the treat-
ment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely
to be related to true outcome
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Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk The study appears to be free of other
sources of bias.
Simonneau 1997
Methods Study design: randomised controlled trial.
Method of randomisation: centrally controlled, computerised.
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: France, Belgium and Switzerland.
Setting: hospital.
No.: 612 participants.
Age: mean 67 years.
Sex: 172 males.
Inclusion criteria: clinically suspected acute PE. PE objectively documented by pul-
monary angiography or ventilation-perfusion lung scanning indicating a high proba-
bility of PE or showing indeterminate results but accompanied by DVT conﬁrmed by
venography or compression ultrasonography
Exclusion criteria: massive PE requiring thrombolytic therapy or pulmonary embolec-
tomy; active bleeding or disorders contraindicating anticoagulant therapy; anticoagulant
therapy at a therapeutic dose for > 24 hours; life expectancy < 3 months; severe hepatic
or renal failure; likely non-compliance; pregnancy
Interventions Treatment: LMWH: tinzaparin, innohep in body weight-adjusted ﬁxed dose, s.c., o.d
Control: UFH: APTT-adjusted dose, continuous i.v. infusion after an initial i.v. bolus
of 50 IU/kg
Treatment duration: at least 5 days; treatment cessation if INR was 2.0 or above on 2
measurements made 24 hours apart
Oral anticoagulation: started between the ﬁrst and third days of initial treatment and
continued for at least 3 months; INR 2.0 to 3.0
Outcomes Primary: symptomatic recurrent VTE during initial treatment (8 days) and at the end
of follow-up (day 90); major haemorrhage during initial treatment (8 days) and at the
end of follow-up (day 90); death at end of follow-up (day 90)
Notes Follow-up: 90 days.
1 participant allocated to UFH and 3 participants allocated to LMWH did not receive
the study drug
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Central randomisationwas performedwith
the use of a 24-hour computer service
Allocation concealment (selection bias) Low risk Central randomisationwas performedwith
the use of a 24-hour computer service
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data on all potential outcome events were
submitted to an independent adjudication
committee whose members were unaware
of the treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk An intention-to-treat analysis was per-
formed, but the authors do not give any in-
formation about loss to follow-up
Selective reporting (reporting bias) Low risk Published report includes all expected out-
comes.
Other bias Low risk The study appears to be free of other
sources of bias.
Thery 1992
Methods Study design: dose-ﬁnding controlled, randomised trial.
Method of randomisation: not stated
Concealment of allocation: not blinded for treatment allocation, blinded for outcome
assessment
Exclusions post-randomisation: none.
Lost to follow-up: none.
Participants Country: France,
Setting: hospital.
No.: 68: Fraxparine 35, UFH 33
Age: Fraxiparine mean 60.1 (SD 2.9) years, UFH mean 64.2 (SD 2.5) years
Sex: Fraxiparine 17 M/18 F, UFH 14 M/19 F
Inclusion criteria: adults > 18 years with a recent angiographically proved PE (within 3
days of the onset of symptoms) and with a pulmonary vascular obstruction assessed by
the local radiologists between 15% and 55% (index of severity according to Miller 5 to
18)
Exclusion criteria: angiographically determined vascular obstruction < 15% or > 55%,
any sign of clinical severity deﬁned as shock, acute cor pulmonale or right heart fail-
ure, any contraindication to heparin, active peptic ulcer, recent history of cerebrovascu-
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lar haemorrhage or ischaemia, known bleeding tendency, previous history of heparin-
induced thrombocytopenia, haemorrhagic diathesis, pre-existing coagulation disorders,
severe renal or hepatic dysfunction, severe systemic hypertension, known pericarditis
or endocarditis, pregnancy, pre-existing DVT or PE within 12 months preceding the
inclusion or use of thrombolytic agents, heparin at therapeutic doses for more than 48
hours before inclusion, oral anticoagulants, acetylsalicylic acid or ticlopidine during the
7 days before inclusion, any contraindication to isotopic or angiographic investigations
and free-ﬂoating inferior vena cava thrombus
Interventions Treatment: LMWH: Fraxiparine 400 anti-factor Xa IU U/kg in 2 daily injections
Control: UFH: i.v. bolus injection of 50 IU/kg followed by continuous infusion of an
initial dose of 600 IU/kg
Treatment duration: 14 days
Oral anticoagulation: none
Outcomes Primary: pulmonary vascular obstruction
Secondary: clinical recurrence of VTE, death and haemorrhagic complications
Notes Follow-up: 8 days
Before completion of the trial, enrolment in 2 Fraxiparine groups stopped because of a
high incidence of major bleedings. Those 2 groups were given Fraxiparine at a high dose
of 600 and 900 anti-factor Xa IU/kg. Data from these groups were not included in the
analyses in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Random treatment allocation
schedules were prepared for each clinical
centre using sealed treatment allocation en-
velopes”
Comment: insufﬁcient information about
the sequence generation process to permit
judgement of ‘Low risk’ or ‘High risk’
Allocation concealment (selection bias) Unclear risk Quote: “Random treatment allocation
schedules were prepared for each clinical
centre using sealed treatment allocation en-
velopes”
Comment: although the use of assignment
envelopes is described, it remains unclear
whether envelopes were sequentially num-
bered and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded for treatment allocation.
Comment: given the clinical outcomes of
the study, review authors judged that the
non-blinding of the participants and staff
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Thery 1992 (Continued)
was unlikely to have affected the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the study could not be per-
formed double-blind because of the dif-
ferent modes of administration and above
all the need for dosage adjustments in the
UFHgroup.However, themain assessment
criterion was blindly evaluated by a central
independent panel of three radiologists”
Comment: review authors judged that the
non-blinding of the participants and staff
was unlikely to have affected the outcomes.
Furthermore, the blinding of outcome as-
sessment was ensured
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for losses to follow-up not clearly
stated.
Selective reporting (reporting bias) Low risk Study reports data on all pre-speciﬁed out-
comes.
Other bias Low risk Study appears to be free from other sources
of bias.
APTT: activated partial thromboplastin time
cm: centimetre
DVT: deep vein thrombosis
F: female
INR: International normalised ratio
IU: International units
i.v.: intravenous
kg: kilogram
LMWH: low molecular weight heparin
M: male
mg: milligram
mL: millilitre
mm: millimetre
mmHg: millimetres of mercury
NSAID: nonsteroidal anti-inﬂammatory drug
PE: pulmonary embolism
PTE: pulmonary thromboembolism
o.d.: once daily
s.c.: subcutaneous
SD: standard deviation
UFH: unfractionated heparin
VKA: vitamin K antagonists
VTE: venous thromboembolism
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aiach 1989 Low molecular weight heparin dosage was adjusted.
Albada 1989 The results from participants treated for venous thrombosis of the upper limb and for pulmonary embolism
could not be distinguished from those of people with leg vein thrombosis, and the outcome was incompletely
evaluated
Banga 1993 This was a dose-ﬁnding study.
Bratt 1985 Intravenous route of administration of low molecular weight heparin, and adjustments were made to dose for
this treatment
Bratt 1990 Low molecular weight heparin dosage was adjusted.
de Valk 1995 This was a dose-ﬁnding study.
Handeland 1990 This was a dose-ﬁnding study.
Harenberg 1989 Abstract with incomplete data.
Harenberg 1990 The results from people treated for venous thrombosis of the upper limb and for pulmonary embolism could
not be distinguished from those of participants with leg vein thrombosis, and the outcome was incompletely
evaluated
Harenberg 2000b Abstract with incomplete data.
Holm 1986 Low molecular weight heparin dosage was adjusted.
Kearon 2006 The administration of unfractionated heparin was not in adjusted dose
Lockner 1985 Intravenous route of administration of low molecular weight heparin
Lockner 1986 Intravenous route of administration of low molecular weight heparin
Ly 1985 Adjustment of low molecular weight heparin dosages.
Monreal 1993 The 2 treatment strategies differ with respect to long-term treatment
Monreal 1994 The 2 treatment strategies differ with respect to long-term treatment
Notarbartolo 1988 Dosage of unfractionated heparin was not adjusted.
Quiros 2001 Not a randomised controlled trial.
Riess 2014 Substudy of Harenberg 1990 and Reiss 2003 studies which are already included in the review
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Siguret 2011 Comparison group were not treated with unfractionated heparin
Stricker 1999 The main outcome of the study was the effect on haemostatic markers which is not within the scope of our
review
Tedoldi 1993 Dosage of unfractionated heparin was not adjusted.
Ucar 2015 Participants were given thrombolytic treatment.
Vogel 1987 Intravenous route of administration of low molecular weight heparin
Zanghi 1988 Dosage of unfractionated heparin was not adjusted.
Characteristics of ongoing studies [ordered by study ID]
NCT00796692
Trial name or title Nadroparin for the Initial Treatment of Pulmonary Thromboembolism (NATSPUTE)
Methods Multicentre, randomised, open-label, parallel assignment controlled trial
Participants Inclusion criteria: 18 to 75 years of age, symptomatic non-massive PTE conﬁrmed either by high probability
ventilation-perfusion lung scanning (V/Q scan) or by the presence of intraluminal ﬁlling defect on spiral
computed tomographic pulmonary angiography (CTPA), haemodynamically stabile, anatomic obstruction
no more than 2 lobes on CTPA, or defect no more than 7 segments on V/Q scan, and normal right ventricular
function, symptoms within 15 days, written informed consent obtained before randomisation
Exclusion criteria: unfractionated heparin anticoagulation for more than 36 hours prior enrolment, massive
PTE or sub-massive PTE requiring thrombolytic therapy or pulmonary embolectomy, active bleeding or disor-
ders contraindicating anticoagulant therapy, chronic thromboembolism pulmonary hypertension (CTEPH)
without evidence of recent episode, severe hepatic or renal failure, allergy to heparin, other components of
tinzaparin or acenocoumarol, pregnant status, a life expectancy of less than 3 months, previous thrombocy-
topaenia induced by heparin, thrombocytopaenia < 100,000/mm³
Interventions Treatment: LMWH given with a weight-adjusted dose of 86 international anti-factor Xa units of nadroparin
(Fraxiparine) per kilogram of body weight (86 anti-factor Xa IU/kg) subcutaneously every 12 hours, which
will be used at least 5 to 7 days
Control: UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous
intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so
that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal
subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had
been measured after a dose adjustment, and otherwise daily. UFH will be used at least 5 to 7 days
Treatment duration: 5 to 7 days.
Oral anticoagulation: warfarin.
Outcomes Primary: clinical and image (including V/Q scan and CTPA) improvement at 14 days
Secondary: recurrent venous thromboembolism (VTE), major bleeding, death and heparin-induced throm-
bocytopaenia at 3 months
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NCT00796692 (Continued)
Starting date June 2002
Contact information Professor Chen Wang, Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, China
Notes Study authors have been contacted for further information but no response received to date
IU: international units
kg: kilogram
LMWH: low molecular weight heparin
mm: millimetre
PTE: pulmonary thromboembolism
UFH: unfractionated heparin
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D A T A A N D A N A L Y S E S
Comparison 1. LMWH versus UFH in patients with venous thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent venous
thromboembolism during
initial treatment
18 6238 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.49, 0.98]
1.1 Nadroparin versus
unfractionated heparin
5 950 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.50 [0.20, 1.26]
1.2 Tinzaparin versus
unfractionated heparin
1 612 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.52 [0.26, 8.80]
1.3 Enoxaparin versus
unfractionated heparin
5 1143 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.51 [0.27, 0.98]
1.4 Dalteparin versus
unfractionated heparin
3 495 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.08 [0.07, 17.43]
1.5 Reviparin versus
unfractionated heparin
1 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.07 [0.52, 2.19]
1.6 Certoparin versus
unfractionated heparin
3 2017 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.35, 1.32]
2 Incidence of recurrent venous
thromboembolism at the end
of follow-up
22 9489 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.72 [0.59, 0.88]
2.1 Nadroparin versus
unfractionated heparin
5 1730 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.74 [0.49, 1.11]
2.2 Tinzaparin versus
unfractionated heparin
3 1581 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.41, 1.40]
2.3 Ardeparin versus
unfractionated heparin
1 80 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.00, 6.49]
2.4 Enoxaparin versus
unfractionated heparin
6 2043 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.49, 1.17]
2.5 Dalteparin versus
unfractionated heparin
2 264 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.71 [0.42, 7.02]
2.6 Reviparin versus
unfractionated heparin
2 1784 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.44, 1.05]
2.7 Certoparin versus
unfractionated heparin
3 2007 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.63 [0.40, 0.99]
3 Incidence of recurrent venous
thromboembolism at 1 month
follow-up
4 1741 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.56, 1.44]
3.1 Nadroparin versus
unfractionated heparin
1 170 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.50 [0.10, 2.55]
3.2 Enoxaparin versus
unfractionated heparin
2 550 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.59 [0.24, 1.48]
3.3 Reviparin versus
unfractionated heparin
1 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.15 [0.64, 2.06]
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4 Incidence of recurrent venous
thromboembolism at 3 months’
follow-up
16 6661 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.56, 0.90]
4.1 Nadroparin versus
unfractionated heparin
5 1730 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.77 [0.49, 1.21]
4.2 Tinzaparin versus
unfractionated heparin
2 1044 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.54 [0.26, 1.08]
4.3 Enoxaparin versus
unfractionated heparin
6 2043 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.49, 1.17]
4.4 Dalteparin versus
unfractionated heparin
1 60 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Reviparin versus
unfractionated heparin
2 1784 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.44, 1.05]
5 Incidence of recurrent venous
thromboembolism at 6 months’
follow-up
7 2841 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.48, 0.96]
5.1 Nadroparin versus
unfractionated heparin
2 570 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.66 [0.37, 1.19]
5.2 Dalteparin versus
unfractionated heparin
1 204 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.71 [0.42, 7.02]
5.3 Certoparin versus
unfractionated heparin
3 2007 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.63 [0.40, 0.99]
5.4 Enoxaparin versus
unfractionated heparin
1 60 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Reduction in thrombus size (pre-
and post-treatment venograms)
16 2909 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.61, 0.82]
6.1 Nadroparin versus
unfractionated heparin
4 507 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.72 [0.50, 1.05]
6.2 Ardeparin versus
unfractionated heparin
1 75 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.37 [0.14, 0.99]
6.3 Enoxaparin versus
unfractionated heparin
1 117 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.17, 0.71]
6.4 Dalteparin versus
unfractionated heparin
5 650 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.25 [0.90, 1.73]
6.5 CY 222 versus
unfractionated heparin
1 59 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.32, 2.62]
6.6 Reviparin versus
unfractionated heparin
1 649 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.59 [0.43, 0.80]
6.7 Certoparin versus
unfractionated heparin
2 649 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.70 [0.50, 0.98]
6.8 Bemiparin versus
unfractionated heparin
1 203 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.42 [0.24, 0.74]
7 Incidence of major haemorrhagic
episodes (during initial
treatment)
25 8780 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.50, 0.95]
7.1 Nadroparin versus
unfractionated heparin
7 1964 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.44 [0.19, 1.01]
7.2 Tinzaparin versus
unfractionated heparin
3 1581 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.41, 1.22]
7.3 Enoxaparin versus
unfractionated heparin
5 1143 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.22 [0.54, 2.75]
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7.4 Dalteparin versus
unfractionated heparin
4 765 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.15 [0.02, 1.44]
7.5 CY 222 versus
unfractionated heparin
1 68 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.01, 1.34]
7.6 Reviparin versus
unfractionated heparin
1 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.49, 3.19]
7.7 Certoparin versus
unfractionated heparin
3 2017 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.50 [0.25, 1.00]
7.8 Bemiparin versus
unfractionated heparin
1 221 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.39 [0.46, 118.89]
8 Overall mortality at the end of
follow-up
24 9663 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.84 [0.70, 1.01]
8.1 Nadroparin versus
unfractionated heparin
5 1504 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.77 [0.48, 1.22]
8.2 Tinzaparin versus
unfractionated heparin
3 1581 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.03 [0.69, 1.53]
8.3 Ardeparin versus
unfractionated heparin
1 80 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 Enoxaparin versus
unfractionated heparin
6 2043 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.92 [0.64, 1.31]
8.5 Dalteparin versus
unfractionated heparin
3 490 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.46 [0.13, 1.60]
8.6 Reviparin versus
unfractionated heparin
2 1784 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.89 [0.59, 1.35]
8.7 Certoparin versus
unfractionated heparin
3 2007 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.59 [0.36, 0.97]
8.8 Bemiparin versus
unfractionated heparin
1 174 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.95 [0.13, 6.90]
Comparison 2. LMWH versus UFH in patients with proximal deep venous thrombosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent venous
thromboembolism at the end
of follow-up
10 4672 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.57 [0.44, 0.75]
1.1 Nadroparin versus
unfractionated heparin
3 864 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.72 [0.44, 1.19]
1.2 Tinzaparin versus
unfractionated heparin
1 432 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.42 [0.17, 1.01]
1.3 Enoxaparin versus
unfractionated heparin
2 634 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.65 [0.32, 1.32]
1.4 Reviparin versus
unfractionated heparin
1 763 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.31 [0.15, 0.63]
1.5 Certoparin versus
unfractionated heparin
2 1758 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.64 [0.40, 1.03]
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1.6 Bemiparin versus
unfractionated heparin
1 221 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Incidence of recurrent deep
venous thrombosis at the end
of follow-up
7 2681 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.61 [0.41, 0.91]
2.1 Nadroparin versus
unfractionated heparin
3 765 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.41, 1.43]
2.2 Tinzaparin versus
unfractionated heparin
1 432 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.37 [0.12, 1.16]
2.3 Enoxaparin versus
unfractionated heparin
1 500 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.74 [0.34, 1.63]
2.4 Reviparin versus
unfractionated heparin
1 763 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.45 [0.17, 1.21]
2.5 Bemiparin versus
unfractionated heparin
1 221 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.01, 2.14]
3 Incidence of pulmonary
embolism at the end of
follow-up
7 3024 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.45 [0.28, 0.74]
3.1 Nadroparin versus
unfractionated heparin
2 570 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.65 [0.27, 1.60]
3.2 Tinzaparin versus
unfractionated heparin
1 432 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.52 [0.14, 1.95]
3.3 Enoxaparin versus
unfractionated heparin
1 500 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.52 [0.05, 5.07]
3.4 Reviparin versus
unfractionated heparin
1 763 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.27 [0.10, 0.73]
3.5 Certoparin versus
unfractionated heparin
1 538 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.32 [0.11, 0.92]
3.6 Bemiparin versus
unfractionated heparin
1 221 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.94 [0.20, 18.86]
4 Reduction in thrombus size (pre-
and post-treatment venograms)
2 230 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.47 [0.27, 0.80]
4.1 Bemiparin versus
unfractionated heparin
1 203 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.42 [0.24, 0.74]
4.2 Dalteparin versus
unfractionated heparin
1 27 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.47 [0.22, 9.90]
5 Incidence of major haemorrhagic
episodes (during initial
treatment)
8 3589 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.50 [0.29, 0.85]
5.1 Nadroparin versus
unfractionated heparin
3 765 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.42 [0.09, 1.85]
5.2 Tinzaparin versus
unfractionated heparin
1 432 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.19 [0.06, 0.59]
5.3 Enoxaparin versus
unfractionated heparin
2 634 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.70 [0.42, 6.87]
5.4 Certoparin versus
unfractionated heparin
2 1758 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.55 [0.26, 1.17]
6 Overall mortality at the end of
follow-up
9 4331 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.63 [0.47, 0.85]
6.1 Nadroparin versus
unfractionated heparin
2 570 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.38, 1.24]
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6.2 Tinzaparin versus
unfractionated heparin
1 432 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.48 [0.23, 1.00]
6.3 Enoxaparin versus
unfractionated heparin
2 634 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.74 [0.37, 1.50]
6.4 Reviparin versus
unfractionated heparin
1 763 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.32, 1.91]
6.5 Certoparin versus
unfractionated heparin
2 1758 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.54 [0.30, 0.96]
6.6 Bemiparin versus
unfractionated heparin
1 174 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.95 [0.13, 6.90]
Comparison 3. LMWH versus UFH in patients with pulmonary embolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent venous
thromboembolism at the end
of follow-up
7 1407 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.50, 1.61]
1.1 Tinzaparin versus
unfractionated heparin
2 680 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.84 [0.26, 2.77]
1.2 Enoxaparin versus
unfractionated heparin
3 396 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.89 [0.37, 2.16]
1.3 Dalteparin versus
unfractionated heparin
1 60 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Reviparin versus
unfractionated heparin
1 271 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.96 [0.35, 2.64]
2 Reduction in thrombus size (pre-
and post-treatment venograms)
2 106 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.36 [0.23, 8.16]
2.1 Nadroparin versus
unfractionated heparin
1 52 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.53 [0.32, 95.93]
2.2 Dalteparin versus
unfractionated heparin
1 54 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.54 [0.05, 5.43]
3 Mean change in pulmonary
vascular obstruction severity
score
2 106 Mean Difference (IV, Fixed, 95% CI) -3.14 [-4.39, -1.90]
3.1 Nadroparin versus
unfractionated heparin
1 52 Mean Difference (IV, Fixed, 95% CI) -3.28 [-4.55, -2.01]
3.2 Dalteparin versus
unfractionated heparin
1 54 Mean Difference (IV, Fixed, 95% CI) 1.0 [-5.94, 7.94]
4 Incidence of major haemorrhagic
episodes (during initial
treatment)
3 178 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.44 [0.04, 4.29]
4.1 Nadroparin versus
unfractionated heparin
1 68 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.12 [0.01, 2.02]
4.2 Enoxaparin versus
unfractionated heparin
1 50 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.61 [0.11, 297.44]
79Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4.3 Dalteparin versus
unfractionated heparin
1 60 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Overall mortality at end of
follow-up
3 178 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.70 [0.17, 16.71]
5.1 Nadroparin versus
unfractionated heparin
1 68 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.94 [0.06, 15.40]
5.2 Enoxaparin versus
unfractionated heparin
1 50 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.61 [0.11, 297.44]
5.3 Dalteparin versus
unfractionated heparin
1 60 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. LMWH versus UFH in patients with venous thromboembolism and malignant disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at the end of follow-up 6 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Mortality in patients with
malignant disease
6 446 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.53 [0.33, 0.85]
1.2 Mortality in patients with
malignant disease in trial with
adequate concealment
5 430 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.51 [0.31, 0.82]
Comparison 5. LMWH versus UFH in patients with venous thromboembolism without malignant disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at the end of follow-up 6 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Mortality in patients
without malignant disease
6 2139 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.97 [0.61, 1.56]
1.2 Mortality in patients
without malignant disease
in trials with adequate
concealment
5 1951 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.00 [0.62, 1.62]
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Comparison 6. LMWH versus subcutaneous UFH in patients with venous thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent venous
thromboembolism at the end
of follow-up
3 1403 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.56, 1.95]
2 Incidence of major haemorrhagic
episodes (during initial
treatment)
4 1471 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.50, 1.67]
3 Overall mortality at the end of
follow-up
3 1403 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.46 [0.91, 2.35]
Comparison 7. LMWH versus intravenous UFH in patients with venous thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent venous
thromboembolism at the end
of follow-up
21 8375 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.56, 0.86]
2 Incidence of major haemorrhagic
episodes (during initial
treatment)
21 7309 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.62 [0.43, 0.90]
3 Overall mortality at the end of
follow-up
21 8260 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.77 [0.63, 0.93]
Comparison 8. LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent venous
thromboembolism during
initial treatment
10 4862 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.72 [0.50, 1.05]
1.1 Nadroparin versus
unfractionated heparin
3 716 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.50 [0.18, 1.39]
1.2 Tinzaparin versus
unfractionated heparin
1 612 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.52 [0.26, 8.80]
1.3 Enoxaparin versus
unfractionated heparin
3 1034 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.48 [0.24, 0.96]
1.4 Reviparin versus
unfractionated heparin
1 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.07 [0.52, 2.19]
1.5 Certoparin versus
unfractionated heparin
2 1479 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.40, 1.58]
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2 Incidence of recurrent venous
thromboembolism at the end
of follow-up
14 6984 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.60, 0.96]
2.1 Nadroparin versus
unfractionated heparin
4 1436 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.70 [0.45, 1.10]
2.2 Tinzaparin versus
unfractionated heparin
2 1044 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.54 [0.26, 1.08]
2.3 Ardeparin versus
unfractionated heparin
1 81 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.00, 6.65]
2.4 Enoxaparin versus
unfractionated heparin
4 1934 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.51, 1.22]
2.5 Reviparin versus
unfractionated heparin
1 1020 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.08 [0.62, 1.89]
2.6 Certoparin versus
unfractionated heparin
2 1469 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.73 [0.42, 1.25]
3 Incidence of recurrent venous
thromboembolism at 3 months’
follow-up
11 5435 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.60, 1.02]
3.1 Nadroparin versus
unfractionated heparin
4 1436 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.73 [0.44, 1.22]
3.2 Tinzaparin versus
unfractionated heparin
2 1044 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.54 [0.26, 1.08]
3.3 Enoxaparin versus
unfractionated heparin
4 1934 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.51, 1.22]
3.4 Reviparin versus
unfractionated heparin
1 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.09 [0.62, 1.90]
4 Reduction in thrombus size (pre-
and post-treatment venograms)
5 753 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.49 [0.37, 0.66]
4.1 Nadroparin versus
unfractionated heparin
2 302 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.49 [0.31, 0.77]
4.2 Ardeparin versus
unfractionated heparin
1 75 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.37 [0.14, 0.99]
4.3 Enoxparin versus
unfractionated heparin
1 117 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.17, 0.71]
4.4 Certoparin versus
unfractionated heparin
1 259 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.63 [0.38, 1.04]
5 Incidence of major haemorrhagic
episodes (during initial
treatment)
12 6014 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.45, 1.03]
5.1 Nadroparin versus
unfractionated heparin
4 1436 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.51 [0.18, 1.40]
5.2 Tinzaparin versus
unfractionated heparin
2 1044 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.30 [0.12, 0.73]
5.3 Enoxaparin versus
unfractionated heparin
3 1034 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.50, 2.61]
5.4 Reviparin versus
unfractionated heparin
1 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.49, 3.19]
5.5 Certoparin versus
unfractionated heparin
2 1479 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.62 [0.24, 1.56]
6 Overall mortality at the end of
follow-up
14 6984 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.80 [0.65, 0.99]
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6.1 Nadroparin versus
unfractionated heparin
4 1436 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.47, 1.22]
6.2 Tinzaparin versus
unfractionated heparin
2 1044 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.63 [0.37, 1.08]
6.3 Ardeparin versus
unfractionated heparin
1 80 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Enoxaparin versus
unfractionated heparin
4 1934 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.63, 1.29]
6.5 Reviparin versus
unfractionated heparin
1 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.92 [0.57, 1.47]
6.6 Certoparin versus
unfractionated heparin
2 1469 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.70 [0.38, 1.26]
Comparison 9. LMWH versus UFH: all randomised controlled trials that used ISTH definition of major bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of major haemorrhagic
episodes (during initial
treatment)
24 8712 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.52, 0.98]
1.1 Nadroparin versus
unfractionated heparin
7 1964 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.44 [0.19, 1.01]
1.2 Tinzaparin versus
unfractionated heparin
3 1581 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.41, 1.22]
1.3 Enoxaparin versus
unfractionated heparin
5 1143 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.22 [0.54, 2.75]
1.4 Dalteparin versus
unfractionated heparin
4 765 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.15 [0.02, 1.44]
1.5 Reviparin versus
unfractionated heparin
1 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.49, 3.19]
1.6 Certoparin versus
unfractionated heparin
3 2017 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.50 [0.25, 1.00]
1.7 Bemiparin versus
unfractionated heparin
1 221 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.39 [0.46, 118.89]
Comparison 10. LMWH versus UFH by year of publication
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent venous
thromboembolism during
initial treatment
18 6238 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.49, 0.98]
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2 Incidence of recurrent venous
thromboembolism at the end
of follow-up
22 9489 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.72 [0.59, 0.88]
3 Incidence of major haemorrhagic
episodes (during initial
treatment)
25 8790 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.51, 0.95]
4 Overall mortality at the end of
follow-up
24 9663 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.84 [0.70, 1.01]
Analysis 1.1. Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 1
Incidence of recurrent venous thromboembolism during initial treatment.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 LMWH versus UFH in patients with venous thromboembolism
Outcome: 1 Incidence of recurrent venous thromboembolism during initial treatment
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 4/202 5/198 7.0 % 0.78 [ 0.21, 2.92 ]
Lopaciuk 1992 0/74 1/72 0.8 % 0.13 [ 0.00, 6.64 ]
Ninet 1991 1/85 2/81 2.3 % 0.48 [ 0.05, 4.73 ]
Prandoni 1992 1/85 4/85 3.9 % 0.29 [ 0.05, 1.72 ]
Thery 1992 0/35 0/33 Not estimable
Subtotal (95% CI) 481 469 14.0 % 0.50 [ 0.20, 1.26 ]
Total events: 6 (LMWH), 12 (UFH)
Heterogeneity: Chi2 = 1.23, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Tinzaparin versus unfractionated heparin
Simonneau 1997 3/304 2/308 3.9 % 1.52 [ 0.26, 8.80 ]
Subtotal (95% CI) 304 308 3.9 % 1.52 [ 0.26, 8.80 ]
Total events: 3 (LMWH), 2 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
3 Enoxaparin versus unfractionated heparin
Decousus 1998 3/195 8/205 8.5 % 0.41 [ 0.13, 1.37 ]
Findik 2002 0/29 1/30 0.8 % 0.14 [ 0.00, 7.06 ]
Levine 1996 7/247 12/253 14.5 % 0.59 [ 0.24, 1.48 ]
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
P rez de Llano 2003 3/29 2/21 3.5 % 1.09 [ 0.17, 6.98 ]
Simonneau 1993 0/67 2/67 1.6 % 0.13 [ 0.01, 2.15 ]
Subtotal (95% CI) 567 576 28.9 % 0.51 [ 0.27, 0.98 ]
Total events: 13 (LMWH), 25 (UFH)
Heterogeneity: Chi2 = 2.18, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
4 Dalteparin versus unfractionated heparin
Fiessinger 1996 1/111 1/120 1.6 % 1.08 [ 0.07, 17.43 ]
Lindmarker 1994 0/101 0/103 Not estimable
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 241 254 1.6 % 1.08 [ 0.07, 17.43 ]
Total events: 1 (LMWH), 1 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
5 Reviparin versus unfractionated heparin
Columbus 1997 16/510 15/511 23.8 % 1.07 [ 0.52, 2.19 ]
Subtotal (95% CI) 510 511 23.8 % 1.07 [ 0.52, 2.19 ]
Total events: 16 (LMWH), 15 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
6 Certoparin versus unfractionated heparin
Harenberg 2000a 0/265 3/273 2.4 % 0.14 [ 0.01, 1.34 ]
Kirchmaier 1998 1/128 3/131 3.1 % 0.37 [ 0.05, 2.67 ]
Riess 2003 14/627 15/593 22.4 % 0.88 [ 0.42, 1.84 ]
Subtotal (95% CI) 1020 997 27.9 % 0.68 [ 0.35, 1.32 ]
Total events: 15 (LMWH), 21 (UFH)
Heterogeneity: Chi2 = 2.72, df = 2 (P = 0.26); I2 =27%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 3123 3115 100.0 % 0.69 [ 0.49, 0.98 ]
Total events: 54 (LMWH), 76 (UFH)
Heterogeneity: Chi2 = 9.77, df = 14 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Chi2 = 3.63, df = 5 (P = 0.60), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
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Analysis 1.2. Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 2
Incidence of recurrent venous thromboembolism at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 LMWH versus UFH in patients with venous thromboembolism
Outcome: 2 Incidence of recurrent venous thromboembolism at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Belcaro 1999 6/98 13/196 4.2 % 0.92 [ 0.34, 2.46 ]
Koopman 1996 14/202 17/198 7.6 % 0.79 [ 0.38, 1.65 ]
Lopaciuk 1992 0/74 3/72 0.8 % 0.13 [ 0.01, 1.25 ]
Prandoni 1992 6/85 12/85 4.3 % 0.48 [ 0.18, 1.26 ]
Prandoni 2004 14/360 15/360 7.4 % 0.93 [ 0.44, 1.96 ]
Subtotal (95% CI) 819 911 24.3 % 0.74 [ 0.49, 1.11 ]
Total events: 40 (LMWH), 60 (UFH)
Heterogeneity: Chi2 = 3.65, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Tinzaparin versus unfractionated heparin
Hull 1992 6/213 15/219 5.3 % 0.42 [ 0.17, 1.01 ]
Leizorovicz 2011 7/269 3/268 2.6 % 2.25 [ 0.64, 7.85 ]
Simonneau 1997 5/304 6/308 2.9 % 0.84 [ 0.26, 2.77 ]
Subtotal (95% CI) 786 795 10.8 % 0.76 [ 0.41, 1.40 ]
Total events: 18 (LMWH), 24 (UFH)
Heterogeneity: Chi2 = 4.69, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.89 (P = 0.38)
3 Ardeparin versus unfractionated heparin
Goldhaber 1998 0/41 1/39 0.3 % 0.13 [ 0.00, 6.49 ]
Subtotal (95% CI) 41 39 0.3 % 0.13 [ 0.00, 6.49 ]
Total events: 0 (LMWH), 1 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.31)
4 Enoxaparin versus unfractionated heparin
Decousus 1998 10/195 12/205 5.5 % 0.87 [ 0.37, 2.05 ]
Findik 2002 1/29 3/30 1.0 % 0.36 [ 0.05, 2.70 ]
Levine 1996 13/247 17/253 7.5 % 0.77 [ 0.37, 1.62 ]
Merli 2001 21/610 11/290 7.2 % 0.90 [ 0.42, 1.92 ]
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
P rez de Llano 2003 0/29 0/21 Not estimable
Simonneau 1993 0/67 3/67 0.8 % 0.13 [ 0.01, 1.28 ]
Subtotal (95% CI) 1177 866 22.0 % 0.76 [ 0.49, 1.17 ]
Total events: 45 (LMWH), 46 (UFH)
Heterogeneity: Chi2 = 3.10, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
5 Dalteparin versus unfractionated heparin
Lindmarker 1994 5/101 3/103 2.1 % 1.71 [ 0.42, 7.02 ]
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 130 134 2.1 % 1.71 [ 0.42, 7.02 ]
Total events: 5 (LMWH), 3 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
6 Reviparin versus unfractionated heparin
Breddin 2001 7/388 24/375 7.9 % 0.31 [ 0.15, 0.63 ]
Columbus 1997 27/510 25/511 13.1 % 1.09 [ 0.62, 1.90 ]
Subtotal (95% CI) 898 886 21.1 % 0.68 [ 0.44, 1.05 ]
Total events: 34 (LMWH), 49 (UFH)
Heterogeneity: Chi2 = 7.38, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.74 (P = 0.082)
7 Certoparin versus unfractionated heparin
Harenberg 2000a 6/265 15/273 5.4 % 0.42 [ 0.18, 1.01 ]
Kirchmaier 1998 2/125 4/124 1.6 % 0.50 [ 0.10, 2.53 ]
Riess 2003 22/627 27/593 12.5 % 0.76 [ 0.43, 1.35 ]
Subtotal (95% CI) 1017 990 19.4 % 0.63 [ 0.40, 0.99 ]
Total events: 30 (LMWH), 46 (UFH)
Heterogeneity: Chi2 = 1.30, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
Total (95% CI) 4868 4621 100.0 % 0.72 [ 0.59, 0.88 ]
Total events: 172 (LMWH), 229 (UFH)
Heterogeneity: Chi2 = 22.84, df = 19 (P = 0.24); I2 =17%
Test for overall effect: Z = 3.23 (P = 0.0013)
Test for subgroup differences: Chi2 = 2.71, df = 6 (P = 0.84), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
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Analysis 1.3. Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 3
Incidence of recurrent venous thromboembolism at 1 month follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 LMWH versus UFH in patients with venous thromboembolism
Outcome: 3 Incidence of recurrent venous thromboembolism at 1 month follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Prandoni 1992 2/85 4/85 8.4 % 0.50 [ 0.10, 2.55 ]
Subtotal (95% CI) 85 85 8.4 % 0.50 [ 0.10, 2.55 ]
Total events: 2 (LMWH), 4 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
2 Enoxaparin versus unfractionated heparin
Levine 1996 7/247 12/253 26.5 % 0.59 [ 0.24, 1.48 ]
P rez de Llano 2003 0/29 0/21 Not estimable
Subtotal (95% CI) 276 274 26.5 % 0.59 [ 0.24, 1.48 ]
Total events: 7 (LMWH), 12 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
3 Reviparin versus unfractionated heparin
Columbus 1997 25/510 22/511 65.0 % 1.15 [ 0.64, 2.06 ]
Subtotal (95% CI) 510 511 65.0 % 1.15 [ 0.64, 2.06 ]
Total events: 25 (LMWH), 22 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 871 870 100.0 % 0.90 [ 0.56, 1.44 ]
Total events: 34 (LMWH), 38 (UFH)
Heterogeneity: Chi2 = 1.94, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 1.94, df = 2 (P = 0.38), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.4. Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 4
Incidence of recurrent venous thromboembolism at 3 months’ follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 LMWH versus UFH in patients with venous thromboembolism
Outcome: 4 Incidence of recurrent venous thromboembolism at 3 months’ follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Belcaro 1999 6/98 13/196 5.9 % 0.92 [ 0.34, 2.46 ]
Koopman 1996 8/202 10/198 6.5 % 0.78 [ 0.30, 2.00 ]
Lopaciuk 1992 0/74 3/72 1.1 % 0.13 [ 0.01, 1.25 ]
Prandoni 1992 4/85 7/85 3.9 % 0.56 [ 0.17, 1.89 ]
Prandoni 2004 14/360 15/360 10.4 % 0.93 [ 0.44, 1.96 ]
Subtotal (95% CI) 819 911 27.8 % 0.77 [ 0.49, 1.21 ]
Total events: 32 (LMWH), 48 (UFH)
Heterogeneity: Chi2 = 3.02, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Tinzaparin versus unfractionated heparin
Hull 1992 6/213 15/219 7.5 % 0.42 [ 0.17, 1.01 ]
Simonneau 1997 5/304 6/308 4.1 % 0.84 [ 0.26, 2.77 ]
Subtotal (95% CI) 517 527 11.5 % 0.54 [ 0.26, 1.08 ]
Total events: 11 (LMWH), 21 (UFH)
Heterogeneity: Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
3 Enoxaparin versus unfractionated heparin
Decousus 1998 10/195 12/205 7.8 % 0.87 [ 0.37, 2.05 ]
Findik 2002 1/29 3/30 1.4 % 0.36 [ 0.05, 2.70 ]
Levine 1996 13/247 17/253 10.6 % 0.77 [ 0.37, 1.62 ]
Merli 2001 21/610 11/290 10.1 % 0.90 [ 0.42, 1.92 ]
P rez de Llano 2003 0/29 0/21 Not estimable
Simonneau 1993 0/67 3/67 1.1 % 0.13 [ 0.01, 1.28 ]
Subtotal (95% CI) 1177 866 31.0 % 0.76 [ 0.49, 1.17 ]
Total events: 45 (LMWH), 46 (UFH)
Heterogeneity: Chi2 = 3.10, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
4 Dalteparin versus unfractionated heparin
0.01 0.1 1 10 100
Favours LMWH Favours UFH
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 29 31 Not estimable
Total events: 0 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Reviparin versus unfractionated heparin
Breddin 2001 7/388 24/375 11.1 % 0.31 [ 0.15, 0.63 ]
Columbus 1997 27/510 25/511 18.5 % 1.09 [ 0.62, 1.90 ]
Subtotal (95% CI) 898 886 29.6 % 0.68 [ 0.44, 1.05 ]
Total events: 34 (LMWH), 49 (UFH)
Heterogeneity: Chi2 = 7.38, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 3440 3221 100.0 % 0.71 [ 0.56, 0.90 ]
Total events: 122 (LMWH), 164 (UFH)
Heterogeneity: Chi2 = 15.22, df = 13 (P = 0.29); I2 =15%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Chi2 = 0.86, df = 3 (P = 0.83), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours UFH
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Analysis 1.5. Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 5
Incidence of recurrent venous thromboembolism at 6 months’ follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 LMWH versus UFH in patients with venous thromboembolism
Outcome: 5 Incidence of recurrent venous thromboembolism at 6 months’ follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 14/202 17/198 22.8 % 0.79 [ 0.38, 1.65 ]
Prandoni 1992 6/85 12/85 12.9 % 0.48 [ 0.18, 1.26 ]
Subtotal (95% CI) 287 283 35.7 % 0.66 [ 0.37, 1.19 ]
Total events: 20 (LMWH), 29 (UFH)
Heterogeneity: Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Dalteparin versus unfractionated heparin
Lindmarker 1994 5/101 3/103 6.1 % 1.71 [ 0.42, 7.02 ]
Subtotal (95% CI) 101 103 6.1 % 1.71 [ 0.42, 7.02 ]
Total events: 5 (LMWH), 3 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
3 Certoparin versus unfractionated heparin
Harenberg 2000a 6/265 15/273 16.1 % 0.42 [ 0.18, 1.01 ]
Kirchmaier 1998 2/125 4/124 4.7 % 0.50 [ 0.10, 2.53 ]
Riess 2003 22/627 27/593 37.4 % 0.76 [ 0.43, 1.35 ]
Subtotal (95% CI) 1017 990 58.2 % 0.63 [ 0.40, 0.99 ]
Total events: 30 (LMWH), 46 (UFH)
Heterogeneity: Chi2 = 1.30, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
4 Enoxaparin versus unfractionated heparin
P rez de Llano 2003 0/29 0/31 Not estimable
Subtotal (95% CI) 29 31 Not estimable
Total events: 0 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1434 1407 100.0 % 0.68 [ 0.48, 0.96 ]
Total events: 55 (LMWH), 78 (UFH)
Heterogeneity: Chi2 = 3.76, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Chi2 = 1.78, df = 2 (P = 0.41), I2 =0.0%
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Analysis 1.6. Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 6
Reduction in thrombus size (pre- and post-treatment venograms).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 LMWH versus UFH in patients with venous thromboembolism
Outcome: 6 Reduction in thrombus size (pre- and post-treatment venograms)
Study or subgroup LMWH UFH
Peto Odds
Ratio(Non-event) Weight
Peto Odds
Ratio(Non-event)
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Lopaciuk 1992 45/68 32/66 5.0 % 0.49 [ 0.25, 0.96 ]
Ninet 1991 24/78 30/75 5.3 % 1.49 [ 0.77, 2.89 ]
Prandoni 1992 50/83 36/85 6.4 % 0.49 [ 0.27, 0.90 ]
Thery 1992 29/31 21/21 0.3 % 5.53 [ 0.32, 95.93 ]
Subtotal (95% CI) 260 247 16.9 % 0.72 [ 0.50, 1.05 ]
Total events: 148 (LMWH), 119 (UFH)
Heterogeneity: Chi2 = 9.45, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 1.72 (P = 0.086)
2 Ardeparin versus unfractionated heparin
Goldhaber 1998 31/39 21/36 2.4 % 0.37 [ 0.14, 0.99 ]
Subtotal (95% CI) 39 36 2.4 % 0.37 [ 0.14, 0.99 ]
Total events: 31 (LMWH), 21 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
3 Enoxaparin versus unfractionated heparin
Simonneau 1993 35/60 18/57 4.4 % 0.34 [ 0.17, 0.71 ]
Subtotal (95% CI) 60 57 4.4 % 0.34 [ 0.17, 0.71 ]
Total events: 35 (LMWH), 18 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0038)
4 Dalteparin versus unfractionated heparin
Fiessinger 1996 31/96 41/103 7.0 % 1.38 [ 0.78, 2.46 ]
Lindmarker 1994 36/91 33/89 6.5 % 0.90 [ 0.49, 1.64 ]
Luomanmaki 1996 47/92 61/98 7.1 % 1.57 [ 0.89, 2.79 ]
Meyer 1995 25/26 26/28 0.4 % 0.54 [ 0.05, 5.43 ]
Moreno-Palomares 2001 11/14 11/13 0.6 % 1.47 [ 0.22, 9.90 ]
Subtotal (95% CI) 319 331 21.5 % 1.25 [ 0.90, 1.73 ]
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Study or subgroup LMWH UFH
Peto Odds
Ratio(Non-event) Weight
Peto Odds
Ratio(Non-event)
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 150 (LMWH), 172 (UFH)
Heterogeneity: Chi2 = 2.42, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
5 CY 222 versus unfractionated heparin
Faivre 1988 11/30 10/29 2.1 % 0.91 [ 0.32, 2.62 ]
Subtotal (95% CI) 30 29 2.1 % 0.91 [ 0.32, 2.62 ]
Total events: 11 (LMWH), 10 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
6 Reviparin versus unfractionated heparin
Breddin 2001 175/328 129/321 24.4 % 0.59 [ 0.43, 0.80 ]
Subtotal (95% CI) 328 321 24.4 % 0.59 [ 0.43, 0.80 ]
Total events: 175 (LMWH), 129 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 3.36 (P = 0.00078)
7 Certoparin versus unfractionated heparin
Harenberg 2000a 60/198 48/192 11.8 % 0.77 [ 0.49, 1.20 ]
Kirchmaier 1998 55/128 42/131 9.2 % 0.63 [ 0.38, 1.04 ]
Subtotal (95% CI) 326 323 21.0 % 0.70 [ 0.50, 0.98 ]
Total events: 115 (LMWH), 90 (UFH)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
8 Bemiparin versus unfractionated heparin
Kakkar 2003 76/105 51/98 7.2 % 0.42 [ 0.24, 0.74 ]
Subtotal (95% CI) 105 98 7.2 % 0.42 [ 0.24, 0.74 ]
Total events: 76 (LMWH), 51 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0028)
Total (95% CI) 1467 1442 100.0 % 0.71 [ 0.61, 0.82 ]
Total events: 741 (LMWH), 610 (UFH)
Heterogeneity: Chi2 = 33.91, df = 15 (P = 0.004); I2 =56%
Test for overall effect: Z = 4.45 (P < 0.00001)
Test for subgroup differences: Chi2 = 21.70, df = 7 (P = 0.00), I2 =68%
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Analysis 1.7. Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 7
Incidence of major haemorrhagic episodes (during initial treatment).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 LMWH versus UFH in patients with venous thromboembolism
Outcome: 7 Incidence of major haemorrhagic episodes (during initial treatment)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Belcaro 1999 0/98 0/196 Not estimable
Koopman 1996 1/202 2/198 1.9 % 0.50 [ 0.05, 4.85 ]
Lopaciuk 1992 0/74 1/72 0.6 % 0.13 [ 0.00, 6.64 ]
Ninet 1991 2/85 4/81 3.8 % 0.48 [ 0.09, 2.43 ]
Prandoni 1992 1/85 3/85 2.5 % 0.36 [ 0.05, 2.61 ]
Prandoni 2004 3/360 4/360 4.5 % 0.75 [ 0.17, 3.32 ]
Thery 1992 0/35 2/33 1.3 % 0.12 [ 0.01, 2.02 ]
Subtotal (95% CI) 939 1025 14.6 % 0.44 [ 0.19, 1.01 ]
Total events: 7 (LMWH), 16 (UFH)
Heterogeneity: Chi2 = 1.71, df = 5 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Tinzaparin versus unfractionated heparin
Hull 1992 1/213 11/219 7.6 % 0.19 [ 0.06, 0.59 ]
Leizorovicz 2011 18/269 15/268 20.1 % 1.21 [ 0.60, 2.44 ]
Simonneau 1997 3/304 5/308 5.1 % 0.61 [ 0.15, 2.46 ]
Subtotal (95% CI) 786 795 32.8 % 0.71 [ 0.41, 1.22 ]
Total events: 22 (LMWH), 31 (UFH)
Heterogeneity: Chi2 = 7.48, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 1.24 (P = 0.21)
3 Enoxaparin versus unfractionated heparin
Decousus 1998 7/195 8/205 9.4 % 0.92 [ 0.33, 2.57 ]
Findik 2002 0/29 0/30 Not estimable
Levine 1996 5/247 3/253 5.1 % 1.70 [ 0.42, 6.87 ]
P rez de Llano 2003 1/29 0/21 0.6 % 5.61 [ 0.11, 297.44 ]
Simonneau 1993 0/67 0/67 Not estimable
Subtotal (95% CI) 567 576 15.1 % 1.22 [ 0.54, 2.75 ]
Total events: 13 (LMWH), 11 (UFH)
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: Chi2 = 1.08, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
4 Dalteparin versus unfractionated heparin
Fiessinger 1996 0/120 2/133 1.3 % 0.15 [ 0.01, 2.39 ]
Lindmarker 1994 0/101 0/103 Not estimable
Luomanmaki 1996 0/117 1/131 0.6 % 0.15 [ 0.00, 7.64 ]
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 367 398 1.9 % 0.15 [ 0.02, 1.44 ]
Total events: 0 (LMWH), 3 (UFH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
5 CY 222 versus unfractionated heparin
Faivre 1988 0/33 3/35 1.9 % 0.13 [ 0.01, 1.34 ]
Subtotal (95% CI) 33 35 1.9 % 0.13 [ 0.01, 1.34 ]
Total events: 0 (LMWH), 3 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.088)
6 Reviparin versus unfractionated heparin
Columbus 1997 10/510 8/511 11.5 % 1.26 [ 0.49, 3.19 ]
Subtotal (95% CI) 510 511 11.5 % 1.26 [ 0.49, 3.19 ]
Total events: 10 (LMWH), 8 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
7 Certoparin versus unfractionated heparin
Harenberg 2000a 4/265 11/273 9.4 % 0.40 [ 0.14, 1.10 ]
Kirchmaier 1998 1/128 4/131 3.2 % 0.30 [ 0.05, 1.77 ]
Riess 2003 6/627 7/593 8.3 % 0.81 [ 0.27, 2.41 ]
Subtotal (95% CI) 1020 997 21.0 % 0.50 [ 0.25, 1.00 ]
Total events: 11 (LMWH), 22 (UFH)
Heterogeneity: Chi2 = 1.26, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
8 Bemiparin versus unfractionated heparin
Kakkar 2003 2/111 0/110 1.3 % 7.39 [ 0.46, 118.89 ]
Subtotal (95% CI) 111 110 1.3 % 7.39 [ 0.46, 118.89 ]
Total events: 2 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 4333 4447 100.0 % 0.69 [ 0.50, 0.95 ]
Total events: 65 (LMWH), 94 (UFH)
Heterogeneity: Chi2 = 23.42, df = 19 (P = 0.22); I2 =19%
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Chi2 = 11.89, df = 7 (P = 0.10), I2 =41%
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.8. Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 8
Overall mortality at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 LMWH versus UFH in patients with venous thromboembolism
Outcome: 8 Overall mortality at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 14/202 16/198 6.1 % 0.85 [ 0.40, 1.78 ]
Lopaciuk 1992 0/74 1/72 0.2 % 0.13 [ 0.00, 6.64 ]
Prandoni 1992 6/85 12/85 3.6 % 0.48 [ 0.18, 1.26 ]
Prandoni 2004 12/360 12/360 5.1 % 1.00 [ 0.44, 2.26 ]
Thery 1992 1/35 1/33 0.4 % 0.94 [ 0.06, 15.40 ]
Subtotal (95% CI) 756 748 15.4 % 0.77 [ 0.48, 1.22 ]
Total events: 33 (LMWH), 42 (UFH)
Heterogeneity: Chi2 = 2.19, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
2 Tinzaparin versus unfractionated heparin
Hull 1992 10/213 21/219 6.3 % 0.48 [ 0.23, 1.00 ]
Leizorovicz 2011 31/269 17/268 9.6 % 1.89 [ 1.04, 3.41 ]
Simonneau 1997 12/304 14/308 5.5 % 0.86 [ 0.39, 1.89 ]
Subtotal (95% CI) 786 795 21.4 % 1.03 [ 0.69, 1.53 ]
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 53 (LMWH), 52 (UFH)
Heterogeneity: Chi2 = 8.40, df = 2 (P = 0.01); I2 =76%
Test for overall effect: Z = 0.15 (P = 0.88)
3 Ardeparin versus unfractionated heparin
Goldhaber 1998 0/41 0/39 Not estimable
Subtotal (95% CI) 41 39 Not estimable
Total events: 0 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Enoxaparin versus unfractionated heparin
Decousus 1998 40/195 43/205 14.5 % 0.97 [ 0.60, 1.58 ]
Findik 2002 0/29 0/30 Not estimable
Levine 1996 11/247 17/253 5.8 % 0.65 [ 0.30, 1.40 ]
Merli 2001 18/610 9/290 5.0 % 0.95 [ 0.42, 2.15 ]
P rez de Llano 2003 1/29 0/21 0.2 % 5.61 [ 0.11, 297.44 ]
Simonneau 1993 3/67 2/67 1.1 % 1.51 [ 0.25, 8.96 ]
Subtotal (95% CI) 1177 866 26.6 % 0.92 [ 0.64, 1.31 ]
Total events: 73 (LMWH), 71 (UFH)
Heterogeneity: Chi2 = 1.93, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
5 Dalteparin versus unfractionated heparin
Lindmarker 1994 2/101 3/103 1.1 % 0.68 [ 0.12, 3.99 ]
Luomanmaki 1996 1/110 4/116 1.1 % 0.31 [ 0.05, 1.82 ]
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 240 250 2.2 % 0.46 [ 0.13, 1.60 ]
Total events: 3 (LMWH), 7 (UFH)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
6 Reviparin versus unfractionated heparin
Breddin 2001 9/388 11/375 4.3 % 0.79 [ 0.32, 1.91 ]
Columbus 1997 36/510 39/511 15.3 % 0.92 [ 0.57, 1.47 ]
Subtotal (95% CI) 898 886 19.6 % 0.89 [ 0.59, 1.35 ]
Total events: 45 (LMWH), 50 (UFH)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
7 Certoparin versus unfractionated heparin
Harenberg 2000a 6/265 15/273 4.4 % 0.42 [ 0.18, 1.01 ]
Kirchmaier 1998 8/125 10/124 3.7 % 0.78 [ 0.30, 2.03 ]
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Riess 2003 11/627 16/593 5.8 % 0.65 [ 0.30, 1.39 ]
Subtotal (95% CI) 1017 990 13.9 % 0.59 [ 0.36, 0.97 ]
Total events: 25 (LMWH), 41 (UFH)
Heterogeneity: Chi2 = 0.94, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
8 Bemiparin versus unfractionated heparin
Kakkar 2003 2/89 2/85 0.9 % 0.95 [ 0.13, 6.90 ]
Subtotal (95% CI) 89 85 0.9 % 0.95 [ 0.13, 6.90 ]
Total events: 2 (LMWH), 2 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 5004 4659 100.0 % 0.84 [ 0.70, 1.01 ]
Total events: 234 (LMWH), 265 (UFH)
Heterogeneity: Chi2 = 18.23, df = 20 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Chi2 = 4.29, df = 6 (P = 0.64), I2 =0.0%
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Analysis 2.1. Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis,
Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 LMWH versus UFH in patients with proximal deep venous thrombosis
Outcome: 1 Incidence of recurrent venous thromboembolism at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Belcaro 1999 6/98 13/196 7.6 % 0.92 [ 0.34, 2.46 ]
Koopman 1996 14/202 17/198 13.7 % 0.79 [ 0.38, 1.65 ]
Prandoni 1992 6/85 12/85 7.7 % 0.48 [ 0.18, 1.26 ]
Subtotal (95% CI) 385 479 29.1 % 0.72 [ 0.44, 1.19 ]
Total events: 26 (LMWH), 42 (UFH)
Heterogeneity: Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Tinzaparin versus unfractionated heparin
Hull 1992 6/213 15/219 9.6 % 0.42 [ 0.17, 1.01 ]
Subtotal (95% CI) 213 219 9.6 % 0.42 [ 0.17, 1.01 ]
Total events: 6 (LMWH), 15 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
3 Enoxaparin versus unfractionated heparin
Levine 1996 13/247 17/253 13.5 % 0.77 [ 0.37, 1.62 ]
Simonneau 1993 0/67 3/67 1.4 % 0.13 [ 0.01, 1.28 ]
Subtotal (95% CI) 314 320 14.9 % 0.65 [ 0.32, 1.32 ]
Total events: 13 (LMWH), 20 (UFH)
Heterogeneity: Chi2 = 2.10, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 1.19 (P = 0.23)
4 Reviparin versus unfractionated heparin
Breddin 2001 7/388 24/375 14.2 % 0.31 [ 0.15, 0.63 ]
Subtotal (95% CI) 388 375 14.2 % 0.31 [ 0.15, 0.63 ]
Total events: 7 (LMWH), 24 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 3.21 (P = 0.0013)
5 Certoparin versus unfractionated heparin
Harenberg 2000a 6/265 15/273 9.7 % 0.42 [ 0.18, 1.01 ]
Riess 2003 22/627 27/593 22.5 % 0.76 [ 0.43, 1.35 ]
Subtotal (95% CI) 892 866 32.2 % 0.64 [ 0.40, 1.03 ]
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 28 (LMWH), 42 (UFH)
Heterogeneity: Chi2 = 1.23, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.84 (P = 0.066)
6 Bemiparin versus unfractionated heparin
Kakkar 2003 0/111 0/110 Not estimable
Subtotal (95% CI) 111 110 Not estimable
Total events: 0 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2303 2369 100.0 % 0.57 [ 0.44, 0.75 ]
Total events: 80 (LMWH), 143 (UFH)
Heterogeneity: Chi2 = 8.80, df = 8 (P = 0.36); I2 =9%
Test for overall effect: Z = 4.01 (P = 0.000062)
Test for subgroup differences: Chi2 = 4.48, df = 4 (P = 0.34), I2 =11%
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Analysis 2.2. Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis,
Outcome 2 Incidence of recurrent deep venous thrombosis at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 LMWH versus UFH in patients with proximal deep venous thrombosis
Outcome: 2 Incidence of recurrent deep venous thrombosis at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Belcaro 1999 6/98 6/97 12.2 % 0.99 [ 0.31, 3.17 ]
Koopman 1996 10/202 12/198 22.4 % 0.81 [ 0.34, 1.91 ]
Prandoni 1992 2/85 5/85 7.3 % 0.41 [ 0.09, 1.86 ]
Subtotal (95% CI) 385 380 41.9 % 0.76 [ 0.41, 1.43 ]
Total events: 18 (LMWH), 23 (UFH)
Heterogeneity: Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Tinzaparin versus unfractionated heparin
Hull 1992 3/213 9/219 12.6 % 0.37 [ 0.12, 1.16 ]
Subtotal (95% CI) 213 219 12.6 % 0.37 [ 0.12, 1.16 ]
Total events: 3 (LMWH), 9 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.088)
3 Enoxaparin versus unfractionated heparin
Levine 1996 11/247 15/253 26.6 % 0.74 [ 0.34, 1.63 ]
Subtotal (95% CI) 247 253 26.6 % 0.74 [ 0.34, 1.63 ]
Total events: 11 (LMWH), 15 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
4 Reviparin versus unfractionated heparin
Breddin 2001 5/388 11/375 16.9 % 0.45 [ 0.17, 1.21 ]
Subtotal (95% CI) 388 375 16.9 % 0.45 [ 0.17, 1.21 ]
Total events: 5 (LMWH), 11 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
5 Bemiparin versus unfractionated heparin
Kakkar 2003 0/111 2/110 2.1 % 0.13 [ 0.01, 2.14 ]
Subtotal (95% CI) 111 110 2.1 % 0.13 [ 0.01, 2.14 ]
Total events: 0 (LMWH), 2 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
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(. . . Continued)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total (95% CI) 1344 1337 100.0 % 0.61 [ 0.41, 0.91 ]
Total events: 37 (LMWH), 60 (UFH)
Heterogeneity: Chi2 = 3.84, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Chi2 = 2.98, df = 4 (P = 0.56), I2 =0.0%
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Analysis 2.3. Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis,
Outcome 3 Incidence of pulmonary embolism at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 LMWH versus UFH in patients with proximal deep venous thrombosis
Outcome: 3 Incidence of pulmonary embolism at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 4/202 5/198 13.9 % 0.78 [ 0.21, 2.92 ]
Prandoni 1992 4/85 7/85 16.3 % 0.56 [ 0.17, 1.89 ]
Subtotal (95% CI) 287 283 30.3 % 0.65 [ 0.27, 1.60 ]
Total events: 8 (LMWH), 12 (UFH)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Tinzaparin versus unfractionated heparin
Hull 1992 3/213 6/219 14.0 % 0.52 [ 0.14, 1.95 ]
Subtotal (95% CI) 213 219 14.0 % 0.52 [ 0.14, 1.95 ]
Total events: 3 (LMWH), 6 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
3 Enoxaparin versus unfractionated heparin
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(. . . Continued)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Levine 1996 1/247 2/253 4.7 % 0.52 [ 0.05, 5.07 ]
Subtotal (95% CI) 247 253 4.7 % 0.52 [ 0.05, 5.07 ]
Total events: 1 (LMWH), 2 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
4 Reviparin versus unfractionated heparin
Breddin 2001 3/388 13/375 24.8 % 0.27 [ 0.10, 0.73 ]
Subtotal (95% CI) 388 375 24.8 % 0.27 [ 0.10, 0.73 ]
Total events: 3 (LMWH), 13 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0095)
5 Certoparin versus unfractionated heparin
Harenberg 2000a 3/265 11/273 21.6 % 0.32 [ 0.11, 0.92 ]
Subtotal (95% CI) 265 273 21.6 % 0.32 [ 0.11, 0.92 ]
Total events: 3 (LMWH), 11 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
6 Bemiparin versus unfractionated heparin
Kakkar 2003 2/111 1/110 4.7 % 1.94 [ 0.20, 18.86 ]
Subtotal (95% CI) 111 110 4.7 % 1.94 [ 0.20, 18.86 ]
Total events: 2 (LMWH), 1 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 1511 1513 100.0 % 0.45 [ 0.28, 0.74 ]
Total events: 20 (LMWH), 45 (UFH)
Heterogeneity: Chi2 = 3.87, df = 6 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.14 (P = 0.0017)
Test for subgroup differences: Chi2 = 3.74, df = 5 (P = 0.59), I2 =0.0%
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Analysis 2.4. Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis,
Outcome 4 Reduction in thrombus size (pre- and post-treatment venograms).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 LMWH versus UFH in patients with proximal deep venous thrombosis
Outcome: 4 Reduction in thrombus size (pre- and post-treatment venograms)
Study or subgroup LMWH UFH
Peto Odds
Ratio(Non-event) Weight
Peto Odds
Ratio(Non-event)
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Bemiparin versus unfractionated heparin
Kakkar 2003 76/105 51/98 91.9 % 0.42 [ 0.24, 0.74 ]
Subtotal (95% CI) 105 98 91.9 % 0.42 [ 0.24, 0.74 ]
Total events: 76 (LMWH), 51 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0028)
2 Dalteparin versus unfractionated heparin
Moreno-Palomares 2001 11/14 11/13 8.1 % 1.47 [ 0.22, 9.90 ]
Subtotal (95% CI) 14 13 8.1 % 1.47 [ 0.22, 9.90 ]
Total events: 11 (LMWH), 11 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 119 111 100.0 % 0.47 [ 0.27, 0.80 ]
Total events: 87 (LMWH), 62 (UFH)
Heterogeneity: Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 2.75 (P = 0.0060)
Test for subgroup differences: Chi2 = 1.52, df = 1 (P = 0.22), I2 =34%
0.002 0.1 1 10 500
Favours LMWH Favours UFH
104Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.5. Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis,
Outcome 5 Incidence of major haemorrhagic episodes (during initial treatment).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 LMWH versus UFH in patients with proximal deep venous thrombosis
Outcome: 5 Incidence of major haemorrhagic episodes (during initial treatment)
Study or subgroup LWMH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Belcaro 1999 0/98 0/97 Not estimable
Koopman 1996 1/202 2/198 5.5 % 0.50 [ 0.05, 4.85 ]
Prandoni 1992 1/85 3/85 7.3 % 0.36 [ 0.05, 2.61 ]
Subtotal (95% CI) 385 380 12.8 % 0.42 [ 0.09, 1.85 ]
Total events: 2 (LWMH), 5 (UFH)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Tinzaparin versus unfractionated heparin
Hull 1992 1/213 11/219 21.7 % 0.19 [ 0.06, 0.59 ]
Subtotal (95% CI) 213 219 21.7 % 0.19 [ 0.06, 0.59 ]
Total events: 1 (LWMH), 11 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0040)
3 Enoxaparin versus unfractionated heparin
Levine 1996 5/247 3/253 14.6 % 1.70 [ 0.42, 6.87 ]
Simonneau 1993 0/67 0/67 Not estimable
Subtotal (95% CI) 314 320 14.6 % 1.70 [ 0.42, 6.87 ]
Total events: 5 (LWMH), 3 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
4 Certoparin versus unfractionated heparin
Harenberg 2000a 4/265 11/273 27.1 % 0.40 [ 0.14, 1.10 ]
Riess 2003 6/627 7/593 23.8 % 0.81 [ 0.27, 2.41 ]
Subtotal (95% CI) 892 866 50.9 % 0.55 [ 0.26, 1.17 ]
Total events: 10 (LWMH), 18 (UFH)
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 1804 1785 100.0 % 0.50 [ 0.29, 0.85 ]
Total events: 18 (LWMH), 37 (UFH)
Heterogeneity: Chi2 = 6.87, df = 5 (P = 0.23); I2 =27%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Chi2 = 5.94, df = 3 (P = 0.11), I2 =50%
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Analysis 2.6. Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis,
Outcome 6 Overall mortality at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 LMWH versus UFH in patients with proximal deep venous thrombosis
Outcome: 6 Overall mortality at the end of follow-up
Study or subgroup LWMH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 14/202 16/198 16.0 % 0.85 [ 0.40, 1.78 ]
Prandoni 1992 6/85 12/85 9.3 % 0.48 [ 0.18, 1.26 ]
Subtotal (95% CI) 287 283 25.3 % 0.69 [ 0.38, 1.24 ]
Total events: 20 (LWMH), 28 (UFH)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Tinzaparin versus unfractionated heparin
Hull 1992 10/213 21/219 16.6 % 0.48 [ 0.23, 1.00 ]
Subtotal (95% CI) 213 219 16.6 % 0.48 [ 0.23, 1.00 ]
Total events: 10 (LWMH), 21 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
3 Enoxaparin versus unfractionated heparin
Levine 1996 11/247 17/253 15.2 % 0.65 [ 0.30, 1.40 ]
Simonneau 1993 3/67 2/67 2.8 % 1.51 [ 0.25, 8.96 ]
Subtotal (95% CI) 314 320 18.0 % 0.74 [ 0.37, 1.50 ]
Total events: 14 (LWMH), 19 (UFH)
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.40)
4 Reviparin versus unfractionated heparin
Breddin 2001 9/388 11/375 11.2 % 0.79 [ 0.32, 1.91 ]
Subtotal (95% CI) 388 375 11.2 % 0.79 [ 0.32, 1.91 ]
Total events: 9 (LWMH), 11 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
5 Certoparin versus unfractionated heparin
Harenberg 2000a 6/265 15/273 11.6 % 0.42 [ 0.18, 1.01 ]
Riess 2003 11/627 16/593 15.2 % 0.65 [ 0.30, 1.39 ]
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(. . . Continued)
Study or subgroup LWMH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Subtotal (95% CI) 892 866 26.8 % 0.54 [ 0.30, 0.96 ]
Total events: 17 (LWMH), 31 (UFH)
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.034)
6 Bemiparin versus unfractionated heparin
Kakkar 2003 2/89 2/85 2.3 % 0.95 [ 0.13, 6.90 ]
Subtotal (95% CI) 89 85 2.3 % 0.95 [ 0.13, 6.90 ]
Total events: 2 (LWMH), 2 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 2183 2148 100.0 % 0.63 [ 0.47, 0.85 ]
Total events: 72 (LWMH), 112 (UFH)
Heterogeneity: Chi2 = 3.60, df = 8 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 1.52, df = 5 (P = 0.91), I2 =0.0%
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Analysis 3.1. Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 1
Incidence of recurrent venous thromboembolism at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 LMWH versus UFH in patients with pulmonary embolism
Outcome: 1 Incidence of recurrent venous thromboembolism at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Tinzaparin versus unfractionated heparin
Simonneau 1997 5/304 6/308 23.7 % 0.84 [ 0.26, 2.77 ]
Thery 1992 0/35 0/33 Not estimable
Subtotal (95% CI) 339 341 23.7 % 0.84 [ 0.26, 2.77 ]
Total events: 5 (LMWH), 6 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
2 Enoxaparin versus unfractionated heparin
Findik 2002 1/29 3/30 8.3 % 0.36 [ 0.05, 2.70 ]
Merli 2001 10/199 4/88 24.9 % 1.11 [ 0.35, 3.55 ]
P rez de Llano 2003 3/29 2/21 9.8 % 1.09 [ 0.17, 6.98 ]
Subtotal (95% CI) 257 139 43.1 % 0.89 [ 0.37, 2.16 ]
Total events: 14 (LMWH), 9 (UFH)
Heterogeneity: Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
3 Dalteparin versus unfractionated heparin
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 29 31 Not estimable
Total events: 0 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Reviparin versus unfractionated heparin
Columbus 1997 8/138 8/133 33.2 % 0.96 [ 0.35, 2.64 ]
Subtotal (95% CI) 138 133 33.2 % 0.96 [ 0.35, 2.64 ]
Total events: 8 (LMWH), 8 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 763 644 100.0 % 0.90 [ 0.50, 1.61 ]
Total events: 27 (LMWH), 23 (UFH)
Heterogeneity: Chi2 = 0.99, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.03, df = 2 (P = 0.99), I2 =0.0%
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Analysis 3.2. Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 2
Reduction in thrombus size (pre- and post-treatment venograms).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 LMWH versus UFH in patients with pulmonary embolism
Outcome: 2 Reduction in thrombus size (pre- and post-treatment venograms)
Study or subgroup LMWH UFH
Peto Odds
Ratio(Non-event) Weight
Peto Odds
Ratio(Non-event)
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Thery 1992 29/31 21/21 39.6 % 5.53 [ 0.32, 95.93 ]
Subtotal (95% CI) 31 21 39.6 % 5.53 [ 0.32, 95.93 ]
Total events: 29 (LMWH), 21 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 Dalteparin versus unfractionated heparin
Meyer 1995 25/26 26/28 60.4 % 0.54 [ 0.05, 5.43 ]
Subtotal (95% CI) 26 28 60.4 % 0.54 [ 0.05, 5.43 ]
Total events: 25 (LMWH), 26 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 57 49 100.0 % 1.36 [ 0.23, 8.16 ]
Total events: 54 (LMWH), 47 (UFH)
Heterogeneity: Chi2 = 1.55, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 1.55, df = 1 (P = 0.21), I2 =35%
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Analysis 3.3. Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 3 Mean
change in pulmonary vascular obstruction severity score.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 LMWH versus UFH in patients with pulmonary embolism
Outcome: 3 Mean change in pulmonary vascular obstruction severity score
Study or subgroup LMWH UFH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Thery 1992 31 20.48 (2.28) 21 23.76 (2.29) 96.8 % -3.28 [ -4.55, -2.01 ]
Subtotal (95% CI) 31 21 96.8 % -3.28 [ -4.55, -2.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.08 (P < 0.00001)
2 Dalteparin versus unfractionated heparin
Meyer 1995 26 17 (13) 28 16 (13) 3.2 % 1.00 [ -5.94, 7.94 ]
Subtotal (95% CI) 26 28 3.2 % 1.00 [ -5.94, 7.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 57 49 100.0 % -3.14 [ -4.39, -1.90 ]
Heterogeneity: Chi2 = 1.41, df = 1 (P = 0.23); I2 =29%
Test for overall effect: Z = 4.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.41, df = 1 (P = 0.23), I2 =29%
-100 -50 0 50 100
Favours LMWH Favours UFH
110Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 4
Incidence of major haemorrhagic episodes (during initial treatment).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 LMWH versus UFH in patients with pulmonary embolism
Outcome: 4 Incidence of major haemorrhagic episodes (during initial treatment)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Thery 1992 0/35 2/33 66.9 % 0.12 [ 0.01, 2.02 ]
Subtotal (95% CI) 35 33 66.9 % 0.12 [ 0.01, 2.02 ]
Total events: 0 (LMWH), 2 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
2 Enoxaparin versus unfractionated heparin
P rez de Llano 2003 1/29 0/21 33.1 % 5.61 [ 0.11, 297.44 ]
Subtotal (95% CI) 29 21 33.1 % 5.61 [ 0.11, 297.44 ]
Total events: 1 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
3 Dalteparin versus unfractionated heparin
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 29 31 Not estimable
Total events: 0 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 93 85 100.0 % 0.44 [ 0.04, 4.29 ]
Total events: 1 (LMWH), 2 (UFH)
Heterogeneity: Chi2 = 2.37, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 2.37, df = 1 (P = 0.12), I2 =58%
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Analysis 3.5. Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 5 Overall
mortality at end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 LMWH versus UFH in patients with pulmonary embolism
Outcome: 5 Overall mortality at end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Thery 1992 1/35 1/33 66.9 % 0.94 [ 0.06, 15.40 ]
Subtotal (95% CI) 35 33 66.9 % 0.94 [ 0.06, 15.40 ]
Total events: 1 (LMWH), 1 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Enoxaparin versus unfractionated heparin
P rez de Llano 2003 1/29 0/21 33.1 % 5.61 [ 0.11, 297.44 ]
Subtotal (95% CI) 29 21 33.1 % 5.61 [ 0.11, 297.44 ]
Total events: 1 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
3 Dalteparin versus unfractionated heparin
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 29 31 Not estimable
Total events: 0 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 93 85 100.0 % 1.70 [ 0.17, 16.71 ]
Total events: 2 (LMWH), 1 (UFH)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 4.1. Comparison 4 LMWH versus UFH in patients with venous thromboembolism and malignant
disease, Outcome 1 Mortality at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 4 LMWH versus UFH in patients with venous thromboembolism and malignant disease
Outcome: 1 Mortality at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Mortality in patients with malignant disease
Columbus 1997 20/119 27/113 55.1 % 0.65 [ 0.34, 1.22 ]
Hull 1992 6/47 13/49 22.6 % 0.42 [ 0.16, 1.15 ]
Lindmarker 1994 2/7 2/9 4.6 % 1.37 [ 0.15, 12.50 ]
Lopaciuk 1992 0/7 0/2 Not estimable
Prandoni 1992 1/15 8/18 9.8 % 0.16 [ 0.03, 0.72 ]
Simonneau 1997 2/26 4/34 7.9 % 0.64 [ 0.12, 3.47 ]
Subtotal (95% CI) 221 225 100.0 % 0.53 [ 0.33, 0.85 ]
Total events: 31 (LMWH), 54 (UFH)
Heterogeneity: Chi2 = 3.78, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
2 Mortality in patients with malignant disease in trial with adequate concealment
Columbus 1997 20/119 27/113 57.8 % 0.65 [ 0.34, 1.22 ]
Hull 1992 6/47 13/49 23.6 % 0.42 [ 0.16, 1.15 ]
Lopaciuk 1992 0/7 0/2 Not estimable
Prandoni 1992 1/15 8/18 10.3 % 0.16 [ 0.03, 0.72 ]
Simonneau 1997 2/26 4/34 8.3 % 0.64 [ 0.12, 3.47 ]
Subtotal (95% CI) 214 216 100.0 % 0.51 [ 0.31, 0.82 ]
Total events: 29 (LMWH), 52 (UFH)
Heterogeneity: Chi2 = 3.03, df = 3 (P = 0.39); I2 =1%
Test for overall effect: Z = 2.75 (P = 0.0059)
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Analysis 5.1. Comparison 5 LMWH versus UFH in patients with venous thromboembolism without
malignant disease, Outcome 1 Mortality at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 5 LMWH versus UFH in patients with venous thromboembolism without malignant disease
Outcome: 1 Mortality at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Mortality in patients without malignant disease
Columbus 1997 16/391 12/398 39.5 % 1.37 [ 0.64, 2.91 ]
Hull 1992 4/166 8/170 17.0 % 0.51 [ 0.16, 1.63 ]
Lindmarker 1994 0/94 1/94 1.5 % 0.14 [ 0.00, 6.82 ]
Lopaciuk 1992 0/67 1/70 1.5 % 0.14 [ 0.00, 7.13 ]
Prandoni 1992 5/70 4/67 12.4 % 1.21 [ 0.31, 4.65 ]
Simonneau 1997 10/278 10/274 28.2 % 0.99 [ 0.40, 2.40 ]
Subtotal (95% CI) 1066 1073 100.0 % 0.97 [ 0.61, 1.56 ]
Total events: 35 (LMWH), 36 (UFH)
Heterogeneity: Chi2 = 3.97, df = 5 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
2 Mortality in patients without malignant disease in trials with adequate concealment
Columbus 1997 16/391 12/398 40.1 % 1.37 [ 0.64, 2.91 ]
Hull 1992 4/166 8/170 17.2 % 0.51 [ 0.16, 1.63 ]
Lopaciuk 1992 0/67 1/70 1.5 % 0.14 [ 0.00, 7.13 ]
Prandoni 1992 5/70 4/67 12.6 % 1.21 [ 0.31, 4.65 ]
Simonneau 1997 10/278 10/274 28.6 % 0.99 [ 0.40, 2.40 ]
Subtotal (95% CI) 972 979 100.0 % 1.00 [ 0.62, 1.62 ]
Total events: 35 (LMWH), 35 (UFH)
Heterogeneity: Chi2 = 2.98, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
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Analysis 6.1. Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism,
Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism
Outcome: 1 Incidence of recurrent venous thromboembolism at the end of follow-up
Study or subgroup LMWH Subcutaneous UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Leizorovicz 2011 7/269 3/268 24.7 % 2.25 [ 0.64, 7.85 ]
Lopaciuk 1992 0/74 3/72 7.4 % 0.13 [ 0.01, 1.25 ]
Prandoni 2004 14/360 14/360 67.8 % 1.00 [ 0.47, 2.13 ]
Total (95% CI) 703 700 100.0 % 1.05 [ 0.56, 1.95 ]
Total events: 21 (LMWH), 20 (Subcutaneous UFH)
Heterogeneity: Chi2 = 4.72, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UFH
115Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.2. Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism,
Outcome 2 Incidence of major haemorrhagic episodes (during initial treatment).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism
Outcome: 2 Incidence of major haemorrhagic episodes (during initial treatment)
Study or subgroup LMWH Subcutaneous UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Faivre 1988 0/33 3/35 6.9 % 0.13 [ 0.01, 1.34 ]
Leizorovicz 2011 18/269 15/268 74.1 % 1.21 [ 0.60, 2.44 ]
Lopaciuk 1992 0/74 1/72 2.4 % 0.13 [ 0.00, 6.64 ]
Prandoni 2004 3/360 4/360 16.6 % 0.75 [ 0.17, 3.32 ]
Total (95% CI) 736 735 100.0 % 0.91 [ 0.50, 1.67 ]
Total events: 21 (LMWH), 23 (Subcutaneous UFH)
Heterogeneity: Chi2 = 4.27, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
116Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.3. Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism,
Outcome 3 Overall mortality at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism
Outcome: 3 Overall mortality at the end of follow-up
Study or subgroup LMWH Subcutaneous UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Leizorovicz 2011 31/269 17/268 64.4 % 1.89 [ 1.04, 3.41 ]
Lopaciuk 1992 0/74 1/72 1.5 % 0.13 [ 0.00, 6.64 ]
Prandoni 2004 12/360 12/360 34.2 % 1.00 [ 0.44, 2.26 ]
Total (95% CI) 703 700 100.0 % 1.46 [ 0.91, 2.35 ]
Total events: 43 (LMWH), 30 (Subcutaneous UFH)
Heterogeneity: Chi2 = 3.00, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism,
Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 7 LMWH versus intravenous UFH in patients with venous thromboembolism
Outcome: 1 Incidence of recurrent venous thromboembolism at the end of follow-up
Study or subgroup LMWH Intravenous UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Belcaro 1999 6/98 13/196 4.7 % 0.92 [ 0.34, 2.46 ]
Breddin 2001 7/388 24/375 8.8 % 0.31 [ 0.15, 0.63 ]
Columbus 1997 27/510 25/511 14.5 % 1.09 [ 0.62, 1.90 ]
Decousus 1998 10/195 12/205 6.1 % 0.87 [ 0.37, 2.05 ]
Findik 2002 1/29 3/30 1.1 % 0.36 [ 0.05, 2.70 ]
Goldhaber 1998 0/41 1/39 0.3 % 0.13 [ 0.00, 6.49 ]
Harenberg 2000a 6/265 15/273 5.9 % 0.42 [ 0.18, 1.01 ]
Hull 1992 6/213 15/219 5.9 % 0.42 [ 0.17, 1.01 ]
Kakkar 2003 0/111 0/110 Not estimable
Kirchmaier 1998 2/125 4/124 1.7 % 0.50 [ 0.10, 2.53 ]
Koopman 1996 14/202 17/198 8.4 % 0.79 [ 0.38, 1.65 ]
Levine 1996 13/247 17/253 8.3 % 0.77 [ 0.37, 1.62 ]
Lindmarker 1994 5/101 3/103 2.3 % 1.71 [ 0.42, 7.02 ]
Merli 2001 21/610 11/290 7.9 % 0.90 [ 0.42, 1.92 ]
Meyer 1995 0/29 0/31 Not estimable
Prandoni 1992 6/85 12/85 4.8 % 0.48 [ 0.18, 1.26 ]
P rez de Llano 2003 3/29 2/21 1.3 % 1.09 [ 0.17, 6.98 ]
Riess 2003 22/627 27/593 13.8 % 0.76 [ 0.43, 1.35 ]
Simonneau 1993 0/67 3/67 0.9 % 0.13 [ 0.01, 1.28 ]
Simonneau 1997 5/304 6/308 3.2 % 0.84 [ 0.26, 2.77 ]
Thery 1992 0/35 0/33 Not estimable
Total (95% CI) 4311 4064 100.0 % 0.69 [ 0.56, 0.86 ]
Total events: 154 (LMWH), 210 (Intravenous UFH)
Heterogeneity: Chi2 = 17.06, df = 17 (P = 0.45); I2 =0%
Test for overall effect: Z = 3.38 (P = 0.00072)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism,
Outcome 2 Incidence of major haemorrhagic episodes (during initial treatment).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 7 LMWH versus intravenous UFH in patients with venous thromboembolism
Outcome: 2 Incidence of major haemorrhagic episodes (during initial treatment)
Study or subgroup LMWH Intravenous UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Belcaro 1999 0/98 0/196 Not estimable
Columbus 1997 10/510 8/511 15.7 % 1.26 [ 0.49, 3.19 ]
Decousus 1998 7/195 8/205 12.8 % 0.92 [ 0.33, 2.57 ]
Fiessinger 1996 0/120 2/133 1.8 % 0.15 [ 0.01, 2.39 ]
Findik 2002 0/29 0/30 Not estimable
Harenberg 2000a 4/265 11/273 13.0 % 0.40 [ 0.14, 1.10 ]
Hull 1992 1/213 11/219 10.4 % 0.19 [ 0.06, 0.59 ]
Kakkar 2003 2/111 0/110 1.8 % 7.39 [ 0.46, 118.89 ]
Kirchmaier 1998 1/128 4/131 4.4 % 0.30 [ 0.05, 1.77 ]
Koopman 1996 1/202 2/198 2.6 % 0.50 [ 0.05, 4.85 ]
Levine 1996 5/247 3/253 7.0 % 1.70 [ 0.42, 6.87 ]
Lindmarker 1994 0/101 0/103 Not estimable
Luomanmaki 1996 0/117 1/131 0.9 % 0.15 [ 0.00, 7.64 ]
Meyer 1995 0/29 0/31 Not estimable
Ninet 1991 2/85 4/81 5.2 % 0.48 [ 0.09, 2.43 ]
Prandoni 1992 1/85 3/85 3.5 % 0.36 [ 0.05, 2.61 ]
P rez de Llano 2003 1/29 0/21 0.9 % 5.61 [ 0.11, 297.44 ]
Riess 2003 6/627 7/593 11.4 % 0.81 [ 0.27, 2.41 ]
Simonneau 1993 0/67 0/67 Not estimable
Simonneau 1997 3/304 5/308 7.0 % 0.61 [ 0.15, 2.46 ]
Thery 1992 0/35 2/33 1.7 % 0.12 [ 0.01, 2.02 ]
Total (95% CI) 3597 3712 100.0 % 0.62 [ 0.43, 0.90 ]
Total events: 44 (LMWH), 71 (Intravenous UFH)
Heterogeneity: Chi2 = 18.06, df = 15 (P = 0.26); I2 =17%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism,
Outcome 3 Overall mortality at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 7 LMWH versus intravenous UFH in patients with venous thromboembolism
Outcome: 3 Overall mortality at the end of follow-up
Study or subgroup LMWH Intravenous UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Breddin 2001 9/388 11/375 5.0 % 0.79 [ 0.32, 1.91 ]
Columbus 1997 36/510 39/511 18.0 % 0.92 [ 0.57, 1.47 ]
Decousus 1998 40/195 43/205 17.0 % 0.97 [ 0.60, 1.58 ]
Findik 2002 0/29 0/30 Not estimable
Goldhaber 1998 0/41 0/39 Not estimable
Harenberg 2000a 6/265 15/273 5.2 % 0.42 [ 0.18, 1.01 ]
Hull 1992 10/213 21/219 7.5 % 0.48 [ 0.23, 1.00 ]
Kakkar 2003 2/89 2/85 1.0 % 0.95 [ 0.13, 6.90 ]
Kirchmaier 1998 8/125 10/124 4.3 % 0.78 [ 0.30, 2.03 ]
Koopman 1996 14/202 16/198 7.2 % 0.85 [ 0.40, 1.78 ]
Levine 1996 11/247 17/253 6.8 % 0.65 [ 0.30, 1.40 ]
Lindmarker 1994 2/101 3/103 1.3 % 0.68 [ 0.12, 3.99 ]
Luomanmaki 1996 1/110 4/116 1.3 % 0.31 [ 0.05, 1.82 ]
Merli 2001 18/610 9/290 5.9 % 0.95 [ 0.42, 2.15 ]
Meyer 1995 0/29 0/31 Not estimable
Prandoni 1992 6/85 12/85 4.2 % 0.48 [ 0.18, 1.26 ]
P rez de Llano 2003 1/29 0/21 0.3 % 5.61 [ 0.11, 297.44 ]
Riess 2003 11/627 16/593 6.8 % 0.65 [ 0.30, 1.39 ]
Simonneau 1993 3/67 2/67 1.3 % 1.51 [ 0.25, 8.96 ]
Simonneau 1997 12/304 14/308 6.4 % 0.86 [ 0.39, 1.89 ]
Thery 1992 1/35 1/33 0.5 % 0.94 [ 0.06, 15.40 ]
Total (95% CI) 4301 3959 100.0 % 0.77 [ 0.63, 0.93 ]
Total events: 191 (LMWH), 235 (Intravenous UFH)
Heterogeneity: Chi2 = 9.17, df = 17 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0085)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate
concealment of allocation, Outcome 1 Incidence of recurrent venous thromboembolism during initial
treatment.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation
Outcome: 1 Incidence of recurrent venous thromboembolism during initial treatment
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 4/202 5/198 7.8 % 0.78 [ 0.21, 2.92 ]
Lopaciuk 1992 0/74 1/72 0.9 % 0.13 [ 0.00, 6.64 ]
Prandoni 1992 1/85 4/85 4.3 % 0.29 [ 0.05, 1.72 ]
Subtotal (95% CI) 361 355 13.0 % 0.50 [ 0.18, 1.39 ]
Total events: 5 (LMWH), 10 (UFH)
Heterogeneity: Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Tinzaparin versus unfractionated heparin
Simonneau 1997 3/304 2/308 4.4 % 1.52 [ 0.26, 8.80 ]
Subtotal (95% CI) 304 308 4.4 % 1.52 [ 0.26, 8.80 ]
Total events: 3 (LMWH), 2 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
3 Enoxaparin versus unfractionated heparin
Decousus 1998 3/195 8/205 9.5 % 0.41 [ 0.13, 1.37 ]
Levine 1996 7/247 12/253 16.2 % 0.59 [ 0.24, 1.48 ]
Simonneau 1993 0/67 2/67 1.8 % 0.13 [ 0.01, 2.15 ]
Subtotal (95% CI) 509 525 27.4 % 0.48 [ 0.24, 0.96 ]
Total events: 10 (LMWH), 22 (UFH)
Heterogeneity: Chi2 = 1.08, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
4 Reviparin versus unfractionated heparin
Columbus 1997 16/510 15/511 26.6 % 1.07 [ 0.52, 2.19 ]
Subtotal (95% CI) 510 511 26.6 % 1.07 [ 0.52, 2.19 ]
Total events: 16 (LMWH), 15 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
5 Certoparin versus unfractionated heparin
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(. . . Continued)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Kirchmaier 1998 1/128 3/131 3.5 % 0.37 [ 0.05, 2.67 ]
Riess 2003 14/627 15/593 25.0 % 0.88 [ 0.42, 1.84 ]
Subtotal (95% CI) 755 724 28.5 % 0.79 [ 0.40, 1.58 ]
Total events: 15 (LMWH), 18 (UFH)
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 2439 2423 100.0 % 0.72 [ 0.50, 1.05 ]
Total events: 49 (LMWH), 67 (UFH)
Heterogeneity: Chi2 = 6.72, df = 9 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Chi2 = 3.76, df = 4 (P = 0.44), I2 =0.0%
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Analysis 8.2. Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate
concealment of allocation, Outcome 2 Incidence of recurrent venous thromboembolism at the end of follow-
up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation
Outcome: 2 Incidence of recurrent venous thromboembolism at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 14/202 17/198 9.9 % 0.79 [ 0.38, 1.65 ]
Lopaciuk 1992 0/74 3/72 1.0 % 0.13 [ 0.01, 1.25 ]
Prandoni 1992 6/85 12/85 5.6 % 0.48 [ 0.18, 1.26 ]
Prandoni 2004 14/360 15/360 9.6 % 0.93 [ 0.44, 1.96 ]
Subtotal (95% CI) 721 715 26.2 % 0.70 [ 0.45, 1.10 ]
Total events: 34 (LMWH), 47 (UFH)
Heterogeneity: Chi2 = 3.41, df = 3 (P = 0.33); I2 =12%
Test for overall effect: Z = 1.53 (P = 0.12)
2 Tinzaparin versus unfractionated heparin
Hull 1992 6/213 15/219 6.9 % 0.42 [ 0.17, 1.01 ]
Simonneau 1997 5/304 6/308 3.7 % 0.84 [ 0.26, 2.77 ]
Subtotal (95% CI) 517 527 10.7 % 0.54 [ 0.26, 1.08 ]
Total events: 11 (LMWH), 21 (UFH)
Heterogeneity: Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
3 Ardeparin versus unfractionated heparin
Goldhaber 1998 0/41 1/40 0.3 % 0.13 [ 0.00, 6.65 ]
Subtotal (95% CI) 41 40 0.3 % 0.13 [ 0.00, 6.65 ]
Total events: 0 (LMWH), 1 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
4 Enoxaparin versus unfractionated heparin
Decousus 1998 10/195 12/205 7.2 % 0.87 [ 0.37, 2.05 ]
Levine 1996 13/247 17/253 9.8 % 0.77 [ 0.37, 1.62 ]
Merli 2001 21/610 11/290 9.3 % 0.90 [ 0.42, 1.92 ]
Simonneau 1993 0/67 3/67 1.0 % 0.13 [ 0.01, 1.28 ]
Subtotal (95% CI) 1119 815 27.4 % 0.79 [ 0.51, 1.22 ]
Total events: 44 (LMWH), 43 (UFH)
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: Chi2 = 2.55, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.29)
5 Reviparin versus unfractionated heparin
Columbus 1997 27/510 25/510 17.1 % 1.08 [ 0.62, 1.89 ]
Subtotal (95% CI) 510 510 17.1 % 1.08 [ 0.62, 1.89 ]
Total events: 27 (LMWH), 25 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
6 Certoparin versus unfractionated heparin
Kirchmaier 1998 2/125 4/124 2.0 % 0.50 [ 0.10, 2.53 ]
Riess 2003 22/627 27/593 16.3 % 0.76 [ 0.43, 1.35 ]
Subtotal (95% CI) 752 717 18.3 % 0.73 [ 0.42, 1.25 ]
Total events: 24 (LMWH), 31 (UFH)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 3660 3324 100.0 % 0.76 [ 0.60, 0.96 ]
Total events: 140 (LMWH), 168 (UFH)
Heterogeneity: Chi2 = 10.49, df = 13 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 3.44, df = 5 (P = 0.63), I2 =0.0%
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Analysis 8.3. Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate
concealment of allocation, Outcome 3 Incidence of recurrent venous thromboembolism at 3 months’ follow-
up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation
Outcome: 3 Incidence of recurrent venous thromboembolism at 3 months’ follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 8/202 10/198 7.9 % 0.78 [ 0.30, 2.00 ]
Lopaciuk 1992 0/74 3/72 1.4 % 0.13 [ 0.01, 1.25 ]
Prandoni 1992 4/85 7/85 4.8 % 0.56 [ 0.17, 1.89 ]
Prandoni 2004 14/360 15/360 12.8 % 0.93 [ 0.44, 1.96 ]
Subtotal (95% CI) 721 715 26.8 % 0.73 [ 0.44, 1.22 ]
Total events: 26 (LMWH), 35 (UFH)
Heterogeneity: Chi2 = 2.85, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
2 Tinzaparin versus unfractionated heparin
Hull 1992 6/213 15/219 9.2 % 0.42 [ 0.17, 1.01 ]
Simonneau 1997 5/304 6/308 5.0 % 0.84 [ 0.26, 2.77 ]
Subtotal (95% CI) 517 527 14.2 % 0.54 [ 0.26, 1.08 ]
Total events: 11 (LMWH), 21 (UFH)
Heterogeneity: Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
3 Enoxaparin versus unfractionated heparin
Decousus 1998 10/195 12/205 9.6 % 0.87 [ 0.37, 2.05 ]
Levine 1996 13/247 17/253 13.0 % 0.77 [ 0.37, 1.62 ]
Merli 2001 21/610 11/290 12.4 % 0.90 [ 0.42, 1.92 ]
Simonneau 1993 0/67 3/67 1.4 % 0.13 [ 0.01, 1.28 ]
Subtotal (95% CI) 1119 815 36.3 % 0.79 [ 0.51, 1.22 ]
Total events: 44 (LMWH), 43 (UFH)
Heterogeneity: Chi2 = 2.55, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.29)
4 Reviparin versus unfractionated heparin
Columbus 1997 27/510 25/511 22.7 % 1.09 [ 0.62, 1.90 ]
Subtotal (95% CI) 510 511 22.7 % 1.09 [ 0.62, 1.90 ]
Total events: 27 (LMWH), 25 (UFH)
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(. . . Continued)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 2867 2568 100.0 % 0.79 [ 0.60, 1.02 ]
Total events: 108 (LMWH), 124 (UFH)
Heterogeneity: Chi2 = 8.77, df = 10 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Chi2 = 2.51, df = 3 (P = 0.47), I2 =0.0%
0.005 0.1 1 10 200
Favours LMWH Favours UFH
Analysis 8.4. Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate
concealment of allocation, Outcome 4 Reduction in thrombus size (pre- and post-treatment venograms).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation
Outcome: 4 Reduction in thrombus size (pre- and post-treatment venograms)
Study or subgroup LMWH UFH
Peto Odds
Ratio(Non-event) Weight
Peto Odds
Ratio(Non-event)
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Lopaciuk 1992 45/68 32/66 18.2 % 0.49 [ 0.25, 0.96 ]
Prandoni 1992 50/83 36/85 23.3 % 0.49 [ 0.27, 0.90 ]
Subtotal (95% CI) 151 151 41.4 % 0.49 [ 0.31, 0.77 ]
Total events: 95 (LMWH), 68 (UFH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 3.10 (P = 0.0019)
2 Ardeparin versus unfractionated heparin
Goldhaber 1998 31/39 21/36 8.9 % 0.37 [ 0.14, 0.99 ]
Subtotal (95% CI) 39 36 8.9 % 0.37 [ 0.14, 0.99 ]
Total events: 31 (LMWH), 21 (UFH)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup LMWH UFH
Peto Odds
Ratio(Non-event) Weight
Peto Odds
Ratio(Non-event)
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Test for overall effect: Z = 1.97 (P = 0.049)
3 Enoxparin versus unfractionated heparin
Simonneau 1993 35/60 18/57 16.1 % 0.34 [ 0.17, 0.71 ]
Subtotal (95% CI) 60 57 16.1 % 0.34 [ 0.17, 0.71 ]
Total events: 35 (LMWH), 18 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0038)
4 Certoparin versus unfractionated heparin
Kirchmaier 1998 55/128 42/131 33.6 % 0.63 [ 0.38, 1.04 ]
Subtotal (95% CI) 128 131 33.6 % 0.63 [ 0.38, 1.04 ]
Total events: 55 (LMWH), 42 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
Total (95% CI) 378 375 100.0 % 0.49 [ 0.37, 0.66 ]
Total events: 216 (LMWH), 149 (UFH)
Heterogeneity: Chi2 = 2.17, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 4.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.17, df = 3 (P = 0.54), I2 =0.0%
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Analysis 8.5. Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate
concealment of allocation, Outcome 5 Incidence of major haemorrhagic episodes (during initial treatment).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation
Outcome: 5 Incidence of major haemorrhagic episodes (during initial treatment)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 1/202 2/198 3.2 % 0.50 [ 0.05, 4.85 ]
Lopaciuk 1992 0/74 1/72 1.1 % 0.13 [ 0.00, 6.64 ]
Prandoni 1992 1/85 3/85 4.3 % 0.36 [ 0.05, 2.61 ]
Prandoni 2004 3/360 4/360 7.5 % 0.75 [ 0.17, 3.32 ]
Subtotal (95% CI) 721 715 16.1 % 0.51 [ 0.18, 1.40 ]
Total events: 5 (LMWH), 10 (UFH)
Heterogeneity: Chi2 = 0.83, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
2 Tinzaparin versus unfractionated heparin
Hull 1992 1/213 11/219 12.7 % 0.19 [ 0.06, 0.59 ]
Simonneau 1997 3/304 5/308 8.6 % 0.61 [ 0.15, 2.46 ]
Subtotal (95% CI) 517 527 21.2 % 0.30 [ 0.12, 0.73 ]
Total events: 4 (LMWH), 16 (UFH)
Heterogeneity: Chi2 = 1.67, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 2.66 (P = 0.0078)
3 Enoxaparin versus unfractionated heparin
Decousus 1998 7/195 8/205 15.7 % 0.92 [ 0.33, 2.57 ]
Levine 1996 5/247 3/253 8.5 % 1.70 [ 0.42, 6.87 ]
Simonneau 1993 0/67 0/67 Not estimable
Subtotal (95% CI) 509 525 24.2 % 1.14 [ 0.50, 2.61 ]
Total events: 12 (LMWH), 11 (UFH)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
4 Reviparin versus unfractionated heparin
Columbus 1997 10/510 8/511 19.2 % 1.26 [ 0.49, 3.19 ]
Subtotal (95% CI) 510 511 19.2 % 1.26 [ 0.49, 3.19 ]
Total events: 10 (LMWH), 8 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
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(. . . Continued)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
5 Certoparin versus unfractionated heparin
Kirchmaier 1998 1/128 4/131 5.3 % 0.30 [ 0.05, 1.77 ]
Riess 2003 6/627 7/593 13.9 % 0.81 [ 0.27, 2.41 ]
Subtotal (95% CI) 755 724 19.3 % 0.62 [ 0.24, 1.56 ]
Total events: 7 (LMWH), 11 (UFH)
Heterogeneity: Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 3012 3002 100.0 % 0.68 [ 0.45, 1.03 ]
Total events: 38 (LMWH), 56 (UFH)
Heterogeneity: Chi2 = 10.64, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Chi2 = 6.79, df = 4 (P = 0.15), I2 =41%
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Analysis 8.6. Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate
concealment of allocation, Outcome 6 Overall mortality at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation
Outcome: 6 Overall mortality at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Koopman 1996 14/202 16/198 7.8 % 0.85 [ 0.40, 1.78 ]
Lopaciuk 1992 0/74 1/72 0.3 % 0.13 [ 0.00, 6.64 ]
Prandoni 1992 6/85 12/85 4.6 % 0.48 [ 0.18, 1.26 ]
Prandoni 2004 12/360 12/360 6.5 % 1.00 [ 0.44, 2.26 ]
Subtotal (95% CI) 721 715 19.2 % 0.76 [ 0.47, 1.22 ]
Total events: 32 (LMWH), 41 (UFH)
Heterogeneity: Chi2 = 2.17, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Tinzaparin versus unfractionated heparin
Hull 1992 10/213 21/219 8.1 % 0.48 [ 0.23, 1.00 ]
Simonneau 1997 12/304 14/308 7.0 % 0.86 [ 0.39, 1.89 ]
Subtotal (95% CI) 517 527 15.2 % 0.63 [ 0.37, 1.08 ]
Total events: 22 (LMWH), 35 (UFH)
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 1.69 (P = 0.091)
3 Ardeparin versus unfractionated heparin
Goldhaber 1998 0/41 0/39 Not estimable
Subtotal (95% CI) 41 39 Not estimable
Total events: 0 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Enoxaparin versus unfractionated heparin
Decousus 1998 40/195 43/205 18.6 % 0.97 [ 0.60, 1.58 ]
Levine 1996 11/247 17/253 7.5 % 0.65 [ 0.30, 1.40 ]
Merli 2001 18/610 9/290 6.5 % 0.95 [ 0.42, 2.15 ]
Simonneau 1993 3/67 2/67 1.4 % 1.51 [ 0.25, 8.96 ]
Subtotal (95% CI) 1119 815 33.9 % 0.90 [ 0.63, 1.29 ]
Total events: 72 (LMWH), 71 (UFH)
Heterogeneity: Chi2 = 1.13, df = 3 (P = 0.77); I2 =0.0%
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(. . . Continued)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Test for overall effect: Z = 0.56 (P = 0.57)
5 Reviparin versus unfractionated heparin
Columbus 1997 36/510 39/511 19.6 % 0.92 [ 0.57, 1.47 ]
Subtotal (95% CI) 510 511 19.6 % 0.92 [ 0.57, 1.47 ]
Total events: 36 (LMWH), 39 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
6 Certoparin versus unfractionated heparin
Kirchmaier 1998 8/125 10/124 4.7 % 0.78 [ 0.30, 2.03 ]
Riess 2003 11/627 16/593 7.4 % 0.65 [ 0.30, 1.39 ]
Subtotal (95% CI) 752 717 12.2 % 0.70 [ 0.38, 1.26 ]
Total events: 19 (LMWH), 26 (UFH)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Total (95% CI) 3660 3324 100.0 % 0.80 [ 0.65, 0.99 ]
Total events: 181 (LMWH), 212 (UFH)
Heterogeneity: Chi2 = 6.32, df = 12 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Chi2 = 1.78, df = 4 (P = 0.78), I2 =0.0%
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Analysis 9.1. Comparison 9 LMWH versus UFH: all randomised controlled trials that used ISTH definition
of major bleeding, Outcome 1 Incidence of major haemorrhagic episodes (during initial treatment).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 9 LMWH versus UFH: all randomised controlled trials that used ISTH deﬁnition of major bleeding
Outcome: 1 Incidence of major haemorrhagic episodes (during initial treatment)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Nadroparin versus unfractionated heparin
Belcaro 1999 0/98 0/196 Not estimable
Koopman 1996 1/202 2/198 2.0 % 0.50 [ 0.05, 4.85 ]
Lopaciuk 1992 0/74 1/72 0.7 % 0.13 [ 0.00, 6.64 ]
Ninet 1991 2/85 4/81 3.8 % 0.48 [ 0.09, 2.43 ]
Prandoni 1992 1/85 3/85 2.6 % 0.36 [ 0.05, 2.61 ]
Prandoni 2004 3/360 4/360 4.6 % 0.75 [ 0.17, 3.32 ]
Thery 1992 0/35 2/33 1.3 % 0.12 [ 0.01, 2.02 ]
Subtotal (95% CI) 939 1025 14.9 % 0.44 [ 0.19, 1.01 ]
Total events: 7 (LMWH), 16 (UFH)
Heterogeneity: Chi2 = 1.71, df = 5 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Tinzaparin versus unfractionated heparin
Hull 1992 1/213 11/219 7.7 % 0.19 [ 0.06, 0.59 ]
Leizorovicz 2011 18/269 15/268 20.5 % 1.21 [ 0.60, 2.44 ]
Simonneau 1997 3/304 5/308 5.2 % 0.61 [ 0.15, 2.46 ]
Subtotal (95% CI) 786 795 33.4 % 0.71 [ 0.41, 1.22 ]
Total events: 22 (LMWH), 31 (UFH)
Heterogeneity: Chi2 = 7.48, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 1.24 (P = 0.21)
3 Enoxaparin versus unfractionated heparin
Decousus 1998 7/195 8/205 9.5 % 0.92 [ 0.33, 2.57 ]
Findik 2002 0/29 0/30 Not estimable
Levine 1996 5/247 3/253 5.2 % 1.70 [ 0.42, 6.87 ]
P rez de Llano 2003 1/29 0/21 0.6 % 5.61 [ 0.11, 297.44 ]
Simonneau 1993 0/67 0/67 Not estimable
Subtotal (95% CI) 567 576 15.4 % 1.22 [ 0.54, 2.75 ]
Total events: 13 (LMWH), 11 (UFH)
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: Chi2 = 1.08, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
4 Dalteparin versus unfractionated heparin
Fiessinger 1996 0/120 2/133 1.3 % 0.15 [ 0.01, 2.39 ]
Lindmarker 1994 0/101 0/103 Not estimable
Luomanmaki 1996 0/117 1/131 0.7 % 0.15 [ 0.00, 7.64 ]
Meyer 1995 0/29 0/31 Not estimable
Subtotal (95% CI) 367 398 2.0 % 0.15 [ 0.02, 1.44 ]
Total events: 0 (LMWH), 3 (UFH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
5 Reviparin versus unfractionated heparin
Columbus 1997 10/510 8/511 11.7 % 1.26 [ 0.49, 3.19 ]
Subtotal (95% CI) 510 511 11.7 % 1.26 [ 0.49, 3.19 ]
Total events: 10 (LMWH), 8 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
6 Certoparin versus unfractionated heparin
Harenberg 2000a 4/265 11/273 9.6 % 0.40 [ 0.14, 1.10 ]
Kirchmaier 1998 1/128 4/131 3.2 % 0.30 [ 0.05, 1.77 ]
Riess 2003 6/627 7/593 8.5 % 0.81 [ 0.27, 2.41 ]
Subtotal (95% CI) 1020 997 21.4 % 0.50 [ 0.25, 1.00 ]
Total events: 11 (LMWH), 22 (UFH)
Heterogeneity: Chi2 = 1.26, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
7 Bemiparin versus unfractionated heparin
Kakkar 2003 2/111 0/110 1.3 % 7.39 [ 0.46, 118.89 ]
Subtotal (95% CI) 111 110 1.3 % 7.39 [ 0.46, 118.89 ]
Total events: 2 (LMWH), 0 (UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 4300 4412 100.0 % 0.71 [ 0.52, 0.98 ]
Total events: 65 (LMWH), 91 (UFH)
Heterogeneity: Chi2 = 21.45, df = 18 (P = 0.26); I2 =16%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 9.92, df = 6 (P = 0.13), I2 =39%
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Analysis 10.1. Comparison 10 LMWH versus UFH by year of publication, Outcome 1 Incidence of recurrent
venous thromboembolism during initial treatment.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 10 LMWH versus UFH by year of publication
Outcome: 1 Incidence of recurrent venous thromboembolism during initial treatment
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Ninet 1991 1/85 2/81 2.3 % 0.48 [ 0.05, 4.73 ]
Prandoni 1992 1/85 4/85 3.9 % 0.29 [ 0.05, 1.72 ]
Lopaciuk 1992 0/74 1/72 0.8 % 0.13 [ 0.00, 6.64 ]
Thery 1992 0/35 0/33 Not estimable
Simonneau 1993 0/67 2/67 1.6 % 0.13 [ 0.01, 2.15 ]
Lindmarker 1994 0/101 0/103 Not estimable
Meyer 1995 0/29 0/31 Not estimable
Levine 1996 7/247 12/253 14.5 % 0.59 [ 0.24, 1.48 ]
Fiessinger 1996 1/111 1/120 1.6 % 1.08 [ 0.07, 17.43 ]
Koopman 1996 4/202 5/198 7.0 % 0.78 [ 0.21, 2.92 ]
Simonneau 1997 3/304 2/308 3.9 % 1.52 [ 0.26, 8.80 ]
Columbus 1997 16/510 15/511 23.8 % 1.07 [ 0.52, 2.19 ]
Kirchmaier 1998 1/128 3/131 3.1 % 0.37 [ 0.05, 2.67 ]
Decousus 1998 3/195 8/205 8.5 % 0.41 [ 0.13, 1.37 ]
Harenberg 2000a 0/265 3/273 2.4 % 0.14 [ 0.01, 1.34 ]
Findik 2002 0/29 1/30 0.8 % 0.14 [ 0.00, 7.06 ]
Riess 2003 14/627 15/593 22.4 % 0.88 [ 0.42, 1.84 ]
P rez de Llano 2003 3/29 2/21 3.5 % 1.09 [ 0.17, 6.98 ]
Total (95% CI) 3123 3115 100.0 % 0.69 [ 0.49, 0.98 ]
Total events: 54 (LMWH), 76 (UFH)
Heterogeneity: Chi2 = 9.77, df = 14 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 LMWH versus UFH by year of publication, Outcome 2 Incidence of recurrent
venous thromboembolism at the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 10 LMWH versus UFH by year of publication
Outcome: 2 Incidence of recurrent venous thromboembolism at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Prandoni 1992 6/85 12/85 4.3 % 0.48 [ 0.18, 1.26 ]
Hull 1992 6/213 15/219 5.3 % 0.42 [ 0.17, 1.01 ]
Lopaciuk 1992 0/74 3/72 0.8 % 0.13 [ 0.01, 1.25 ]
Simonneau 1993 0/67 3/67 0.8 % 0.13 [ 0.01, 1.28 ]
Lindmarker 1994 5/101 3/103 2.0 % 1.71 [ 0.42, 7.02 ]
Meyer 1995 0/29 0/31 Not estimable
Koopman 1996 14/202 17/198 7.5 % 0.79 [ 0.38, 1.65 ]
Levine 1996 13/247 17/253 7.4 % 0.77 [ 0.37, 1.62 ]
Simonneau 1997 5/304 6/308 2.8 % 0.84 [ 0.26, 2.77 ]
Columbus 1997 27/510 25/511 13.0 % 1.09 [ 0.62, 1.90 ]
Decousus 1998 10/195 12/205 5.5 % 0.87 [ 0.37, 2.05 ]
Goldhaber 1998 0/41 1/39 0.3 % 0.13 [ 0.00, 6.49 ]
Kirchmaier 1998 2/125 4/124 1.5 % 0.50 [ 0.10, 2.53 ]
Belcaro 1999 6/98 13/196 4.2 % 0.92 [ 0.34, 2.46 ]
Harenberg 2000a 6/265 15/273 5.3 % 0.42 [ 0.18, 1.01 ]
Merli 2001 21/610 11/290 7.1 % 0.90 [ 0.42, 1.92 ]
Breddin 2001 7/388 24/375 7.8 % 0.31 [ 0.15, 0.63 ]
Findik 2002 1/29 3/30 1.0 % 0.36 [ 0.05, 2.70 ]
P rez de Llano 2003 3/29 2/21 1.2 % 1.09 [ 0.17, 6.98 ]
Riess 2003 22/627 27/593 12.4 % 0.76 [ 0.43, 1.35 ]
Prandoni 2004 14/360 15/360 7.3 % 0.93 [ 0.44, 1.96 ]
Leizorovicz 2011 7/269 3/268 2.6 % 2.25 [ 0.64, 7.85 ]
Total (95% CI) 4868 4621 100.0 % 0.72 [ 0.59, 0.88 ]
Total events: 175 (LMWH), 231 (UFH)
Heterogeneity: Chi2 = 23.04, df = 20 (P = 0.29); I2 =13%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 LMWH versus UFH by year of publication, Outcome 3 Incidence of major
haemorrhagic episodes (during initial treatment).
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 10 LMWH versus UFH by year of publication
Outcome: 3 Incidence of major haemorrhagic episodes (during initial treatment)
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Faivre 1988 0/33 3/35 1.9 % 0.13 [ 0.01, 1.34 ]
Ninet 1991 2/85 4/81 3.8 % 0.48 [ 0.09, 2.43 ]
Lopaciuk 1992 0/74 1/72 0.6 % 0.13 [ 0.00, 6.64 ]
Hull 1992 1/213 11/219 7.6 % 0.19 [ 0.06, 0.59 ]
Thery 1992 0/35 2/33 1.3 % 0.12 [ 0.01, 2.02 ]
Prandoni 1992 1/85 3/85 2.5 % 0.36 [ 0.05, 2.61 ]
Simonneau 1993 0/67 0/67 Not estimable
Lindmarker 1994 0/101 0/103 Not estimable
Meyer 1995 0/29 0/31 Not estimable
Luomanmaki 1996 0/117 1/131 0.6 % 0.15 [ 0.00, 7.64 ]
Levine 1996 5/247 3/253 5.1 % 1.70 [ 0.42, 6.87 ]
Fiessinger 1996 0/120 2/133 1.3 % 0.15 [ 0.01, 2.39 ]
Koopman 1996 1/202 2/198 1.9 % 0.50 [ 0.05, 4.85 ]
Simonneau 1997 3/304 5/308 5.1 % 0.61 [ 0.15, 2.46 ]
Columbus 1997 10/510 8/511 11.4 % 1.26 [ 0.49, 3.19 ]
Kirchmaier 1998 1/128 4/131 3.2 % 0.30 [ 0.05, 1.77 ]
Decousus 1998 7/195 8/205 9.4 % 0.92 [ 0.33, 2.57 ]
Belcaro 1999 0/98 0/196 Not estimable
Harenberg 2000a 4/265 11/273 9.4 % 0.40 [ 0.14, 1.10 ]
Findik 2002 0/29 0/30 Not estimable
Kakkar 2003 2/111 0/110 1.3 % 7.39 [ 0.46, 118.89 ]
P rez de Llano 2003 1/29 0/31 0.6 % 7.92 [ 0.16, 399.84 ]
Riess 2003 6/627 7/593 8.3 % 0.81 [ 0.27, 2.41 ]
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Prandoni 2004 3/360 4/360 4.5 % 0.75 [ 0.17, 3.32 ]
Leizorovicz 2011 18/269 15/268 20.1 % 1.21 [ 0.60, 2.44 ]
Total (95% CI) 4333 4457 100.0 % 0.69 [ 0.51, 0.95 ]
Total events: 65 (LMWH), 94 (UFH)
Heterogeneity: Chi2 = 23.84, df = 19 (P = 0.20); I2 =20%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
Analysis 10.4. Comparison 10 LMWH versus UFH by year of publication, Outcome 4 Overall mortality at
the end of follow-up.
Review: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 10 LMWH versus UFH by year of publication
Outcome: 4 Overall mortality at the end of follow-up
Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Hull 1992 10/213 21/219 6.3 % 0.48 [ 0.23, 1.00 ]
Prandoni 1992 6/85 12/85 3.6 % 0.48 [ 0.18, 1.26 ]
Lopaciuk 1992 0/74 1/72 0.2 % 0.13 [ 0.00, 6.64 ]
Thery 1992 1/35 1/33 0.4 % 0.94 [ 0.06, 15.40 ]
Simonneau 1993 3/67 2/67 1.1 % 1.51 [ 0.25, 8.96 ]
Lindmarker 1994 2/101 3/103 1.1 % 0.68 [ 0.12, 3.99 ]
Meyer 1995 0/29 0/31 Not estimable
Koopman 1996 14/202 16/198 6.1 % 0.85 [ 0.40, 1.78 ]
Luomanmaki 1996 1/110 4/116 1.1 % 0.31 [ 0.05, 1.82 ]
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
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Study or subgroup LMWH UFH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Levine 1996 11/247 17/253 5.8 % 0.65 [ 0.30, 1.40 ]
Columbus 1997 36/510 39/511 15.3 % 0.92 [ 0.57, 1.47 ]
Simonneau 1997 12/304 14/308 5.5 % 0.86 [ 0.39, 1.89 ]
Decousus 1998 40/195 43/205 14.5 % 0.97 [ 0.60, 1.58 ]
Kirchmaier 1998 8/125 10/124 3.7 % 0.78 [ 0.30, 2.03 ]
Goldhaber 1998 0/41 0/39 Not estimable
Harenberg 2000a 6/265 15/273 4.4 % 0.42 [ 0.18, 1.01 ]
Breddin 2001 9/388 11/375 4.3 % 0.79 [ 0.32, 1.91 ]
Merli 2001 18/610 9/290 5.0 % 0.95 [ 0.42, 2.15 ]
Findik 2002 0/29 0/30 Not estimable
Riess 2003 11/627 16/593 5.8 % 0.65 [ 0.30, 1.39 ]
Kakkar 2003 2/89 2/85 0.9 % 0.95 [ 0.13, 6.90 ]
P rez de Llano 2003 1/29 0/21 0.2 % 5.61 [ 0.11, 297.44 ]
Prandoni 2004 12/360 12/360 5.1 % 1.00 [ 0.44, 2.26 ]
Leizorovicz 2011 31/269 17/268 9.6 % 1.89 [ 1.04, 3.41 ]
Total (95% CI) 5004 4659 100.0 % 0.84 [ 0.70, 1.01 ]
Total events: 234 (LMWH), 265 (UFH)
Heterogeneity: Chi2 = 18.23, df = 20 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours LMWH Favours UFH
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Thrombosis 1231
#2 MESH DESCRIPTOR Thromboembolism 892
#3 MESH DESCRIPTOR Venous Thromboembolism 233
#4 MESHDESCRIPTOR Venous Thrombosis EXPLODE ALL
TREES
1996
#5 (thromboprophyla* or thrombus* or thrombotic* or throm-
bolic* or thromboemboli* or thrombos* or embol*):TI,AB,
KY
17001
#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE
ALL TREES
729
#7 (PE or DVT or VTE):TI,AB,KY 4480
#8 (((vein* or ven*) near thromb*)):TI,AB,KY 6111
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 20325
#10 MESH DESCRIPTOR Heparin EXPLODE ALL TREES 3815
#11 heparin*:TI,AB,KY 8661
#12 LMWH:TI,AB,KY 790
#13 UFH:TI,AB,KY 437
#14 UH:TI,AB,KY 84
#15 (nadroparin* or fraxiparin* or enoxaparin or Clexane or klex-
ane or lovenox or dalteparin or Fragmin or ardeparin or normi-
ﬂo or tinzaparin or logiparin or Innohep or certoparin or san-
doparin or reviparin or clivarin* or danaproid or danaparoid)
:TI,AB,KY
2405
#16 (antixarin or ardeparin* or bemiparin* or Zibor or cy 222 or
embolex or monoembolex or parnaparin* or “rd 11885” or
tedelparin or Kabi-2165 or Kabi 2165):TI,AB,KY
149
#17 (emt-966 or emt-967 or “pk-10 169” or pk-10169 or
pk10169):TI,AB,KY
8
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#18 (fr-860 or cy-216 or cy216 or seleparin* or tedegliparin or
seleparin* or tedegliparin*):TI,AB,KY
51
#19 (“kb 101” or kb101 or lomoparan or orgaran):TI,AB,KY 31
#20 (parnaparin or ﬂuxum or lohepa or lowhepa or “op 2123” or
parvoparin or AVE5026):TI,AB,KY
36
#21 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR
#17 OR #19 OR #20
9580
#22 #9 AND #21 4334
Appendix 2. Trials registries searches
Clinicaltrials.gov
134 studies found for: subcutaneous AND heparin
WHO
57 records for 42 trials found for: subcutaneous AND heparin
ISRCTN
13 results subcutaneous AND heparin
F E E D B A C K
Anticoagulant feedback, 14 February 2011
Summary
Feedback received on this review, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial Unit website
at http://www.editorial-unit.cochrane.org/anticoagulants-feedback.
WH A T ’ S N E W
Last assessed as up-to-date: 15 September 2016.
Date Event Description
15 September 2016 New search has been performed Searches rerun. Six new studies included, ﬁve new
studies excluded and one ongoing study identiﬁed
15 September 2016 New citation required but conclusions have not
changed
Searches rerun. Six new studies included, ﬁve new
studies excluded and one ongoing study identiﬁed.
Review updated according to current Cochrane stan-
140Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous
thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
dards. New authors have taken over this review. Con-
clusions not changed
H I S T O R Y
Protocol ﬁrst published: Issue 3, 1997
Review ﬁrst published: Issue 2, 1998
Date Event Description
14 February 2011 Amended Link to anticoagulant feedback added
14 July 2010 New search has been performed The reviewwas updated, one additional trial was added
to the included studies and two additional trials were
excluded
27 April 2010 New citation required but conclusions have not
changed
There was a change in authors in the updated review.
20 October 2008 Amended Converted to new review format.
14 November 2005 Amended Minor copy edits made.
23 August 2004 New citation required but conclusions have not
changed
Change in authors.
23 August 2004 New search has been performed Review substantively updated by the addition of eight
new included studies. Conclusions unchanged
15 February 1999 New search has been performed One additional trial included but no change to con-
clusions.
C O N T R I B U T I O N S O F A U T H O R S
LR: selected studies for inclusion in this update, assessed the quality of studies, carried out data extraction, performed data analysis and
wrote the review.
LJ: selected studies for inclusion in this update, assessed the quality of the studies and carried out data extraction.
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D E C L A R A T I O N S O F I N T E R E S T
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LJ: none known.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Included post hoc sensitivity analysis for ISTH bleeding deﬁnitions in order to assess the effect of bleeding deﬁnitions used.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticoagulants [∗administration & dosage; adverse effects]; Hemorrhage [chemically induced]; Heparin [administration & dosage;
adverse effects]; Heparin, Low-Molecular-Weight [∗administration & dosage; adverse effects]; Injections, Subcutaneous; Pulmonary
Embolism [∗drug therapy; mortality]; Randomized Controlled Trials as Topic; Recurrence; Venous Thrombosis [∗drug therapy; mor-
tality]
MeSH check words
Humans
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